BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183:788-824. [PMID: 21471066 DOI: 10.1164/rccm.2009-040gl] [Cited by in Crossref: 4088] [Cited by in F6Publishing: 1877] [Article Influence: 371.6] [Reference Citation Analysis]
Number Citing Articles
1 Labrador-Horrillo M, Martinez MA, Selva-O'Callaghan A, Trallero-Araguas E, Balada E, Vilardell-Tarres M, Juárez C. Anti-MDA5 antibodies in a large Mediterranean population of adults with dermatomyositis. J Immunol Res 2014;2014:290797. [PMID: 24741583 DOI: 10.1155/2014/290797] [Cited by in Crossref: 92] [Cited by in F6Publishing: 78] [Article Influence: 11.5] [Reference Citation Analysis]
2 Xie T, Han L, Chen Y, Wu H. Progranulin and Activin A Concentrations are Elevated in Serum from Patients with Acute Exacerbations of Idiopathic Pulmonary Fibrosis. Lung 2021;199:467-73. [PMID: 34462814 DOI: 10.1007/s00408-021-00470-6] [Reference Citation Analysis]
3 Hirabayashi R, Takahashi Y, Nagata K, Morimoto T, Wakata K, Nakagawa A, Tachikawa R, Otsuka K, Tomii K. The validity and reliability of four-meter gait speed test for stable interstitial lung disease patients: the prospective study. J Thorac Dis 2020;12:1296-304. [PMID: 32395266 DOI: 10.21037/jtd.2020.02.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Callahan SJ, Xia M, Murray S, Flaherty KR. Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis. Respir Med 2016;119:96-101. [PMID: 27692155 DOI: 10.1016/j.rmed.2016.08.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
5 Zinellu A, Collu C, Nasser M, Paliogiannis P, Mellino S, Zinellu E, Traclet J, Ahmad K, Mangoni AA, Carru C, Pirina P, Fois AG, Cottin V. The Aggregate Index of Systemic Inflammation (AISI): A Novel Prognostic Biomarker in Idiopathic Pulmonary Fibrosis. J Clin Med 2021;10:4134. [PMID: 34575245 DOI: 10.3390/jcm10184134] [Reference Citation Analysis]
6 Tortora M, Gemini L, D’iglio I, Ugga L, Spadarella G, Cuocolo R. Spectral Photon-Counting Computed Tomography: A Review on Technical Principles and Clinical Applications. J Imaging 2022;8:112. [DOI: 10.3390/jimaging8040112] [Reference Citation Analysis]
7 Korfei M, Mahavadi P, Guenther A. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option. Cells 2022;11:1626. [DOI: 10.3390/cells11101626] [Reference Citation Analysis]
8 Edvardsen A, Jarosch I, Grongstad A, Wiegand L, Gloeckl R, Kenn K, Spruit MA. A randomized cross-over trial on the direct effects of oxygen supplementation therapy using different devices on cycle endurance in hypoxemic patients with Interstitial Lung Disease. PLoS One 2018;13:e0209069. [PMID: 30592724 DOI: 10.1371/journal.pone.0209069] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
9 Ghosh AJ, Hobbs BD, Yun JH, Saferali A, Moll M, Xu Z, Chase RP, Morrow J, Ziniti J, Sciurba F, Barwick L, Limper AH, Flaherty K, Criner G, Brown KK, Wise R, Martinez FJ, McGoldrick D, Cho MH, DeMeo DL, Silverman EK, Castaldi PJ, Hersh CP; NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Lung tissue shows divergent gene expression between chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis. Respir Res 2022;23:97. [PMID: 35449067 DOI: 10.1186/s12931-022-02013-w] [Reference Citation Analysis]
10 Kulkarni T, O'Reilly P, Antony VB, Gaggar A, Thannickal VJ. Matrix Remodeling in Pulmonary Fibrosis and Emphysema. Am J Respir Cell Mol Biol 2016;54:751-60. [PMID: 26741177 DOI: 10.1165/rcmb.2015-0166PS] [Cited by in Crossref: 63] [Cited by in F6Publishing: 31] [Article Influence: 12.6] [Reference Citation Analysis]
11 Kamikawaji K, Seki N, Watanabe M, Mataki H, Kumamoto T, Takagi K, Mizuno K, Inoue H. Regulation of LOXL2 and SERPINH1 by antitumor microRNA-29a in lung cancer with idiopathic pulmonary fibrosis. J Hum Genet 2016;61:985-93. [PMID: 27488440 DOI: 10.1038/jhg.2016.99] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 5.5] [Reference Citation Analysis]
12 Millaire É, Ouellet É, Fortin M, Martel S, Milot J, Bilodeau L, Conti M, Provencher S, Dion G. Outcomes Following Surgical Lung Biopsy for Interstitial Lung Diseases: A Monocenter Experience. Thorac Cardiovasc Surg 2022. [PMID: 35151233 DOI: 10.1055/s-0041-1740548] [Reference Citation Analysis]
13 Lassenius MI, Toppila I, Pöntynen N, Kasslin L, Kaunisto J, Kilpeläinen M, Laitinen T. Forced Vital Capacity (FVC) decline, mortality and healthcare resource utilization in idiopathic pulmonary fibrosis. Eur Clin Respir J 2020;7:1702618. [PMID: 32002175 DOI: 10.1080/20018525.2019.1702618] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, Sumikawa H, Johkoh T, Nakashima R, Imura Y, Mimori T, Suda T. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS One 2015;10:e0120313. [PMID: 25789468 DOI: 10.1371/journal.pone.0120313] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 6.4] [Reference Citation Analysis]
15 Hou Z, Ye Q, Qiu M, Hao Y, Han J, Zeng H. Increased activated regulatory T cells proportion correlate with the severity of idiopathic pulmonary fibrosis. Respir Res 2017;18:170. [PMID: 28886713 DOI: 10.1186/s12931-017-0653-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
16 Tsai MJ, Chang WA, Liao SH, Chang KF, Sheu CC, Kuo PL. The Effects of Epigallocatechin Gallate (EGCG) on Pulmonary Fibroblasts of Idiopathic Pulmonary Fibrosis (IPF)-A Next-Generation Sequencing and Bioinformatic Approach. Int J Mol Sci 2019;20:E1958. [PMID: 31013581 DOI: 10.3390/ijms20081958] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
17 Yan F, Wen Z, Wang R, Luo W, Du Y, Wang W, Chen X. Identification of the lipid biomarkers from plasma in idiopathic pulmonary fibrosis by Lipidomics. BMC Pulm Med 2017;17:174. [PMID: 29212488 DOI: 10.1186/s12890-017-0513-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
18 Chen L, Zhao X. Characterization of air flow and lung function in the pulmonary acinus by fluid-structure interaction in idiopathic interstitial pneumonias. PLoS One 2019;14:e0214441. [PMID: 30921412 DOI: 10.1371/journal.pone.0214441] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Kochan A, Ong S, Guler S, Johannson KA, Ryerson CJ, Goobie GC. Social Media Content of Idiopathic Pulmonary Fibrosis Groups and Pages on Facebook: Cross-sectional Analysis. JMIR Public Health Surveill 2021;7:e24199. [PMID: 34057425 DOI: 10.2196/24199] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Snyder LD, Mosher C, Holtze CH, Lancaster LH, Flaherty KR, Noth I, Neely ML, Hellkamp AS, Bender S, Conoscenti CS, de Andrade JA, Whelan TP. Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry. BMJ Open Respir Res 2020;7:e000567. [PMID: 32624493 DOI: 10.1136/bmjresp-2020-000567] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
21 Kugler MC, Joyner AL, Loomis CA, Munger JS. Sonic hedgehog signaling in the lung. From development to disease. Am J Respir Cell Mol Biol 2015;52:1-13. [PMID: 25068457 DOI: 10.1165/rcmb.2014-0132TR] [Cited by in Crossref: 96] [Cited by in F6Publishing: 57] [Article Influence: 13.7] [Reference Citation Analysis]
22 Kim YJ, Shin SH, Park JW, Kyung SY, Kang SM, Lee SP, Sung YM, Kim YK, Jeong SH. Annual Change in Pulmonary Function and Clinical Characteristics of Combined Pulmonary Fibrosis and Emphysema and Idiopathic Pulmonary Fibrosis: Over a 3-Year Follow-up. Tuberc Respir Dis (Seoul) 2014;77:18-23. [PMID: 25114699 DOI: 10.4046/trd.2014.77.1.18] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
23 Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med 2015;8:309-18. [PMID: 26451121 DOI: 10.2147/IJGM.S74880] [Cited by in Crossref: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
24 Raghu G, Mehta S. Interstitial lung disease (ILD) in India: Insights and lessons from the prospective, landmark ILD-India registry. Lung India 2016;33:589-91. [PMID: 27890985 DOI: 10.4103/0970-2113.192874] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
25 Pitsiou G, Bagalas V, Boutou A, Stanopoulos I, Argyropoulou-Pataka P. Should we routinely screen patients with idiopathic pulmonary fibrosis for nocturnal hypoxemia? Sleep Breath. 2013;17:447-448. [PMID: 22562264 DOI: 10.1007/s11325-012-0716-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
26 Takeda T, Kunimatsu Y, Tani N, Hashimoto I, Kurono Y, Hirose K. Improvement in Subjective Symptoms and Tolerability in Response to Nintedanib Treatment in Elderly Patients with Idiopathic Pulmonary Fibrosis. J Clin Med 2020;9:E755. [PMID: 32168781 DOI: 10.3390/jcm9030755] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
27 Kim GHJ, Weigt SS, Belperio JA, Brown MS, Shi Y, Lai JH, Goldin JG. Prediction of idiopathic pulmonary fibrosis progression using early quantitative changes on CT imaging for a short term of clinical 18-24-month follow-ups. Eur Radiol 2020;30:726-34. [PMID: 31451973 DOI: 10.1007/s00330-019-06402-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
28 Aso S, Matsui H, Fushimi K, Yasunaga H. Effect of cyclosporine A on mortality after acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis 2018;10:5275-82. [PMID: 30416775 DOI: 10.21037/jtd.2018.08.08] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, Jouen F, Jacquot S, Mariampillai K, Musset L, Grenier P, Devilliers H, Hij A, Boyer O, Herson S, Benveniste O. Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II Trial. PLoS One 2015;10:e0133702. [PMID: 26539981 DOI: 10.1371/journal.pone.0133702] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 6.9] [Reference Citation Analysis]
30 Ong PG, Debiane LG, Casal RF. Recent advances in diagnostic bronchoscopy. J Thorac Dis 2016;8:3808-17. [PMID: 28149581 DOI: 10.21037/jtd.2016.12.70] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
31 Sobiecka M, Lewandowska K, Kober J, Franczuk M, Skoczylas A, Tomkowski W, Kuś J, Szturmowicz M. Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases? Lung 2020;198:547-54. [PMID: 32206858 DOI: 10.1007/s00408-020-00346-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Ferrara G, Arnheim-Dahlström L, Bartley K, Janson C, Kirchgässler KU, Levine A, Sköld CM. Epidemiology of Pulmonary Fibrosis: A Cohort Study Using Healthcare Data in Sweden. Pulm Ther 2019;5:55-68. [PMID: 32026424 DOI: 10.1007/s41030-019-0087-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
33 Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733-748. [PMID: 24032382 DOI: 10.1164/rccm.201308-1483st] [Cited by in Crossref: 1825] [Cited by in F6Publishing: 843] [Article Influence: 202.8] [Reference Citation Analysis]
34 Oishi K, Aoe K, Mimura Y, Murata Y, Sakamoto K, Koutoku W, Matsumoto T, Ueoka H, Yano M. Survival from an Acute Exacerbation of Idiopathic Pulmonary Fibrosis with or without Direct Hemoperfusion with a Polymyxin B-immobilized Fiber Column: A Retrospective Analysis. Intern Med 2016;55:3551-9. [PMID: 27980253 DOI: 10.2169/internalmedicine.55.6056] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
35 Enomoto N, Kusagaya H, Oyama Y, Kono M, Kaida Y, Kuroishi S, Hashimoto D, Fujisawa T, Yokomura K, Inui N, Nakamura Y, Suda T. Quantitative analysis of lung elastic fibers in idiopathic pleuroparenchymal fibroelastosis (IPPFE): comparison of clinical, radiological, and pathological findings with those of idiopathic pulmonary fibrosis (IPF). BMC Pulm Med 2014;14:91. [PMID: 24886550 DOI: 10.1186/1471-2466-14-91] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
36 Wang X, Li X, Wang LN, Pan JJ, Yang X, Wei YL. Buyang Huanwu Decoction Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats via Downregulation of Related Protein and Gene Expression. Evid Based Complement Alternat Med 2018;2018:9185485. [PMID: 29681987 DOI: 10.1155/2018/9185485] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
37 Kanayama M, Mori M, Matsumiya H, Taira A, Shinohara S, Kuwata T, Imanishi N, Yoneda K, Kuroda K, Tanaka F. Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis. Surg Today 2020;50:469-74. [PMID: 31773277 DOI: 10.1007/s00595-019-01923-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
38 Trawinska MA, Rupesinghe RD, Hart SP. Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. Ther Clin Risk Manag 2016;12:563-74. [PMID: 27114711 DOI: 10.2147/TCRM.S81144] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
39 Devine MS, Garcia CK. Genetic interstitial lung disease. Clin Chest Med 2012;33:95-110. [PMID: 22365249 DOI: 10.1016/j.ccm.2011.11.001] [Cited by in Crossref: 28] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
40 Schaefer-Prokop C. [HRCT patterns of the most important interstitial lung diseases]. Radiologe 2014;54:1170-9. [PMID: 25503518 DOI: 10.1007/s00117-014-2734-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
41 Lococo F, Luppi F, Cerri S, Montanari G, Stefani A, Rossi G. Pulmonary Carcinosarcoma Arising in the Framework of an Idiopathic Pulmonary Fibrosis. Lung 2016;194:171-3. [PMID: 26475461 DOI: 10.1007/s00408-015-9818-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
42 Leuschner G, Behr J. Acute Exacerbation in Interstitial Lung Disease. Front Med (Lausanne) 2017;4:176. [PMID: 29109947 DOI: 10.3389/fmed.2017.00176] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 10.0] [Reference Citation Analysis]
43 Prayer F, Röhrich S, Pan J, Hofmanninger J, Langs G, Prosch H. [Artificial intelligence in lung imaging]. Radiologe 2020;60:42-7. [PMID: 31754738 DOI: 10.1007/s00117-019-00611-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
44 Kronborg-White S, Sritharan SS, Madsen LB, Folkersen B, Voldby N, Poletti V, Rasmussen TR, Bendstrup E. Integration of cryobiopsies for interstitial lung disease diagnosis is a valid and safe diagnostic strategy-experiences based on 250 biopsy procedures. J Thorac Dis 2021;13:1455-65. [PMID: 33841938 DOI: 10.21037/jtd-20-2431] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Yan W, Peng LY, Ban CJ, Xu XF, Zhu M, Liu Y, Zhang S, Zhai ZG, Wang C, Dai HP. Incidence and clinical characteristics of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chin Med J (Engl) 2015;128:896-901. [PMID: 25836609 DOI: 10.4103/0366-6999.154284] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
46 Garcia-Morales LJ, Chen NY, Weng T, Luo F, Davies J, Philip K, Volcik KA, Melicoff E, Amione-Guerra J, Bunge RR, Bruckner BA, Loebe M, Eltzschig HK, Pandit LM, Blackburn MR, Karmouty-Quintana H. Altered Hypoxic-Adenosine Axis and Metabolism in Group III Pulmonary Hypertension. Am J Respir Cell Mol Biol 2016;54:574-83. [PMID: 26414702 DOI: 10.1165/rcmb.2015-0145OC] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 3.7] [Reference Citation Analysis]
47 Li X, Chen C, Xu J, Liu J, Yi X, Sun X, Shi J. Nonspecific interstitial pneumonia and usual interstitial pneumonia: comparison of the clinicopathologic features and prognosis. J Thorac Dis 2014;6:1476-81. [PMID: 25364525 DOI: 10.3978/j.issn.2072-1439.2014.10.16] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
48 Senoo S, Miyahara N, Taniguchi A, Oda N, Itano J, Higo H, Hara N, Watanabe H, Kano H, Suwaki T, Fuchimoto Y, Kajimoto K, Ichikawa H, Kudo K, Shibayama T, Tanimoto Y, Kuyama S, Kanehiro A, Maeda Y, Kiura K; Okayama Respiratory Disease Study Group (ORDSG). Nintedanib can be used safely and effectively for idiopathic pulmonary fibrosis with predicted forced vital capacity ≤ 50%: A multi-center retrospective analysis. PLoS One 2020;15:e0236935. [PMID: 32853277 DOI: 10.1371/journal.pone.0236935] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
49 Organ L, Bacci B, Koumoundouros E, Barcham G, Milne M, Kimpton W, Samuel C, Snibson K. Structural and functional correlations in a large animal model of bleomycin-induced pulmonary fibrosis. BMC Pulm Med 2015;15:81. [PMID: 26227819 DOI: 10.1186/s12890-015-0071-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
50 Shi H, Yin D, Bonella F, Kreuter M, Oltmanns U, Li X, Peng S, Wei L. Efficacy, safety, and tolerability of combined pirfenidone and N-acetylcysteine therapy: a systematic review and meta-analysis. BMC Pulm Med 2020;20:128. [PMID: 32380989 DOI: 10.1186/s12890-020-1121-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
51 Wu J, Song D, Li Z, Guo B, Xiao Y, Liu W, Liang L, Feng C, Gao T, Chen Y, Li Y, Wang Z, Wen J, Yang S, Liu P, Wang L, Wang Y, Peng L, Stacey GN, Hu Z, Feng G, Li W, Huo Y, Jin R, Shyh-Chang N, Zhou Q, Wang L, Hu B, Dai H, Hao J. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Res 2020;30:794-809. [PMID: 32546764 DOI: 10.1038/s41422-020-0354-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
52 Wang Z, Rankine L, Bier EA, Mummy D, Lu J, Church A, Tighe RM, Swaminathan A, Huang YT, Que LG, Mammarappallil JG, Rajagopal S, Driehuys B. Using hyperpolarized 129Xe gas-exchange MRI to model the regional airspace, membrane, and capillary contributions to diffusing capacity. J Appl Physiol (1985) 2021;130:1398-409. [PMID: 33734831 DOI: 10.1152/japplphysiol.00702.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
53 Nishiyama O, Kataoka K, Ando M, Arizono S, Morino A, Nishimura K, Ogawa T, Shiraki A, Watanabe F, Kozu R, Ogura T, Kondoh Y. Protocol for long-term effect of pulmonary rehabilitation under nintedanib in idiopathic pulmonary fibrosis. ERJ Open Res 2021;7:00321-2021. [PMID: 34435033 DOI: 10.1183/23120541.00321-2021] [Reference Citation Analysis]
54 Cottin V. The role of pirfenidone in the treatment of idiopathic pulmonary fibrosis. Respir Res 2013;14 Suppl 1:S5. [PMID: 23734908 DOI: 10.1186/1465-9921-14-S1-S5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
55 Sato S, Shimizu Y, Goto T, Kitahara A, Koike T, Ishikawa H, Watanabe T, Tsuchida M. Survival after repeated surgery for lung cancer with idiopathic pulmonary fibrosis: a retrospective study. BMC Pulm Med 2018;18:134. [PMID: 30097033 DOI: 10.1186/s12890-018-0703-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
56 Trimble A, Gochuico BR, Markello TC, Fischer R, Gahl WA, Lee JK, Kim Y, Burdick MD, Strieter RM, Mehrad B. Circulating fibrocytes as biomarker of prognosis in Hermansky-Pudlak syndrome. Am J Respir Crit Care Med 2014;190:1395-401. [PMID: 25347450 DOI: 10.1164/rccm.201407-1287OC] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
57 Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO™ Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res 2019;20:105. [PMID: 31142314 DOI: 10.1186/s12931-019-1043-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 5.7] [Reference Citation Analysis]
58 Davidsen JR, Lund LC, Laursen CB, Hallas J, Henriksen DP. Dynamics in diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis. ERJ Open Res 2020;6:00479-2020. [PMID: 33263059 DOI: 10.1183/23120541.00479-2020] [Reference Citation Analysis]
59 Choe J, Hwang HJ, Seo JB, Lee SM, Yun J, Kim MJ, Jeong J, Lee Y, Jin K, Park R, Kim J, Jeon H, Kim N, Yi J, Yu D, Kim B. Content-based Image Retrieval by Using Deep Learning for Interstitial Lung Disease Diagnosis with Chest CT. Radiology 2021;:204164. [PMID: 34636634 DOI: 10.1148/radiol.2021204164] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
60 Li Y, Li M, Wang Y, Guan L, Liu X, Zeng M. The interplay between ASMase signaling pathway and NLRP3 in the epithelial to mesenchymal transition of HBE cells induced by silica. J Appl Toxicol 2021. [PMID: 34969174 DOI: 10.1002/jat.4277] [Reference Citation Analysis]
61 Nishikiori H, Chiba H, Ariki S, Kuronuma K, Otsuka M, Shiratori M, Ikeda K, Watanabe A, Kuroki Y, Takahashi H. Distinct compartmentalization of SP-A and SP-D in the vasculature and lungs of patients with idiopathic pulmonary fibrosis. BMC Pulm Med 2014;14:196. [PMID: 25488319 DOI: 10.1186/1471-2466-14-196] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
62 Vianello A, Arcaro G, Molena B, Turato C, Braccioni F, Paladini L, Vio S, Ferrarese S, Peditto P, Gallan F, Saetta M. High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2019;13:1753466619847130. [PMID: 31170875 DOI: 10.1177/1753466619847130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
63 Guo H, Su Y, Deng F. Effects of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in Lung Diseases: Current Status and Future Perspectives. Stem Cell Rev Rep 2021;17:440-58. [PMID: 33211245 DOI: 10.1007/s12015-020-10085-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
64 Pedraza-Serrano F, López de Andrés A, Jiménez-García R, Jiménez-Trujillo I, Hernández-Barrera V, Sánchez-Muñoz G, Puente-Maestu L, de Miguel-Díez J. Retrospective observational study of trends in hospital admissions for idiopathic pulmonary fibrosis in Spain (2004-2013) using administrative data. BMJ Open 2017;7:e013156. [PMID: 28193850 DOI: 10.1136/bmjopen-2016-013156] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
65 Ghisa M, Marinelli C, Savarino V, Savarino E. Idiopathic pulmonary fibrosis and GERD: links and risks. Ther Clin Risk Manag 2019;15:1081-93. [PMID: 31564886 DOI: 10.2147/TCRM.S184291] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
66 Kesireddy VS, Chillappagari S, Ahuja S, Knudsen L, Henneke I, Graumann J, Meiners S, Ochs M, Ruppert C, Korfei M, Seeger W, Mahavadi P. Susceptibility of microtubule-associated protein 1 light chain 3β (MAP1LC3B/LC3B) knockout mice to lung injury and fibrosis. FASEB J 2019;33:12392-408. [PMID: 31431059 DOI: 10.1096/fj.201900854R] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
67 Molyneaux PL, Willis-Owen SAG, Cox MJ, James P, Cowman S, Loebinger M, Blanchard A, Edwards LM, Stock C, Daccord C, Renzoni EA, Wells AU, Moffatt MF, Cookson WOC, Maher TM. Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2017;195:1640-50. [PMID: 28085486 DOI: 10.1164/rccm.201607-1408OC] [Cited by in Crossref: 102] [Cited by in F6Publishing: 61] [Article Influence: 20.4] [Reference Citation Analysis]
68 Nouno T, Okamoto M, Ohnishi K, Kaieda S, Tominaga M, Zaizen Y, Ichiki M, Momosaki S, Nakamura M, Fujimoto K, Fukuoka J, Shimizu S, Komohara Y, Hoshino T. Elevation of pulmonary CD163+ and CD204+ macrophages is associated with the clinical course of idiopathic pulmonary fibrosis patients. J Thorac Dis. 2019;11:4005-4017. [PMID: 31656675 DOI: 10.21037/jtd.2019.09.03] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
69 Ueda T, Aokage K, Nishikawa H, Neri S, Nakamura H, Sugano M, Tane K, Miyoshi T, Kojima M, Fujii S, Kuwata T, Ochiai A, Kusumoto M, Suzuki K, Tsuboi M, Ishii G. Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. J Cancer Res Clin Oncol 2018;144:835-44. [PMID: 29435735 DOI: 10.1007/s00432-018-2602-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
70 Pajares V, Núñez-Delgado M, Bonet G, Pérez-Pallarés J, Martínez R, Cubero N, Zabala T, Cordovilla R, Flandes J, Disdier C, Torrego A; MULTICRIO Group researchers. Transbronchial biopsy results according to diffuse interstitial lung disease classification. Cryobiopsy versus forceps: MULTICRIO study. PLoS One 2020;15:e0239114. [PMID: 32956379 DOI: 10.1371/journal.pone.0239114] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
71 Shi L, Wang J, Guo HX, Han XL, Tang YP, Liu GY. Circulating Th2 cell reduction and Th1/Th2 imbalance are correlated with primary Sjogren's syndrome-associated interstitial lung disease. Arthritis Res Ther 2022;24:121. [PMID: 35606782 DOI: 10.1186/s13075-022-02811-z] [Reference Citation Analysis]
72 Swigris JJ, Wilson H, Esser D, Conoscenti CS, Stansen W, Kline Leidy N, Brown KK. Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis: insights from the INPULSIS trials. BMJ Open Respir Res 2018;5:e000278. [PMID: 29862029 DOI: 10.1136/bmjresp-2018-000278] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
73 Fukui M, Takamochi K, Suzuki K, Hotta A, Ando K, Matsunaga T, Oh S, Suzuki K. Lobe-specific outcomes of surgery for lung cancer patients with idiopathic interstitial pneumonias. Gen Thorac Cardiovasc Surg 2020;68:812-9. [PMID: 32040817 DOI: 10.1007/s11748-019-01277-2] [Reference Citation Analysis]
74 Naccache JM, Montil M, Cadranel J, Cachanado M, Cottin V, Crestani B, Valeyre D, Wallaert B, Simon T, Nunes H. Study protocol: exploring the efficacy of cyclophosphamide added to corticosteroids for treating acute exacerbation of idiopathic pulmonary fibrosis; a randomized double-blind, placebo-controlled, multi-center phase III trial (EXAFIP). BMC Pulm Med 2019;19:75. [PMID: 30971235 DOI: 10.1186/s12890-019-0830-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
75 Xie Y, Wang JJ, Li GY, Li XL, Li JS. Acupuncture for idiopathic pulmonary fibrosis: Protocol for a systematic review. Medicine (Baltimore) 2017;96:e9114. [PMID: 29384901 DOI: 10.1097/MD.0000000000009114] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
76 Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U. Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension. Thorax 2018;73:581-3. [PMID: 28993537 DOI: 10.1136/thoraxjnl-2016-209701] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 6.4] [Reference Citation Analysis]
77 Larson-Casey JL, Gu L, Davis D, Cai GQ, Ding Q, He C, Carter AB. Post-translational regulation of PGC-1α modulates fibrotic repair. FASEB J 2021;35:e21675. [PMID: 34038004 DOI: 10.1096/fj.202100339R] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
78 Rathinasabapathy A, Bruce E, Espejo A, Horowitz A, Sudhan DR, Nair A, Guzzo D, Francis J, Raizada MK, Shenoy V, Katovich MJ. Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. Br J Pharmacol 2016;173:2859-79. [PMID: 27448286 DOI: 10.1111/bph.13562] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
79 Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, Batra K, Torrealba J, Garcia CK, Wolters PJ. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med 2017;5:639-47. [PMID: 28648751 DOI: 10.1016/S2213-2600(17)30216-3] [Cited by in Crossref: 119] [Cited by in F6Publishing: 56] [Article Influence: 23.8] [Reference Citation Analysis]
80 Tzouvelekis A, Karampitsakos T, Ntolios P, Tzilas V, Bouros E, Markozannes E, Malliou I, Anagnostopoulos A, Granitsas A, Steiropoulos P, Dimakou K, Chrysikos S, Koulouris N, Bouros D. Longitudinal "Real-World" Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Front Med (Lausanne) 2017;4:213. [PMID: 29238708 DOI: 10.3389/fmed.2017.00213] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 6.0] [Reference Citation Analysis]
81 Nevadunsky NS, Mbagwu C, Mizrahi N, Burton E, Goldberg GL. Pulmonary fibrosis after pegylated liposomal Doxorubicin in a patient with uterine papillary serous carcinoma. J Clin Oncol 2013;31:e167-9. [PMID: 23358980 DOI: 10.1200/JCO.2012.44.5767] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
82 Maher TM, Molina-Molina M, Russell AM, Bonella F, Jouneau S, Ripamonti E, Axmann J, Vancheri C. Unmet needs in the treatment of idiopathic pulmonary fibrosis-insights from patient chart review in five European countries. BMC Pulm Med 2017;17:124. [PMID: 28915874 DOI: 10.1186/s12890-017-0468-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 7.8] [Reference Citation Analysis]
83 Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, Vij R, Strek ME, Chung JH. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. Ann Am Thorac Soc 2019;16:580-8. [PMID: 30653927 DOI: 10.1513/AnnalsATS.201807-443OC] [Cited by in Crossref: 35] [Cited by in F6Publishing: 11] [Article Influence: 17.5] [Reference Citation Analysis]
84 Jo HE, Corte TJ, Moodley Y, Levin K, Westall G, Hopkins P, Chambers D, Glaspole I. Evaluating the interstitial lung disease multidisciplinary meeting: a survey of expert centres. BMC Pulm Med 2016;16:22. [PMID: 26831722 DOI: 10.1186/s12890-016-0179-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
85 Neys SFH, Heukels P, van Hulst JAC, Rip J, Wijsenbeek MS, Hendriks RW, Corneth OBJ. Aberrant B Cell Receptor Signaling in Naïve B Cells from Patients with Idiopathic Pulmonary Fibrosis. Cells 2021;10:1321. [PMID: 34073225 DOI: 10.3390/cells10061321] [Reference Citation Analysis]
86 Abou Youssuf HA, Sabry YY, Abd El-hafeez AM, Mohamed HA. Correlation between high-resolution computed tomography of the chest and pulmonary functions in idiopathic pulmonary fibrosis. Egypt J Bronchol 2016;10:330-6. [DOI: 10.4103/1687-8426.193633] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
87 Kishaba T. Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis. J Thorac Dis 2018;10:5974-8. [PMID: 30622766 DOI: 10.21037/jtd.2018.10.84] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Zagami D, Hockenhull J, Bodger A, Sriram KB. Communication of Pulmonary Function Test Results: A Survey of Patient's Preferences. PLoS One 2015;10:e0126617. [PMID: 25950951 DOI: 10.1371/journal.pone.0126617] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
89 Alhamad EH, Cal JG, Shakoor Z, Almogren A, AlBoukai AA. Cytokine gene polymorphisms and serum cytokine levels in patients with idiopathic pulmonary fibrosis. BMC Med Genet 2013;14:66. [PMID: 23815594 DOI: 10.1186/1471-2350-14-66] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
90 Traila D, Oancea C, Tudorache E, Mladinescu OF, Timar B, Tudorache V. Clinical profile of unclassifiable interstitial lung disease: Comparison with chronic fibrosing idiopathic interstitial pneumonias. J Int Med Res 2018;46:448-56. [PMID: 28758849 DOI: 10.1177/0300060517719767] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
91 Wuyts WA, Dahlqvist C, Slabbynck H, Schlesser M, Gusbin N, Compere C, Maddens S, Rizzo S, Kirchgaessler K, Bartley K, Bondue B. Quality of Life and Healthcare Resource Use in a Real-world Patient Population with Idiopathic Pulmonary Fibrosis: The PROOF Registry. Pulm Ther. [DOI: 10.1007/s41030-022-00187-8] [Reference Citation Analysis]
92 Tatler AL, Goodwin AT, Gbolahan O, Saini G, Porte J, John AE, Clifford RL, Violette SM, Weinreb PH, Parfrey H, Wolters PJ, Gauldie J, Kolb M, Jenkins G. Amplification of TGFβ Induced ITGB6 Gene Transcription May Promote Pulmonary Fibrosis. PLoS One 2016;11:e0158047. [PMID: 27494713 DOI: 10.1371/journal.pone.0158047] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.7] [Reference Citation Analysis]
93 Kreuter M, Bonella F, Wijsenbeek M, Maher TM, Spagnolo P. Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. Biomed Res Int 2015;2015:329481. [PMID: 26779535 DOI: 10.1155/2015/329481] [Cited by in Crossref: 28] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
94 Rochwerg B, Schünemann HJ, Raghu G. Idiopathic pulmonary fibrosis - clinical management guided by the evidence-based GRADE approach: what arguments can be made against transparency in guideline development? BMC Med 2016;14:22. [PMID: 26860831 DOI: 10.1186/s12916-016-0563-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
95 Tomioka H, Takata H. Treatment with nintedanib for acute exacerbation of idiopathic pulmonary fibrosis. Respirol Case Rep 2017;5:e00215. [PMID: 28096998 DOI: 10.1002/rcr2.215] [Cited by in Crossref: 4] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
96 Moor CC, Heukels P, Kool M, Wijsenbeek MS. Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 2017;4:226. [PMID: 29326935 DOI: 10.3389/fmed.2017.00226] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
97 Jones DL, Haak AJ, Caporarello N, Choi KM, Ye Z, Yan H, Varelas X, Ordog T, Ligresti G, Tschumperlin DJ. TGFβ-induced fibroblast activation requires persistent and targeted HDAC-mediated gene repression. J Cell Sci 2019;132:jcs233486. [PMID: 31527052 DOI: 10.1242/jcs.233486] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
98 Yount SE, Beaumont JL, Chen SY, Kaiser K, Wortman K, Van Brunt DL, Swigris J, Cella D. Health-Related Quality of Life in Patients with Idiopathic Pulmonary Fibrosis. Lung 2016;194:227-34. [PMID: 26861885 DOI: 10.1007/s00408-016-9850-y] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 9.0] [Reference Citation Analysis]
99 Fraser E, St Noble V, Hoyles RK, Benamore R, Ho LP. Readily accessible CT scoring method to quantify fibrosis in IPF. BMJ Open Respir Res 2020;7:e000584. [PMID: 32527873 DOI: 10.1136/bmjresp-2020-000584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
100 Saito S, Alkhatib A, Kolls JK, Kondoh Y, Lasky JA. Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). J Thorac Dis 2019;11:S1740-54. [PMID: 31632751 DOI: 10.21037/jtd.2019.04.62] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
101 Park Y, Ahn C, Kim TH. Occupational and environmental risk factors of idiopathic pulmonary fibrosis: a systematic review and meta-analyses. Sci Rep 2021;11:4318. [PMID: 33654111 DOI: 10.1038/s41598-021-81591-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
102 Matsuda T, Taniguchi H, Ando M, Kondoh Y, Kimura T, Kataoka K, Nishimura K, Nishiyama O, Sakamoto K, Hasegawa Y. Depression Is Significantly Associated with the Health Status in Patients with Idiopathic Pulmonary Fibrosis. Intern Med 2017;56:1637-44. [PMID: 28674350 DOI: 10.2169/internalmedicine.56.7019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
103 Richeldi L, Yasothan U, Kirkpatrick P. Pirfenidone. Nat Rev Drug Discov 2011;10:489-90. [PMID: 21837822 DOI: 10.1038/nrd3495] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
104 Bondesson D, Schneider MJ, Silbernagel E, Behr J, Reichenberger F, Dinkel J. Automated evaluation of probe-based confocal laser endomicroscopy in the lung. PLoS One 2020;15:e0232847. [PMID: 32374768 DOI: 10.1371/journal.pone.0232847] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
105 Han S, Lee YJ, Park JS, Cho YJ, Yoon HI, Lee JH, Lee CT, Chung JH, Lee KW, Lee SH. Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis. Sci Rep 2019;9:12561. [PMID: 31467375 DOI: 10.1038/s41598-019-49026-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
106 Kono M, Nakamura Y, Enomoto N, Hashimoto D, Fujisawa T, Inui N, Maekawa M, Suda T, Colby TV, Chida K. Usual interstitial pneumonia preceding collagen vascular disease: a retrospective case control study of patients initially diagnosed with idiopathic pulmonary fibrosis. PLoS One 2014;9:e94775. [PMID: 24736601 DOI: 10.1371/journal.pone.0094775] [Cited by in Crossref: 43] [Cited by in F6Publishing: 38] [Article Influence: 5.4] [Reference Citation Analysis]
107 Belkin A, Albright K, Swigris JJ. A qualitative study of informal caregivers' perspectives on the effects of idiopathic pulmonary fibrosis. BMJ Open Respir Res 2014;1:e000007. [PMID: 25478168 DOI: 10.1136/bmjresp-2013-000007] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 5.3] [Reference Citation Analysis]
108 Crews MS, Bartholmai BJ, Adegunsoye A, Oldham JM, Montner SM, Karwoski RA, Husain AN, Vij R, Noth I, Strek ME, Chung JH. Automated CT Analysis of Major Forms of Interstitial Lung Disease. J Clin Med 2020;9:E3776. [PMID: 33238466 DOI: 10.3390/jcm9113776] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
109 Folcik VA, Garofalo M, Coleman J, Donegan JJ, Rabbani E, Suster S, Nuovo A, Magro CM, Di Leva G, Nuovo GJ. Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri. Mod Pathol 2014;27:851-62. [PMID: 24232864 DOI: 10.1038/modpathol.2013.198] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 3.4] [Reference Citation Analysis]
110 Huang MX, Chen YQ, Liu RD, Huang Y, Zhang C. Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis. Molecules 2022;27:3452. [PMID: 35684390 DOI: 10.3390/molecules27113452] [Reference Citation Analysis]
111 Enomoto N, Mikamo M, Oyama Y, Kono M, Hashimoto D, Fujisawa T, Inui N, Nakamura Y, Yasuda H, Kato A, Mimuro S, Doi M, Sato S, Suda T. Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulm Med 2015;15:15. [PMID: 25887940 DOI: 10.1186/s12890-015-0004-4] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 6.4] [Reference Citation Analysis]
112 Wang T, Liu Y, Zou JF, Cheng ZS. Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the TGF-β1 mediated Smad2/3 and ERK1/2 activation. PLoS One 2017;12:e0183972. [PMID: 28873461 DOI: 10.1371/journal.pone.0183972] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
113 Collard HR, Yow E, Richeldi L, Anstrom KJ, Glazer C; IPFnet investigators. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. Respir Res 2013;14:73. [PMID: 23848435 DOI: 10.1186/1465-9921-14-73] [Cited by in Crossref: 121] [Cited by in F6Publishing: 109] [Article Influence: 13.4] [Reference Citation Analysis]
114 Kasam RK, Ghandikota S, Soundararajan D, Reddy GB, Huang SK, Jegga AG, Madala SK. Inhibition of Aurora Kinase B attenuates fibroblast activation and pulmonary fibrosis. EMBO Mol Med 2020;12:e12131. [PMID: 32761869 DOI: 10.15252/emmm.202012131] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
115 Sheth JS, Xia M, Murray S, Martinez CH, Meldrum CA, Belloli EA, Salisbury ML, White ES, Holtze CH, Flaherty KR. Frailty and geriatric conditions in older patients with idiopathic pulmonary fibrosis. Respir Med 2019;148:6-12. [PMID: 30827476 DOI: 10.1016/j.rmed.2019.01.008] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
116 Walsh SL, Wells AU, Sverzellati N, Devaraj A, von der Thüsen J, Yousem SA, Colby TV, Nicholson AG, Hansell DM. Relationship between fibroblastic foci profusion and high resolution CT morphology in fibrotic lung disease. BMC Med 2015;13:241. [PMID: 26399508 DOI: 10.1186/s12916-015-0479-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
117 Li Y, Wang L, Zhang Q, Tian L, Gan C, Liu H, Yin W, Ye T. Blueberry Juice Attenuates Pulmonary Fibrosis via Blocking the TGF-β1/Smad Signaling Pathway. Front Pharmacol 2022;13:825915. [PMID: 35418869 DOI: 10.3389/fphar.2022.825915] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
118 Speranskaia AA. The role of artificial intelligence in assessing the progression of fibrosing lung diseases. Terapevticheskii arkhiv 2022;94:409-12. [DOI: 10.26442/00403660.2022.03.201407] [Reference Citation Analysis]
119 Lucarini L, Durante M, Sgambellone S, Lanzi C, Bigagli E, Akgul O, Masini E, Supuran CT, Carta F. Effects of New NSAID-CAI Hybrid Compounds in Inflammation and Lung Fibrosis. Biomolecules 2020;10:E1307. [PMID: 32927723 DOI: 10.3390/biom10091307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
120 Kang J, Han M, Song JW. Antifibrotic treatment improves clinical outcomes in patients with idiopathic pulmonary fibrosis: a propensity score matching analysis. Sci Rep 2020;10:15620. [PMID: 32973215 DOI: 10.1038/s41598-020-72607-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
121 Karhadkar TR, Meek TD, Gomer RH. Inhibiting Sialidase-Induced TGF-β1 Activation Attenuates Pulmonary Fibrosis in Mice. J Pharmacol Exp Ther 2021;376:106-17. [PMID: 33144389 DOI: 10.1124/jpet.120.000258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
122 Shen Q, Guo T, Song M, Guo W, Zhang Y, Duan W, Peng Y, Ni S, Ouyang X, Peng H. Pain is a common problem in patients with ILD. Respir Res 2020;21:297. [PMID: 33176795 DOI: 10.1186/s12931-020-01564-0] [Reference Citation Analysis]
123 Koyauchi T, Yasui H, Enomoto N, Hasegawa H, Hozumi H, Suzuki Y, Karayama M, Furuhashi K, Fujisawa T, Nakamura Y, Inui N, Yokomura K, Suda T. Pulse oximetric saturation to fraction of inspired oxygen (SpO2/FIO2) ratio 24 hours after high-flow nasal cannula (HFNC) initiation is a good predictor of HFNC therapy in patients with acute exacerbation of interstitial lung disease. Ther Adv Respir Dis 2020;14:1753466620906327. [PMID: 32046604 DOI: 10.1177/1753466620906327] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Li HH, Liu CC, Hsu TW, Lin JH, Hsu JW, Li AF, Yeh YC, Hung SC, Hsu HS. Upregulation of ACE2 and TMPRSS2 by particulate matter and idiopathic pulmonary fibrosis: a potential role in severe COVID-19. Part Fibre Toxicol 2021;18:11. [PMID: 33706759 DOI: 10.1186/s12989-021-00404-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Spencer LG, Loughenbury M, Chaudhuri N, Spiteri M, Parfrey H. Idiopathic pulmonary fibrosis in the UK: analysis of the British Thoracic Society electronic registry between 2013 and 2019. ERJ Open Res 2021;7:00187-2020. [PMID: 33532476 DOI: 10.1183/23120541.00187-2020] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
126 Boland JW, Reigada C, Yorke J, Hart SP, Bajwah S, Ross J, Wells A, Papadopoulos A, Currow DC, Grande G, Macleod U, Johnson MJ. The Adaptation, Face, and Content Validation of a Needs Assessment Tool: Progressive Disease for People with Interstitial Lung Disease. J Palliat Med 2016;19:549-55. [PMID: 26840603 DOI: 10.1089/jpm.2015.0355] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
127 Lee JH, Park CS, Song JW. Obstructive sleep apnea in patients with interstitial lung disease: Prevalence and predictive factors. PLoS One 2020;15:e0239963. [PMID: 33017401 DOI: 10.1371/journal.pone.0239963] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
128 Vittal R, Fisher A, Gu H, Mickler EA, Panitch A, Lander C, Cummings OW, Sandusky GE, Wilkes DS. Peptide-mediated inhibition of mitogen-activated protein kinase-activated protein kinase-2 ameliorates bleomycin-induced pulmonary fibrosis. Am J Respir Cell Mol Biol 2013;49:47-57. [PMID: 23470623 DOI: 10.1165/rcmb.2012-0389OC] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
129 Swapna R, Roshan R, Chhabra SK. Platypnea-orthodeoxia syndrome in idiopathic pulmonary fibrosis with Pneumocystis jiroveci pneumonia. Lung India 2017;34:372-5. [PMID: 28671170 DOI: 10.4103/0970-2113.209236] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
130 Sharp C, Adamali HI, Millar AB. A comparison of published multidimensional indices to predict outcome in idiopathic pulmonary fibrosis. ERJ Open Res 2017;3:00096-2016. [PMID: 28326312 DOI: 10.1183/23120541.00096-2016] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
131 Takeda A, Tsurugai Y, Sanuki N, Enomoto T, Shinkai M, Mizuno T, Aoki Y, Oku Y, Akiba T, Hara Y, Kunieda E. Clarithromycin mitigates radiation pneumonitis in patients with lung cancer treated with stereotactic body radiotherapy. J Thorac Dis 2018;10:247-61. [PMID: 29600055 DOI: 10.21037/jtd.2017.12.22] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
132 van Cleemput J, Sonaglioni A, Wuyts WA, Bengus M, Stauffer JL, Harari S. Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. Adv Ther 2019;36:298-317. [PMID: 30554332 DOI: 10.1007/s12325-018-0857-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
133 Lagares D, Ghassemi-Kakroodi P, Tremblay C, Santos A, Probst CK, Franklin A, Santos DM, Grasberger P, Ahluwalia N, Montesi SB, Shea BS, Black KE, Knipe R, Blati M, Baron M, Wu B, Fahmi H, Gandhi R, Pardo A, Selman M, Wu J, Pelletier JP, Martel-Pelletier J, Tager AM, Kapoor M. ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. Nat Med 2017;23:1405-15. [PMID: 29058717 DOI: 10.1038/nm.4419] [Cited by in Crossref: 47] [Cited by in F6Publishing: 45] [Article Influence: 9.4] [Reference Citation Analysis]
134 Cicchitto G, Musella V, Acitorio M, Capuano N, Fiorenzano G, Owen CA, Polverino M, Polverino F. Idiopathic pulmonary fibrosis and coronary artery disease. Multidiscip Respir Med 2014;9:31. [PMID: 24976970 DOI: 10.1186/2049-6958-9-31] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
135 Song X, Yu W, Guo F. Pirfenidone suppresses bleomycin-induced pulmonary fibrosis and periostin expression in rats. Exp Ther Med 2018;16:1800-6. [PMID: 30186404 DOI: 10.3892/etm.2018.6378] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
136 Lin H, Jiang S. Combined pulmonary fibrosis and emphysema (CPFE): an entity different from emphysema or pulmonary fibrosis alone. J Thorac Dis 2015;7:767-79. [PMID: 25973246 DOI: 10.3978/j.issn.2072-1439.2015.04.17] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
137 Pastre J, Barnett S, Ksovreli I, Taylor J, Brown AW, Shlobin OA, Ahmad K, Khangoora V, Aryal S, King CS, Nathan SD. Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. Respir Res 2021;22:5. [PMID: 33407450 DOI: 10.1186/s12931-020-01600-z] [Reference Citation Analysis]
138 Johannson K, Collard HR. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal. Curr Respir Care Rep 2013;2. [PMID: 24416637 DOI: 10.1007/s13665-013-0065-x] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 3.4] [Reference Citation Analysis]
139 Li R, Wang Y, Song X, Sun W, Zhang J, Liu Y, Li H, Meng C, Zhang J, Zheng Q, Lv C. Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis. Int J Mol Med 2018;42:3256-68. [PMID: 30272257 DOI: 10.3892/ijmm.2018.3892] [Cited by in Crossref: 8] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
140 Higashiguchi M, Kijima T, Sumikawa H, Honda O, Minami T, Hirata H, Inoue K, Nagatomo I, Takeda Y, Kida H, Tomiyama N, Kumanogoh A. A retrospective study of prognostic factors in patients with interstitial pneumonia receiving long-term oxygen therapy. Lung 2014;192:729-37. [PMID: 25056241 DOI: 10.1007/s00408-014-9623-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
141 Bondue B, Pieters T, Alexander P, De Vuyst P, Ruiz Patino M, Hoton D, Remmelink M, Leduc D. Role of Transbronchial Lung Cryobiopsies in Diffuse Parenchymal Lung Diseases: Interest of a Sequential Approach. Pulm Med 2017;2017:6794343. [PMID: 28512583 DOI: 10.1155/2017/6794343] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
142 Stahl M, Schupp J, Jäger B, Schmid M, Zissel G, Müller-Quernheim J, Prasse A. Lung collagens perpetuate pulmonary fibrosis via CD204 and M2 macrophage activation. PLoS One. 2013;8:e81382. [PMID: 24278429 DOI: 10.1371/journal.pone.0081382] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
143 Jacob J, Aksman L, Mogulkoc N, Procter AJ, Gholipour B, Cross G, Barnett J, Brereton CJ, Jones MG, van Moorsel CH, van Es W, van Beek F, Veltkamp M, Desai SR, Judge E, Burd T, Kokosi M, Savas R, Bayraktaroglu S, Altmann A, Wells AU. Serial CT analysis in idiopathic pulmonary fibrosis: comparison of visual features that determine patient outcome. Thorax 2020;75:648-54. [PMID: 32345689 DOI: 10.1136/thoraxjnl-2019-213865] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
144 Kurosaki T, Kanda H, Hashizume J, Sato K, Harasawa H, Nakamura T, Sasaki H, Kodama Y. Delivery of pDNA to the Lung by Lipopolyplexes Using N-Lauroylsarcosine and Effect on the Pulmonary Fibrosis. Pharmaceutics 2021;13:1983. [PMID: 34834398 DOI: 10.3390/pharmaceutics13111983] [Reference Citation Analysis]
145 Adegunsoye A, Hrusch CL, Bonham CA, Jaffery MR, Blaine KM, Sullivan M, Churpek MM, Strek ME, Noth I, Sperling AI. Skewed Lung CCR4 to CCR6 CD4+ T Cell Ratio in Idiopathic Pulmonary Fibrosis Is Associated with Pulmonary Function. Front Immunol 2016;7:516. [PMID: 27933058 DOI: 10.3389/fimmu.2016.00516] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
146 Lodhi T, Hughes G, Stanel S, Chaudhuri N, Hayton C. Transbronchial Lung Cryobiopsy in Idiopathic Pulmonary Fibrosis: A State of the Art Review. Adv Ther 2019;36:2193-204. [PMID: 31363997 DOI: 10.1007/s12325-019-01036-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
147 Sgalla G, Cerri S, Ferrari R, Ricchieri MP, Poletti S, Ori M, Garuti M, Montanari G, Luppi F, Petropulacos K, Richeldi L. Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy. BMJ Open Respir Res 2015;2:e000065. [PMID: 25806113 DOI: 10.1136/bmjresp-2014-000065] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
148 Althobiani M, Alqahtani JS, Hurst JR, Russell AM, Porter J. Telehealth for patients with interstitial lung diseases (ILD): results of an international survey of clinicians. BMJ Open Respir Res 2021;8:e001088. [PMID: 34969772 DOI: 10.1136/bmjresp-2021-001088] [Reference Citation Analysis]
149 Choi Y, Lu J, Hu Z, Pankratz DG, Jiang H, Cao M, Marchisano C, Huiras J, Fedorowicz G, Wong MG, Anderson JR, Tom EY, Babiarz J, Imtiaz U, Barth NM, Walsh PS, Kennedy GC, Huang J. Analytical performance of Envisia: a genomic classifier for usual interstitial pneumonia. BMC Pulm Med 2017;17:141. [PMID: 29149880 DOI: 10.1186/s12890-017-0485-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
150 Lee YH, Cha SI, Lim JK, Yoo SS, Lee SY, Lee J, Kim CH, Park JY. Clinical and radiological features of pulmonary tuberculosis in patients with idiopathic pulmonary fibrosis. Respir Investig 2019;57:544-51. [PMID: 31563638 DOI: 10.1016/j.resinv.2019.08.001] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
151 Lu Y, Chen J, Tang K, Wang S, Tian Z, Wang M, Zhao J, Xie J. Development and Validation of the Prognostic Index Based on Inflammation-Related Gene Analysis in Idiopathic Pulmonary Fibrosis. Front Mol Biosci 2021;8:667459. [PMID: 34368225 DOI: 10.3389/fmolb.2021.667459] [Reference Citation Analysis]
152 Enomoto Y, Nakamura Y, Colby TV, Johkoh T, Sumikawa H, Nishimoto K, Yoshimura K, Matsushima S, Oyama Y, Hozumi H, Kono M, Fujisawa T, Enomoto N, Inui N, Iwashita T, Suda T. Radiologic pleuroparenchymal fibroelastosis-like lesion in connective tissue disease-related interstitial lung disease. PLoS One 2017;12:e0180283. [PMID: 28666014 DOI: 10.1371/journal.pone.0180283] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 7.2] [Reference Citation Analysis]
153 Bozzetti F, Paladini I, Rabaiotti E, Franceschini A, Alfieri V, Chetta A, Crisafulli E, Silva M, Pastorino U, Sverzellati N. Are interstitial lung abnormalities associated with COPD? A nested case-control study. Int J Chron Obstruct Pulmon Dis 2016;11:1087-96. [PMID: 27307724 DOI: 10.2147/COPD.S103256] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Schamberger AC, Schiller HB, Fernandez IE, Sterclova M, Heinzelmann K, Hennen E, Hatz R, Behr J, Vašáková M, Mann M, Eickelberg O, Staab-Weijnitz CA. Glutathione peroxidase 3 localizes to the epithelial lining fluid and the extracellular matrix in interstitial lung disease. Sci Rep 2016;6:29952. [PMID: 27435875 DOI: 10.1038/srep29952] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
155 Hyldgaard C, Møller J, Bendstrup E. Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality. Eur Clin Respir J 2020;7:1807682. [PMID: 32944203 DOI: 10.1080/20018525.2020.1807682] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
156 Gershman E, Zer A, Pertzov B, Shtraichman O, Shitenberg D, Heching M, Rosengarten D, Kramer M. Characteristics of lung cancer in idiopathic pulmonary fibrosis with single lung transplant versus non-transplanted patients: a retrospective observational study. BMJ Open Respir Res 2020;7:e000566. [PMID: 32565443 DOI: 10.1136/bmjresp-2020-000566] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
157 Cottin V. [French recommendations for idiopathic pulmonary fibrosis: An updated working document for clinicians]. Rev Mal Respir 2017;34:789-90. [PMID: 29102032 DOI: 10.1016/j.rmr.2017.09.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
158 Kulkarni T, Valentine VG, Fei F, Tran-Nguyen TK, Quesada-Arias LD, Mkorombindo T, Pham HP, Simmons SC, Dsouza KG, Luckhardt T, Duncan SR. Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations. PLoS One 2021;16:e0260345. [PMID: 34813613 DOI: 10.1371/journal.pone.0260345] [Reference Citation Analysis]
159 Meyer KC, Decker CA. Role of pirfenidone in the management of pulmonary fibrosis. Ther Clin Risk Manag 2017;13:427-37. [PMID: 28435277 DOI: 10.2147/TCRM.S81141] [Cited by in Crossref: 23] [Cited by in F6Publishing: 11] [Article Influence: 4.6] [Reference Citation Analysis]
160 Cuerpo S, Moisés J, Hernández-González F, Benegas M, Ramirez J, Sánchez M, Agustí À, Sellares J. Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter? Chron Respir Dis 2019;16:1479973119869334. [PMID: 31431063 DOI: 10.1177/1479973119869334] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
161 Monaghan-Benson E, Wittchen ES, Doerschuk CM, Burridge K. A Rnd3/p190RhoGAP pathway regulates RhoA activity in idiopathic pulmonary fibrosis fibroblasts. Mol Biol Cell 2018;29:2165-75. [PMID: 29995590 DOI: 10.1091/mbc.E17-11-0642] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
162 Inoue Y, Suda T, Kitamura H, Okamoto M, Azuma A, Inase N, Kuwana M, Makino S, Nishioka Y, Ogura T, Takizawa A, Ugai H, Stowasser S, Schlenker-Herceg R, Takeuchi T. Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respir Med 2021;187:106574. [PMID: 34564020 DOI: 10.1016/j.rmed.2021.106574] [Reference Citation Analysis]
163 Leuschner G, Reiter F, Stocker F, Crispin A, Kneidinger N, Veit T, Klenner F, Ceelen F, Zimmermann G, Leuchte H, Reu S, Dinkel J, Behr J, Neurohr C. Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management. Lung 2018;196:401-8. [PMID: 29761229 DOI: 10.1007/s00408-018-0123-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Matsuoka S, Yamashiro T, Matsushita S, Kotoku A, Fujikawa A, Yagihashi K, Nakajima Y. Quantitative CT evaluation in patients with combined pulmonary fibrosis and emphysema: correlation with pulmonary function. Acad Radiol 2015;22:626-31. [PMID: 25728361 DOI: 10.1016/j.acra.2015.01.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
165 Kagimoto A, Mimura T, Kamigaichi A, Yamashita Y. Prognosis of resected non-small cell lung cancer with pleural plaques on intrathoracic findings. BMC Cancer 2022;22:469. [PMID: 35484615 DOI: 10.1186/s12885-022-09600-6] [Reference Citation Analysis]
166 George MD, Shah R, Kreider M, Miller WT Jr, Merkel PA, Werth VP. Pulmonary function tests, interstitial lung disease and lung function decline in outpatients with classic and clinically amyopathic dermatomyositis. Br J Dermatol 2017;176:262-4. [PMID: 27229750 DOI: 10.1111/bjd.14771] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
167 Johannson KA, Ley B, Collard HR. Models of disease behavior in idiopathic pulmonary fibrosis. BMC Med 2015;13:165. [PMID: 26400574 DOI: 10.1186/s12916-015-0403-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
168 Kimman ML, Rotteveel AH, Wijsenbeek M, Mostard R, Tak NC, van Jaarsveld X, Storm M, Wijnsma KL, Gelens M, van de Kar NCAJ, Wetzels J, Dirksen CD. Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). Patient 2017;10:629-42. [PMID: 28357591 DOI: 10.1007/s40271-017-0234-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
169 Kropski JA, Blackwell TS. Progress in Understanding and Treating Idiopathic Pulmonary Fibrosis. Annu Rev Med 2019;70:211-24. [PMID: 30691371 DOI: 10.1146/annurev-med-041317-102715] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 12.7] [Reference Citation Analysis]
170 Jiang CG, Fu Q, Zheng CM. Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone. Ther Adv Respir Dis 2019;13:1753466619888119. [PMID: 31722622 DOI: 10.1177/1753466619888119] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
171 Behr J. [Interstitial lung disease - what the gereneral practitioner should know]. MMW Fortschr Med 2018;160:38-42. [PMID: 29464621 DOI: 10.1007/s15006-018-0198-5] [Reference Citation Analysis]
172 Hobbs S, Chung JH, Leb J, Kaproth-Joslin K, Lynch DA. Practical Imaging Interpretation in Patients Suspected of Having Idiopathic Pulmonary Fibrosis: Official Recommendations from the Radiology Working Group of the Pulmonary Fibrosis Foundation. Radiol Cardiothorac Imaging 2021;3:e200279. [PMID: 33778653 DOI: 10.1148/ryct.2021200279] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
173 Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllärniemi M, Saarto T. mMRC dyspnoea scale indicates impaired quality of life and increased pain in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2017;3:00084-2017. [PMID: 29255720 DOI: 10.1183/23120541.00084-2017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
174 Li D, Wang B, Liu Y, Wang H. Prevalence and impact of comorbid obstructive sleep apnoea in diffuse parenchymal lung diseases. PLoS One 2021;16:e0246878. [PMID: 33571266 DOI: 10.1371/journal.pone.0246878] [Reference Citation Analysis]
175 Zhang XL, Dai HP, Zhang H, Gao B, Zhang L, Han T, Wang C. Obstructive Sleep Apnea in Patients With Fibrotic Interstitial Lung Disease and COPD. J Clin Sleep Med 2019;15:1807-15. [PMID: 31855166 DOI: 10.5664/jcsm.8090] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
176 Thickett D, Voorham J, Ryan R, Jones R, Coker R, Wilson AM, Yang S, Ow MY, Raju P, Chaudhry I, Hardjojo A, Carter V, Price DB. Historical database cohort study addressing the clinical patterns prior to idiopathic pulmonary fibrosis (IPF) diagnosis in UK primary care. BMJ Open 2020;10:e034428. [PMID: 32474425 DOI: 10.1136/bmjopen-2019-034428] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
177 Zhang L, Ji YX, Jiang WL, Lv CJ. Protective roles of pulmonary rehabilitation mixture in experimental pulmonary fibrosis in vitro and in vivo. Braz J Med Biol Res 2015;48:545-52. [PMID: 25992646 DOI: 10.1590/1414-431X20144301] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
178 Ide M, Tanaka K, Sunami S, Asoh T, Maeyama T, Tsuruta N, Nakanishi Y, Okamoto I. Durable response to nivolumab in a lung adenocarcinoma patient with idiopathic pulmonary fibrosis. Thorac Cancer 2018;9:1519-21. [PMID: 30152594 DOI: 10.1111/1759-7714.12853] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
179 Akram KM, Samad S, Spiteri MA, Forsyth NR. Mesenchymal stem cells promote alveolar epithelial cell wound repair in vitro through distinct migratory and paracrine mechanisms. Respir Res. 2013;14:9. [PMID: 23350749 DOI: 10.1186/1465-9921-14-9] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 8.3] [Reference Citation Analysis]
180 Weill D. Lung transplantation: indications and contraindications. J Thorac Dis 2018;10:4574-87. [PMID: 30174910 DOI: 10.21037/jtd.2018.06.141] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
181 Comelli A, Coronnello C, Dahiya N, Benfante V, Palmucci S, Basile A, Vancheri C, Russo G, Yezzi A, Stefano A. Lung Segmentation on High-Resolution Computerized Tomography Images Using Deep Learning: A Preliminary Step for Radiomics Studies. J Imaging 2020;6:125. [PMID: 34460569 DOI: 10.3390/jimaging6110125] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 6.5] [Reference Citation Analysis]
182 Fraser E, Hoyles RK. Therapeutic advances in idiopathic pulmonary fibrosis. Clin Med (Lond) 2016;16:42-51. [PMID: 26833513 DOI: 10.7861/clinmedicine.16-1-42] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
183 Azuma A, Richeldi L. New Era of Management Concept on Pulmonary Fibrosis with Revisiting Framework of Interstitial Lung Diseases. Tuberc Respir Dis (Seoul) 2020;83:195-200. [PMID: 32578412 DOI: 10.4046/trd.2020.0005] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
184 Pfeifer M. [Chronic critically ill patients from a pneumological perspective]. Med Klin Intensivmed Notfmed 2013;108:279-84. [PMID: 23576009 DOI: 10.1007/s00063-012-0192-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
185 Dutta P, Funston W, Mossop H, Ryan V, Jones R, Forbes R, Sen S, Pearson J, Griffin SM, Smith JA, Ward C, Forrest IA, Simpson AJ. Randomised, double-blind, placebo-controlled pilot trial of omeprazole in idiopathic pulmonary fibrosis. Thorax 2019;74:346-53. [PMID: 30610155 DOI: 10.1136/thoraxjnl-2018-212102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
186 Lee JH, Park CS, Song JW. Obstructive sleep apnea in patients with interstitial lung disease: Prevalence and predictive factors. PLoS One 2020;15:e0239963. [PMID: 33017401 DOI: 10.1371/journal.pone.0239963] [Reference Citation Analysis]
187 Zhang R, Tan Y, Yong C, Jiao Y, Tang X, Wang D. Pirfenidone ameliorates early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome by inhibiting endothelial-to-mesenchymal transition via the Hedgehog signaling pathway. International Immunopharmacology 2022;109:108805. [DOI: 10.1016/j.intimp.2022.108805] [Reference Citation Analysis]
188 Lear T, McKelvey AC, Rajbhandari S, Dunn SR, Coon TA, Connelly W, Zhao JY, Kass DJ, Zhang Y, Liu Y, Chen BB. Ubiquitin E3 ligase FIEL1 regulates fibrotic lung injury through SUMO-E3 ligase PIAS4. J Exp Med 2016;213:1029-46. [PMID: 27162139 DOI: 10.1084/jem.20151229] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 3.5] [Reference Citation Analysis]
189 Barratt SL, Adamali HH, Cotton C, Mulhearn B, Iftikhar H, Pauling JD, Spencer L, Adamali HI, Gunawardena H. Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services. BMJ Open Respir Res 2021;8:e000829. [PMID: 33419741 DOI: 10.1136/bmjresp-2020-000829] [Reference Citation Analysis]
190 Fujisawa T, Hozumi H, Kono M, Enomoto N, Hashimoto D, Nakamura Y, Inui N, Yokomura K, Koshimizu N, Toyoshima M, Shirai T, Yasuda K, Hayakawa H, Suda T. Prognostic factors for myositis-associated interstitial lung disease. PLoS One. 2014;9:e98824. [PMID: 24905449 DOI: 10.1371/journal.pone.0098824] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 9.8] [Reference Citation Analysis]
191 Nunes FS, Pastre J, Brown AW, Shlobin OA, King C, Weir NA, Nathan SD. Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis? Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021005. [PMID: 33867792 DOI: 10.36141/svdld.v38i1.9258] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
192 Kishore A, Žižková V, Kocourková L, Petřek M. A Dataset of 26 Candidate Gene and Pro-Inflammatory Cytokine Variants for Association Studies in Idiopathic Pulmonary Fibrosis: Frequency Distribution in Normal Czech Population. Front Immunol 2015;6:476. [PMID: 26441981 DOI: 10.3389/fimmu.2015.00476] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
193 De Biasi S, Cerri S, Bianchini E, Gibellini L, Persiani E, Montanari G, Luppi F, Carbonelli CM, Zucchi L, Bocchino M, Zamparelli AS, Vancheri C, Sgalla G, Richeldi L, Cossarizza A. Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments. BMC Med 2015;13:277. [PMID: 26552487 DOI: 10.1186/s12916-015-0515-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
194 Zhang Y, Kaminski N. Biomarkers in idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2012;18:441-446. [PMID: 22847105 DOI: 10.1097/mcp.0b013e328356d03c] [Cited by in Crossref: 69] [Cited by in F6Publishing: 34] [Article Influence: 6.9] [Reference Citation Analysis]
195 Murata O, Suzuki K, Takeuchi T, Maemondo M. The Risk Factors of Exacerbation in Interstitial Pneumonia With Autoimmune Features: A Single-Center Observational Cohort Study. Rheumatol Ther 2021;8:1693-710. [PMID: 34536219 DOI: 10.1007/s40744-021-00371-3] [Reference Citation Analysis]
196 Duerr J, Leitz DHW, Szczygiel M, Dvornikov D, Fraumann SG, Kreutz C, Zadora PK, Seyhan Agircan A, Konietzke P, Engelmann TA, Hegermann J, Mulugeta S, Kawabe H, Knudsen L, Ochs M, Rotin D, Muley T, Kreuter M, Herth FJF, Wielpütz MO, Beers MF, Klingmüller U, Mall MA. Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice. Nat Commun 2020;11:2012. [PMID: 32332792 DOI: 10.1038/s41467-020-15743-6] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 8.5] [Reference Citation Analysis]
197 Nardocci C, Simon J, Kiss F, Györke T, Szántó P, Tárnoki ÁD, Tárnoki DL, Müller V, Maurovich-horvat P. The role of imaging in the diagnosis and management of idiopathic pulmonary fibrosis. Imaging 2021. [DOI: 10.1556/1647.2021.00048] [Reference Citation Analysis]
198 Lindell KO, Nouraie M, Klesen MJ, Klein S, Gibson KF, Kass DJ, Rosenzweig MQ. Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations. BMJ Open Respir Res 2018;5:e000272. [PMID: 29531748 DOI: 10.1136/bmjresp-2017-000272] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
199 Lambers C, Roth M, Jaksch P, Muraközy G, Tamm M, Klepetko W, Ghanim B, Zhao F. Treprostinil inhibits proliferation and extracellular matrix deposition by fibroblasts through cAMP activation. Sci Rep 2018;8:1087. [PMID: 29348469 DOI: 10.1038/s41598-018-19294-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
200 Palmucci S, Roccasalva F, Puglisi S, Torrisi SE, Vindigni V, Mauro LA, Ettorre GC, Piccoli M, Vancheri C. Clinical and radiological features of idiopathic interstitial pneumonias (IIPs): a pictorial review. Insights Imaging 2014;5:347-64. [PMID: 24844883 DOI: 10.1007/s13244-014-0335-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
201 Wells AU. The revised ATS/ERS/JRS/ALAT diagnostic criteria for idiopathic pulmonary fibrosis (IPF)--practical implications. Respir Res 2013;14 Suppl 1:S2. [PMID: 23734820 DOI: 10.1186/1465-9921-14-S1-S2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 21] [Article Influence: 4.1] [Reference Citation Analysis]
202 Senanayake S, Harrison N, Lewis M. Influence of physical rehabilitation on heart rate dynamics in patients with idiopathic pulmonary fibrosis. J Exerc Rehabil 2019;15:160-9. [PMID: 30899753 DOI: 10.12965/jer.1836452.226] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
203 Smith M, Dalurzo M, Panse P, Parish J, Leslie K. Usual interstitial pneumonia-pattern fibrosis in surgical lung biopsies. Clinical, radiological and histopathological clues to aetiology. J Clin Pathol 2013;66:896-903. [PMID: 23703852 DOI: 10.1136/jclinpath-2013-201442] [Cited by in Crossref: 60] [Cited by in F6Publishing: 40] [Article Influence: 6.7] [Reference Citation Analysis]
204 Koyama K, Sakamoto S, Isshiki T, Shimizu H, Kurosaki A, Homma S. The Activities of Daily Living after an Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Intern Med 2017;56:2837-43. [PMID: 28943534 DOI: 10.2169/internalmedicine.7875-16] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
205 Ikeda T, Kinoshita Y, Ueda Y, Sasaki T, Kushima H, Ishii H. Physiological Criteria Are Useful for the Diagnosis of Idiopathic Pleuroparenchymal Fibroelastosis. J Clin Med 2020;9:E3761. [PMID: 33266381 DOI: 10.3390/jcm9113761] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
206 Hewitt RJ, Molyneaux PL. The respiratory microbiome in idiopathic pulmonary fibrosis. Ann Transl Med 2017;5:250. [PMID: 28706918 DOI: 10.21037/atm.2017.01.56] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
207 Cano-Jiménez E, Vázquez Rodríguez T, Martín-Robles I, Castillo Villegas D, Juan García J, Bollo de Miguel E, Robles-Pérez A, Ferrer Galván M, Mouronte Roibas C, Herrera Lara S, Bermudo G, García Moyano M, Rodríguez Portal JA, Sellarés Torres J, Narváez J, Molina-Molina M. Diagnostic delay of associated interstitial lung disease increases mortality in rheumatoid arthritis. Sci Rep 2021;11:9184. [PMID: 33911185 DOI: 10.1038/s41598-021-88734-2] [Reference Citation Analysis]
208 Swigris J, Olson AL, Brown K. Understanding and optimizing health-related quality of life and physical functional capacity in idiopathic pulmonary fibrosis. PROM. [DOI: 10.2147/prom.s74857] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
209 Üçsular F, Karadeniz G, Polat G, Yalnız E, Ayrancı A, Çinkooğlu A, Savaş R, Solmaz H, Güldaval F, Büyükşirin M. Quantitative CT in mortality prediction in pulmonary fibrosis with or without emphysema. Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021024. [PMID: 34744420 DOI: 10.36141/svdld.v38i3.11044] [Reference Citation Analysis]
210 Oh JH, Oh DJ, Koo SM, Kim YK, Kim KU, Kim HJ, Kim DW, Uh ST. Different Responses to Clarithromycin in Patients with Cryptogenic Organizing Pneumonia. Tuberc Respir Dis (Seoul) 2015;78:401-7. [PMID: 26508933 DOI: 10.4046/trd.2015.78.4.401] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
211 Wang S, Liu M, Li X, Zhang J, Wang F, Zhang C, Roden A, Ryu JH, Warrington KJ, Sun J, Matteson EL, Tschumperlin DJ, Vassallo R. Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis. FASEB J 2022;36:e22336. [PMID: 35522243 DOI: 10.1096/fj.202101436R] [Reference Citation Analysis]
212 Tanner L, Bergwik J, Single AB, Bhongir RKV, Erjefält JS, Egesten A. Zoledronic Acid Targeting of the Mevalonate Pathway Causes Reduced Cell Recruitment and Attenuates Pulmonary Fibrosis. Front Pharmacol 2022;13:899469. [PMID: 35721132 DOI: 10.3389/fphar.2022.899469] [Reference Citation Analysis]
213 Sorace J, Aberle DR, Elimam D, Lawvere S, Tawfik O, Wallace WD. Integrating pathology and radiology disciplines: an emerging opportunity? BMC Med 2012;10:100. [PMID: 22950414 DOI: 10.1186/1741-7015-10-100] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 3.2] [Reference Citation Analysis]
214 Jacob J, Bartholmai BJ, Egashira R, Brun AL, Rajagopalan S, Karwoski R, Kokosi M, Hansell DM, Wells AU. Chronic hypersensitivity pneumonitis: identification of key prognostic determinants using automated CT analysis. BMC Pulm Med 2017;17:81. [PMID: 28472939 DOI: 10.1186/s12890-017-0418-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
215 O'Reilly PJ, Ding Q, Akthar S, Cai G, Genschmer KR, Patel DF, Jackson PL, Viera L, Roda M, Locy ML, Bernstein EA, Lloyd CM, Bernstein KE, Snelgrove RJ, Blalock JE. Angiotensin-converting enzyme defines matrikine-regulated inflammation and fibrosis. JCI Insight 2017;2:91923. [PMID: 29202450 DOI: 10.1172/jci.insight.91923] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
216 Wang K, Ju Q, Cao J, Tang W, Zhang J. Impact of serum SP-A and SP-D levels on comparison and prognosis of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7083. [PMID: 28591049 DOI: 10.1097/MD.0000000000007083] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
217 El-Chemaly S, Malide D, Yao J, Nathan SD, Rosas IO, Gahl WA, Moss J, Gochuico BR. Glucose transporter-1 distribution in fibrotic lung disease: association with [¹⁸F]-2-fluoro-2-deoxyglucose-PET scan uptake, inflammation, and neovascularization. Chest 2013;143:1685-91. [PMID: 23699745 DOI: 10.1378/chest.12-1359] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
218 Tzouvelekis A, Yu G, Lino Cardenas CL, Herazo-Maya JD, Wang R, Woolard T, Zhang Y, Sakamoto K, Lee H, Yi JS, DeIuliis G, Xylourgidis N, Ahangari F, Lee PJ, Aidinis V, Herzog EL, Homer R, Bennett AM, Kaminski N. SH2 Domain-Containing Phosphatase-2 Is a Novel Antifibrotic Regulator in Pulmonary Fibrosis. Am J Respir Crit Care Med 2017;195:500-14. [PMID: 27736153 DOI: 10.1164/rccm.201602-0329OC] [Cited by in Crossref: 34] [Cited by in F6Publishing: 17] [Article Influence: 6.8] [Reference Citation Analysis]
219 Behr J, Hoeper MM, Kreuter M, Klotsche J, Wirtz H, Pittrow D. Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry. BMJ Open Respir Res 2014;1:e000010. [PMID: 25478169 DOI: 10.1136/bmjresp-2013-000010] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
220 Kim YB, Yoon YS, Choi YH, Park EM, Kang JL. Interaction of macrophages with apoptotic cells inhibits transdifferentiation and invasion of lung fibroblasts. Oncotarget 2017;8:112297-312. [PMID: 29348826 DOI: 10.18632/oncotarget.22737] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
221 Sisto M, Ribatti D, Lisi S. Organ Fibrosis and Autoimmunity: The Role of Inflammation in TGFβ-Dependent EMT. Biomolecules 2021;11:310. [PMID: 33670735 DOI: 10.3390/biom11020310] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
222 Baqué-Juston M, Mondot L, Leroy S, Padovani B. Multiple lung parenchymal abnormalities: Don't panic, let's be pragmatic! The 6 question rule - a checklist strategy. Diagn Interv Imaging 2014;95:361-76. [PMID: 24055120 DOI: 10.1016/j.diii.2013.08.014] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
223 Nurmi HM, Purokivi MK, Kärkkäinen MS, Kettunen HP, Selander TA, Kaarteenaho RL. Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes. BMC Pulm Med 2016;16:107. [PMID: 27461264 DOI: 10.1186/s12890-016-0269-2] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 4.8] [Reference Citation Analysis]
224 Ren H, Wang K, Yang H, Gao L. Efficacy and adverse events of pirfenidone in treating idiopathic pulmonary fibrosis. Saudi Med J 2017;38:889-94. [PMID: 28889145 DOI: 10.15537/smj.2017.9.19349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
225 Durheim MT, Hoffmann-Vold AM, Eagan TM, Hovden AO, Lund MB, Bjerke G, Birring SS, Jonassen TM, Johansen OE, Sjåheim T. ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF. BMJ Open Respir Res 2020;7:e000598. [PMID: 32576559 DOI: 10.1136/bmjresp-2020-000598] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
226 Kimura T, Nojiri T, Hino J, Hosoda H, Miura K, Shintani Y, Inoue M, Zenitani M, Takabatake H, Miyazato M, Okumura M, Kangawa K. C-type natriuretic peptide ameliorates pulmonary fibrosis by acting on lung fibroblasts in mice. Respir Res 2016;17:19. [PMID: 26895702 DOI: 10.1186/s12931-016-0335-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
227 Pereira DA, Kawassaki Ade M, Baldi BG. Interpretation of autoantibody positivity in interstitial lung disease and lung-dominant connective tissue disease. J Bras Pneumol 2013;39:728-41. [PMID: 24473767 DOI: 10.1590/S1806-37132013000600012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
228 Oh CK, Murray LA, Molfino NA. Smoking and idiopathic pulmonary fibrosis. Pulm Med 2012;2012:808260. [PMID: 22448328 DOI: 10.1155/2012/808260] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 3.5] [Reference Citation Analysis]
229 Diamantopoulos A, Maher TM, Schoof N, Esser D, LeReun C. Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use. Pharmacoecon Open 2019;3:81-91. [PMID: 29943133 DOI: 10.1007/s41669-018-0085-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
230 Li X, Yu R, Wang P, Wang A, Huang H. Effects of Exercise Training on Cardiopulmonary Function and Quality of Life in Elderly Patients with Pulmonary Fibrosis: A Meta-Analysis. Int J Environ Res Public Health 2021;18:7643. [PMID: 34300094 DOI: 10.3390/ijerph18147643] [Reference Citation Analysis]
231 Harari S, Madotto F, Caminati A, Conti S, Cesana G. Epidemiology of Idiopathic Pulmonary Fibrosis in Northern Italy. PLoS One 2016;11:e0147072. [PMID: 26841042 DOI: 10.1371/journal.pone.0147072] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
232 Tanizawa K, Ley B, Vittinghoff E, Elicker BM, Henry TS, Wolters PJ, Brownell R, Liu S, Collard HR, Jones KD. Significance of bronchiolocentric fibrosis in patients with histopathological usual interstitial pneumonia. Histopathology 2019;74:1088-97. [PMID: 30742318 DOI: 10.1111/his.13840] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
233 Kreuter M, Picker N, Schwarzkopf L, Baumann S, Cerani A, Postema R, Maywald U, Dittmar A, Langley J, Patel H. Epidemiology, healthcare utilization, and related costs among patients with IPF: results from a German claims database analysis. Respir Res 2022;23. [DOI: 10.1186/s12931-022-01976-0] [Reference Citation Analysis]
234 Rodríguez-Portal JA. Efficacy and Safety of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis: An Update. Drugs R D 2018;18:19-25. [PMID: 29209910 DOI: 10.1007/s40268-017-0221-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 4.5] [Reference Citation Analysis]
235 Mutsaers SE, Birnie K, Lansley S, Herrick SE, Lim CB, Prêle CM. Mesothelial cells in tissue repair and fibrosis. Front Pharmacol 2015;6:113. [PMID: 26106328 DOI: 10.3389/fphar.2015.00113] [Cited by in Crossref: 88] [Cited by in F6Publishing: 88] [Article Influence: 12.6] [Reference Citation Analysis]
236 Marchioni A, Tonelli R, Ball L, Fantini R, Castaniere I, Cerri S, Luppi F, Malerba M, Pelosi P, Clini E. Acute exacerbation of idiopathic pulmonary fibrosis: lessons learned from acute respiratory distress syndrome? Crit Care 2018;22:80. [PMID: 29566734 DOI: 10.1186/s13054-018-2002-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 6.3] [Reference Citation Analysis]
237 Park AM, Kanai K, Itoh T, Sato T, Tsukui T, Inagaki Y, Selman M, Matsushima K, Yoshie O. Heat Shock Protein 27 Plays a Pivotal Role in Myofibroblast Differentiation and in the Development of Bleomycin-Induced Pulmonary Fibrosis. PLoS One 2016;11:e0148998. [PMID: 26859835 DOI: 10.1371/journal.pone.0148998] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
238 Levin DL. Deep learning and the evaluation of pulmonary fibrosis. Lancet Respir Med 2018;6:803-5. [PMID: 30232047 DOI: 10.1016/S2213-2600(18)30371-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
239 Machado FVC, Bloem AEM, Schneeberger T, Jarosch I, Gloeckl R, Winterkamp S, Franssen FME, Koczulla AR, Pitta F, Spruit MA, Kenn K. Relationship between body composition, exercise capacity and health-related quality of life in idiopathic pulmonary fibrosis. BMJ Open Respir Res 2021;8:e001039. [PMID: 34711642 DOI: 10.1136/bmjresp-2021-001039] [Reference Citation Analysis]
240 Murray LA, Habiel DM, Hohmann M, Camelo A, Shang H, Zhou Y, Coelho AL, Peng X, Gulati M, Crestani B, Sleeman MA, Mustelin T, Moore MW, Ryu C, Osafo-Addo AD, Elias JA, Lee CG, Hu B, Herazo-Maya JD, Knight DA, Hogaboam CM, Herzog EL. Antifibrotic role of vascular endothelial growth factor in pulmonary fibrosis. JCI Insight 2017;2:92192. [PMID: 28814671 DOI: 10.1172/jci.insight.92192] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
241 Sturluson A, Huynh MT, Kaija AR, Laird C, Yoon S, Hou F, Feng Z, Wilmer CE, Colón YJ, Chung YG, Siderius DW, Simon CM. The role of molecular modelling and simulation in the discovery and deployment of metal-organic frameworks for gas storage and separation. Mol Simul 2019;45. [PMID: 31579352 DOI: 10.1080/08927022.2019.1648809] [Cited by in Crossref: 37] [Cited by in F6Publishing: 17] [Article Influence: 12.3] [Reference Citation Analysis]
242 Bier EA, Robertson SH, Schrank GM, Rackley C, Mammarappallil JG, Rajagopal S, McAdams HP, Driehuys B. A protocol for quantifying cardiogenic oscillations in dynamic 129 Xe gas exchange spectroscopy: The effects of idiopathic pulmonary fibrosis. NMR Biomed 2019;32:e4029. [PMID: 30457202 DOI: 10.1002/nbm.4029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
243 Kakugawa T, Tabata K, Ogawara D, Tsuchiya T, Hara S, Sakamoto N, Ishimatsu Y, Ashizawa K, Nagayasu T, Fukuoka J, Kohno S. Acute exacerbation of airspace enlargement with fibrosis. Respir Med Case Rep 2014;13:19-23. [PMID: 26029552 DOI: 10.1016/j.rmcr.2014.07.005] [Reference Citation Analysis]
244 Yoo JW, Kim J, Song JW. Impact of the revised definition on incidence and outcomes of acute exacerbation of idiopathic pulmonary fibrosis. Sci Rep 2022;12:8817. [PMID: 35614114 DOI: 10.1038/s41598-022-12693-5] [Reference Citation Analysis]
245 Awonuga AO, Chatzicharalampous C, Thakur M, Rambhatla A, Qadri F, Awonuga M, Saed G, Diamond MP. Genetic and Epidemiological Similarities, and Differences Between Postoperative Intraperitoneal Adhesion Development and Other Benign Fibro-proliferative Disorders. Reprod Sci 2021. [PMID: 34515982 DOI: 10.1007/s43032-021-00726-9] [Reference Citation Analysis]
246 Guler SA, Wohlfarth E, Berezowska S, Geiser TK, Ebner L, Funke-Chambour M. Performance of a diagnostic algorithm for fibrotic hypersensitivity pneumonitis. A case-control study. Respir Res 2021;22:120. [PMID: 33892724 DOI: 10.1186/s12931-021-01727-7] [Reference Citation Analysis]
247 Tokura S, Okuma T, Akira M, Arai T, Inoue Y, Kitaichi M. Utility of expiratory thin-section CT for fibrotic interstitial pneumonia. Acta Radiol 2014;55:1050-5. [PMID: 24252818 DOI: 10.1177/0284185113512300] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
248 Désogère P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med 2017;9:eaaf4696. [PMID: 28381537 DOI: 10.1126/scitranslmed.aaf4696] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 11.6] [Reference Citation Analysis]
249 Bonella F, Cottin V, Valenzuela C, Wijsenbeek M, Voss F, Rohr KB, Stowasser S, Maher TM. Meta-Analysis of Effect of Nintedanib on Reducing FVC Decline Across Interstitial Lung Diseases. Adv Ther 2022. [PMID: 35576048 DOI: 10.1007/s12325-022-02145-x] [Reference Citation Analysis]
250 Cho SJ, Moon JS, Nikahira K, Yun HS, Harris R, Hong KS, Huang H, Choi AMK, Stout-Delgado H. GLUT1-dependent glycolysis regulates exacerbation of fibrosis via AIM2 inflammasome activation. Thorax 2020;75:227-36. [PMID: 31822523 DOI: 10.1136/thoraxjnl-2019-213571] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 3.7] [Reference Citation Analysis]
251 Kaarteenaho R, Lappi-Blanco E. Tissue is an issue in the search for biomarkers in idiopathic pulmonary fibrosis. Fibrogenesis Tissue Repair 2015;8:3. [PMID: 25733981 DOI: 10.1186/s13069-015-0020-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
252 Yang M, Dong J, An J, Liu L, Chen L. Effect of anti-reflux therapy on pulmonary function in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. J Thorac Dis 2021;13:5776-87. [PMID: 34795926 DOI: 10.21037/jtd-21-771] [Reference Citation Analysis]
253 Kim SJ, Cheresh P, Jablonski RP, Rachek L, Yeldandi A, Piseaux-Aillon R, Ciesielski MJ, Ridge K, Gottardi C, Lam AP, Pardo A, Selman M, Natarajan V, Kamp DW. Mitochondrial 8-oxoguanine DNA glycosylase mitigates alveolar epithelial cell PINK1 deficiency, mitochondrial DNA damage, apoptosis, and lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2020;318:L1084-96. [PMID: 32209025 DOI: 10.1152/ajplung.00069.2019] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
254 Kishaba T. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Eurasian J Med 2017;49:204-6. [PMID: 29123445 DOI: 10.5152/eurasianjmed.2017.17219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
255 Evans CM, Fingerlin TE, Schwarz MI, Lynch D, Kurche J, Warg L, Yang IV, Schwartz DA. Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. Physiol Rev 2016;96:1567-91. [PMID: 27630174 DOI: 10.1152/physrev.00004.2016] [Cited by in Crossref: 108] [Cited by in F6Publishing: 98] [Article Influence: 21.6] [Reference Citation Analysis]
256 Jacobs SS, Krishnan JA, Lederer DJ, Ghazipura M, Hossain T, Tan AM, Carlin B, Drummond MB, Ekström M, Garvey C, Graney BA, Jackson B, Kallstrom T, Knight SL, Lindell K, Prieto-Centurion V, Renzoni EA, Ryerson CJ, Schneidman A, Swigris J, Upson D, Holland AE. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020;202:e121-41. [PMID: 33185464 DOI: 10.1164/rccm.202009-3608ST] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
257 Aghaei M, Dastghaib S, Aftabi S, Aghanoori MR, Alizadeh J, Mokarram P, Mehrbod P, Ashrafizadeh M, Zarrabi A, McAlinden KD, Eapen MS, Sohal SS, Sharma P, Zeki AA, Ghavami S. The ER Stress/UPR Axis in Chronic Obstructive Pulmonary Disease and Idiopathic Pulmonary Fibrosis. Life (Basel) 2020;11:1. [PMID: 33374938 DOI: 10.3390/life11010001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
258 Xu X, Dai H, Geng J, Wan X, Huang X, Li F, Jiang D, Wang C. Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase. Lab Invest 2015;95:846-59. [PMID: 26192087 DOI: 10.1038/labinvest.2015.68] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
259 Agassandian M, Tedrow JR, Sembrat J, Kass DJ, Zhang Y, Goncharova EA, Kaminski N, Mallampalli RK, Vuga LJ. VCAM-1 is a TGF-β1 inducible gene upregulated in idiopathic pulmonary fibrosis. Cell Signal 2015;27:2467-73. [PMID: 26386411 DOI: 10.1016/j.cellsig.2015.09.003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.6] [Reference Citation Analysis]
260 Kishaba T, Nagano H, Nei Y, Yamashiro S. Clinical characteristics of idiopathic pulmonary fibrosis patients according to their smoking status. J Thorac Dis 2016;8:1112-20. [PMID: 27293827 DOI: 10.21037/jtd.2016.03.89] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
261 Tyagi R, Kant S, Pradhan A, Wakhlu A, Bajaj DK, Bajpai J. Estimates of Prevalence of Pulmonary Hypertension according to Different International Definitions. Can Respir J 2021;2021:1385322. [PMID: 34876943 DOI: 10.1155/2021/1385322] [Reference Citation Analysis]
262 Novelli L, Aliberti S, Pesci A. Dyspnea in crackling lungs. Eur J Intern Med 2014;25:e115-6. [PMID: 24998757 DOI: 10.1016/j.ejim.2014.06.011] [Reference Citation Analysis]
263 Guiot J, Henket M, Corhay JL, Moermans C, Louis R. Sputum biomarkers in IPF: Evidence for raised gene expression and protein level of IGFBP-2, IL-8 and MMP-7. PLoS One 2017;12:e0171344. [PMID: 28178340 DOI: 10.1371/journal.pone.0171344] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
264 Goda C, Balli D, Black M, Milewski D, Le T, Ustiyan V, Ren X, Kalinichenko VV, Kalin TV. Loss of FOXM1 in macrophages promotes pulmonary fibrosis by activating p38 MAPK signaling pathway. PLoS Genet 2020;16:e1008692. [PMID: 32271749 DOI: 10.1371/journal.pgen.1008692] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
265 Morell F. Fibrosis pulmonar ¿idiopática?: una forma de presentación de otras fibrosis pulmonares. Archivos de Bronconeumología 2020;56:773-4. [DOI: 10.1016/j.arbres.2019.12.014] [Reference Citation Analysis]
266 Tomaru A, Kobayashi T, Hinneh JA, Baffour Tonto P, D'Alessandro-Gabazza CN, Fujimoto H, Fujiwara K, Takahashi Y, Ohnishi M, Yasuma T, Nishihama K, Yoshino M, Takao K, Toda M, Totoki T, Takei Y, Yoshikawa K, Taguchi O, Gabazza EC. Oligonucleotide-targeting periostin ameliorates pulmonary fibrosis. Gene Ther 2017;24:706-16. [PMID: 28820502 DOI: 10.1038/gt.2017.80] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
267 Veerappan A, O'Connor NJ, Brazin J, Reid AC, Jung A, McGee D, Summers B, Branch-Elliman D, Stiles B, Worgall S, Kaner RJ, Silver RB. Mast cells: a pivotal role in pulmonary fibrosis. DNA Cell Biol 2013;32:206-18. [PMID: 23570576 DOI: 10.1089/dna.2013.2005] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 5.4] [Reference Citation Analysis]
268 Russell AM, Ripamonti E, Vancheri C. Qualitative European survey of patients with idiopathic pulmonary fibrosis: patients' perspectives of the disease and treatment. BMC Pulm Med 2016;16:10. [PMID: 26762154 DOI: 10.1186/s12890-016-0171-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 8.3] [Reference Citation Analysis]
269 Morisset J, Johannson KA, Jones KD, Wolters PJ, Collard HR, Walsh SLF, Ley B; HP Delphi Collaborators. Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. Am J Respir Crit Care Med 2018;197:1036-44. [PMID: 29172641 DOI: 10.1164/rccm.201710-1986OC] [Cited by in Crossref: 104] [Cited by in F6Publishing: 43] [Article Influence: 20.8] [Reference Citation Analysis]
270 Polastri M, Loforte A, Dell'amore A, Swol J. Physiotherapy and artificial lungs: looking to the future. International Journal of Therapy and Rehabilitation 2021;28:1-4. [DOI: 10.12968/ijtr.2021.0103] [Reference Citation Analysis]
271 Zhao H, Chan-Li Y, Collins SL, Zhang Y, Hallowell RW, Mitzner W, Horton MR. Pulmonary delivery of docosahexaenoic acid mitigates bleomycin-induced pulmonary fibrosis. BMC Pulm Med 2014;14:64. [PMID: 24742272 DOI: 10.1186/1471-2466-14-64] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
272 Garrison G, Huang SK, Okunishi K, Scott JP, Kumar Penke LR, Scruggs AM, Peters-Golden M. Reversal of myofibroblast differentiation by prostaglandin E(2). Am J Respir Cell Mol Biol 2013;48:550-8. [PMID: 23470625 DOI: 10.1165/rcmb.2012-0262OC] [Cited by in Crossref: 66] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
273 Chen WC, Chen NJ, Chen HP, Yu WK, Su VY, Chen H, Wu HH, Yang KY. Nintedanib Reduces Neutrophil Chemotaxis via Activating GRK2 in Bleomycin-Induced Pulmonary Fibrosis. Int J Mol Sci 2020;21:E4735. [PMID: 32630825 DOI: 10.3390/ijms21134735] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
274 Zou RH, Kass DJ, Gibson KF, Lindell KO. The Role of Palliative Care in Reducing Symptoms and Improving Quality of Life for Patients with Idiopathic Pulmonary Fibrosis: A Review. Pulm Ther 2020;6:35-46. [PMID: 32048243 DOI: 10.1007/s41030-019-00108-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
275 Vuga LJ, Milosevic J, Pandit K, Ben-Yehudah A, Chu Y, Richards T, Sciurba J, Myerburg M, Zhang Y, Parwani AV, Gibson KF, Kaminski N. Cartilage oligomeric matrix protein in idiopathic pulmonary fibrosis. PLoS One 2013;8:e83120. [PMID: 24376648 DOI: 10.1371/journal.pone.0083120] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
276 Lavelle LP, Brady D, McEvoy S, Murphy D, Gibney B, Gallagher A, Butler M, Shortt F, McMullen M, Fabre A, Lynch DA, Keane MP, Dodd JD. Pulmonary fibrosis: tissue characterization using late-enhanced MRI compared with unenhanced anatomic high-resolution CT. Diagn Interv Radiol 2017;23:106-11. [PMID: 28067202 DOI: 10.5152/dir.2016.15331] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
277 Inomata M, Kamio K, Azuma A, Matsuda K, Kokuho N, Miura Y, Hayashi H, Nei T, Fujita K, Saito Y. Pirfenidone inhibits fibrocyte accumulation in the lungs in bleomycin-induced murine pulmonary fibrosis. Respir Res. 2014;15:16. [PMID: 24507087 DOI: 10.1186/1465-9921-15-16] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 9.8] [Reference Citation Analysis]
278 Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE Jr, Wolters PJ, Collard HR, Ley B. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax 2017;72:424-9. [PMID: 28082530 DOI: 10.1136/thoraxjnl-2016-209671] [Cited by in Crossref: 73] [Cited by in F6Publishing: 53] [Article Influence: 14.6] [Reference Citation Analysis]
279 Zeinali S, Bichsel CA, Hobi N, Funke M, Marti TM, Schmid RA, Guenat OT, Geiser T. Human microvasculature-on-a chip: anti-neovasculogenic effect of nintedanib in vitro. Angiogenesis 2018;21:861-71. [PMID: 29967964 DOI: 10.1007/s10456-018-9631-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
280 Mori S. Management of Rheumatoid Arthritis Patients with Interstitial Lung Disease: Safety of Biological Antirheumatic Drugs and Assessment of Pulmonary Fibrosis. Clin Med Insights Circ Respir Pulm Med 2015;9:41-9. [PMID: 26401101 DOI: 10.4137/CCRPM.S23288] [Cited by in Crossref: 3] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
281 Zuo WL, Zhao JM, Huang JX, Zhou W, Lei ZH, Huang YM, Huang YF, Li HG. Effect of bosentan is correlated with MMP-9/TIMP-1 ratio in bleomycin-induced pulmonary fibrosis. Biomed Rep 2017;6:201-5. [PMID: 28357073 DOI: 10.3892/br.2016.832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
282 Rad P, Karlsson CA, Janson C. Idiopathic fibrotic lung disease at a university hospital setting: management and prognostic factors. Eur Clin Respir J 2015;2. [PMID: 26557254 DOI: 10.3402/ecrj.v2.26915] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
283 Choi S, Woo JK, Jang YS, Kang JH, Hwang JI, Seong JK, Yoon YS, Oh SH. Ninjurin1 Plays a Crucial Role in Pulmonary Fibrosis by Promoting Interaction between Macrophages and Alveolar Epithelial Cells. Sci Rep 2018;8:17542. [PMID: 30510259 DOI: 10.1038/s41598-018-35997-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
284 Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C. Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet 2019;58:1131-47. [PMID: 31016670 DOI: 10.1007/s40262-019-00766-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 13.5] [Reference Citation Analysis]
285 Mortensen A, Cherrier L, Walia R. Effect of pirfenidone on wound healing in lung transplant patients. Multidiscip Respir Med 2018;13:16. [PMID: 29946463 DOI: 10.1186/s40248-018-0129-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
286 Song MJ, Lee SH, Jung JY, Kang YA, Park MS, Kim YS, Chang J, Kim SY. Effectiveness of pirfenidone in idiopathic pulmonary fibrosis according to the autoantibody status: a retrospective cohort study. BMC Pulm Med 2021;21:145. [PMID: 33941141 DOI: 10.1186/s12890-021-01516-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
287 Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, Park CS, Park SW, Jeong SH, Park YB, Lee HL, Shin JW, Lee EJ, Lee JH, Jegal Y, Lee HK, Kim YH, Song JW, Park MS. Comparison of CPI and GAP models in patients with idiopathic pulmonary fibrosis: a nationwide cohort study. Sci Rep 2018;8:4784. [PMID: 29555917 DOI: 10.1038/s41598-018-23073-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
288 Merino A, Hoogduijn MJ, Molina-Molina M, Arias-Salgado EG, Korevaar SS, Baan CC, Montes-Worboys A. Membrane particles from mesenchymal stromal cells reduce the expression of fibrotic markers on pulmonary cells. PLoS One 2021;16:e0248415. [PMID: 33730089 DOI: 10.1371/journal.pone.0248415] [Reference Citation Analysis]
289 Zhou Y, Peng H, Sun H, Peng X, Tang C, Gan Y, Chen X, Mathur A, Hu B, Slade MD, Montgomery RR, Shaw AC, Homer RJ, White ES, Lee CM, Moore MW, Gulati M, Lee CG, Elias JA, Herzog EL. Chitinase 3-like 1 suppresses injury and promotes fibroproliferative responses in Mammalian lung fibrosis. Sci Transl Med 2014;6:240ra76. [PMID: 24920662 DOI: 10.1126/scitranslmed.3007096] [Cited by in Crossref: 97] [Cited by in F6Publishing: 93] [Article Influence: 13.9] [Reference Citation Analysis]
290 Divo MJ, Martinez CH, Mannino DM. Ageing and the epidemiology of multimorbidity. Eur Respir J. 2014;44:1055-1068. [PMID: 25142482 DOI: 10.1183/09031936.00059814] [Cited by in Crossref: 168] [Cited by in F6Publishing: 148] [Article Influence: 21.0] [Reference Citation Analysis]
291 Vaz Fragoso CA, Gill TM. Respiratory impairment and the aging lung: a novel paradigm for assessing pulmonary function. J Gerontol A Biol Sci Med Sci 2012;67:264-75. [PMID: 22138206 DOI: 10.1093/gerona/glr198] [Cited by in Crossref: 83] [Cited by in F6Publishing: 74] [Article Influence: 7.5] [Reference Citation Analysis]
292 Fraser E, Denney L, Antanaviciute A, Blirando K, Vuppusetty C, Zheng Y, Repapi E, Iotchkova V, Taylor S, Ashley N, St Noble V, Benamore R, Hoyles R, Clelland C, Rastrick JMD, Hardman CS, Alham NK, Rigby RE, Simmons A, Rehwinkel J, Ho LP. Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune Phenotype. Front Immunol 2021;12:623430. [PMID: 33746960 DOI: 10.3389/fimmu.2021.623430] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
293 Liu Y, Lu F, Kang L, Wang Z, Wang Y. Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by regulating Nrf2/Bach1 equilibrium. BMC Pulm Med 2017;17:63. [PMID: 28420366 DOI: 10.1186/s12890-017-0405-7] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
294 Huang Y, Ma SF, Espindola MS, Vij R, Oldham JM, Huffnagle GB, Erb-Downward JR, Flaherty KR, Moore BB, White ES, Zhou T, Li J, Lussier YA, Han MK, Kaminski N, Garcia JGN, Hogaboam CM, Martinez FJ, Noth I; COMET-IPF Investigators. Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2017;196:208-19. [PMID: 28157391 DOI: 10.1164/rccm.201607-1525OC] [Cited by in Crossref: 74] [Cited by in F6Publishing: 52] [Article Influence: 14.8] [Reference Citation Analysis]
295 Juge PA, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, Kannengiesser C, Ottaviani S, Oka S, Tohma S, Tsuchiya N, Rojas-Serrano J, González-Pérez MI, Mejía M, Buendía-Roldán I, Falfán-Valencia R, Ambrocio-Ortiz E, Manali E, Papiris SA, Karageorgas T, Boumpas D, Antoniou K, van Moorsel CHM, van der Vis J, de Man YA, Grutters JC, Wang Y, Borie R, Wemeau-Stervinou L, Wallaert B, Flipo RM, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Marchand-Adam S, Frazier A, Richette P, Allanore Y, Sibilia J, Dromer C, Richez C, Schaeverbeke T, Lioté H, Thabut G, Nathan N, Amselem S, Soubrier M, Cottin V, Clément A, Deane K, Walts AD, Fingerlin T, Fischer A, Ryu JH, Matteson EL, Niewold TB, Assayag D, Gross A, Wolters P, Schwarz MI, Holers M, Solomon JJ, Doyle T, Rosas IO, Blauwendraat C, Nalls MA, Debray MP, Boileau C, Crestani B, Schwartz DA, Dieudé P. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease. N Engl J Med 2018;379:2209-19. [PMID: 30345907 DOI: 10.1056/NEJMoa1801562] [Cited by in Crossref: 144] [Cited by in F6Publishing: 67] [Article Influence: 36.0] [Reference Citation Analysis]
296 Sheth JS, Belperio JA, Fishbein MC, Kazerooni EA, Lagstein A, Murray S, Myers JL, Simon RH, Sisson TH, Sundaram B, White ES, Xia M, Zisman D, Flaherty KR. Utility of Transbronchial vs Surgical Lung Biopsy in the Diagnosis of Suspected Fibrotic Interstitial Lung Disease. Chest 2017;151:389-99. [PMID: 27729263 DOI: 10.1016/j.chest.2016.09.028] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 8.2] [Reference Citation Analysis]
297 Doyle TJ, Lee JS, Dellaripa PF, Lederer JA, Matteson EL, Fischer A, Ascherman DP, Glassberg MK, Ryu JH, Danoff SK, Brown KK, Collard HR, Rosas IO. A roadmap to promote clinical and translational research in rheumatoid arthritis-associated interstitial lung disease. Chest 2014;145:454-63. [PMID: 24590021 DOI: 10.1378/chest.13-2408] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
298 Nakagawa H, Ogawa E, Fukunaga K, Kinose D, Yamaguchi M, Nagao T, Tanaka-Mizuno S, Nakano Y. Quantitative CT analysis of honeycombing area predicts mortality in idiopathic pulmonary fibrosis with definite usual interstitial pneumonia pattern: A retrospective cohort study. PLoS One 2019;14:e0214278. [PMID: 30897161 DOI: 10.1371/journal.pone.0214278] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
299 Meng P, Tan GL, Low SY, Takano A, Ng YL, Anantham D. Fibred confocal fluorescence microscopy in the diagnosis of interstitial lung diseases. J Thorac Dis 2016;8:3505-14. [PMID: 28149543 DOI: 10.21037/jtd.2016.12.60] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
300 Zheng J, Dong H, Zhang T, Ning J, Xu Y, Cai C. Development and Validation of a Novel Gene Signature for Predicting the Prognosis of Idiopathic Pulmonary Fibrosis Based on Three Epithelial-Mesenchymal Transition and Immune-Related Genes. Front Genet 2022;13:865052. [PMID: 35559024 DOI: 10.3389/fgene.2022.865052] [Reference Citation Analysis]
301 Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, Kreuter M, Lynch DA, Maher TM, Martinez FJ, Molina-Molina M, Myers JL, Nicholson AG, Ryerson CJ, Strek ME, Troy LK, Wijsenbeek M, Mammen MJ, Hossain T, Bissell BD, Herman DD, Hon SM, Kheir F, Khor YH, Macrea M, Antoniou KM, Bouros D, Buendia-Roldan I, Caro F, Crestani B, Ho L, Morisset J, Olson AL, Podolanczuk A, Poletti V, Selman M, Ewing T, Jones S, Knight SL, Ghazipura M, Wilson KC. Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 2022;205:e18-47. [PMID: 35486072 DOI: 10.1164/rccm.202202-0399ST] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
302 Nishiyama O, Yamazaki R, Sano H, Iwanaga T, Higashimoto Y, Kume H, Tohda Y. Pulmonary Hemodynamics and Six-Minute Walk Test Outcomes in Patients with Interstitial Lung Disease. Can Respir J 2016;2016:3837182. [PMID: 27445533 DOI: 10.1155/2016/3837182] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
303 Kakugawa T, Yokota S, Ishimatsu Y, Hayashi T, Nakashima S, Hara S, Sakamoto N, Kubota H, Mine M, Matsuoka Y, Mukae H, Nagata K, Kohno S. Serum heat shock protein 47 levels are elevated in acute interstitial pneumonia. BMC Pulm Med 2014;14:48. [PMID: 24650086 DOI: 10.1186/1471-2466-14-48] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
304 Proesmans VLJ, Drent M, Elfferich MDP, Wijnen PAHM, Jessurun NT, Bast A. Self-reported Gastrointestinal Side Effects of Antifibrotic Drugs in Dutch Idiopathic Pulmonary Fibrosis patients. Lung 2019;197:551-8. [PMID: 31440832 DOI: 10.1007/s00408-019-00260-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
305 Guiot J, Bondue B, Henket M, Corhay JL, Louis R. Raised serum levels of IGFBP-1 and IGFBP-2 in idiopathic pulmonary fibrosis. BMC Pulm Med 2016;16:86. [PMID: 27215343 DOI: 10.1186/s12890-016-0249-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 5.7] [Reference Citation Analysis]
306 Kagimoto A, Tsutani Y, Handa Y, Mimae T, Miyata Y, Okada M. Prediction of Acute Exacerbation of Interstitial Pneumonia Using Visual Evaluation of PET. Ann Thorac Surg 2021;112:264-70. [PMID: 33058828 DOI: 10.1016/j.athoracsur.2020.08.018] [Reference Citation Analysis]
307 Epa AP, Thatcher TH, Pollock SJ, Wahl LA, Lyda E, Kottmann RM, Phipps RP, Sime PJ. Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-β Induced Myofibroblast Differentiation via Prostaglandin E2. PLoS One 2015;10:e0135266. [PMID: 26248335 DOI: 10.1371/journal.pone.0135266] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 4.1] [Reference Citation Analysis]
308 Tanaka Y, Suzuki Y, Hasegawa H, Yokomura K, Fukada A, Inoue Y, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Suda T. Standardised 3D-CT lung volumes for patients with idiopathic pulmonary fibrosis. Respir Res 2022;23:142. [PMID: 35650599 DOI: 10.1186/s12931-022-02062-1] [Reference Citation Analysis]
309 Hoffman M, Mellerick C, Symons K, Glaspole I, Holland AE. Pulmonary rehabilitation for interstitial lung disease: Referral and patient experiences. Chron Respir Dis 2021;18:14799731211046022. [PMID: 34637351 DOI: 10.1177/14799731211046022] [Reference Citation Analysis]
310 He Y, Shang Y, Li Y, Wang M, Yu D, Yang Y, Ning S, Chen H. An 8-ferroptosis-related genes signature from Bronchoalveolar Lavage Fluid for prognosis in patients with idiopathic pulmonary fibrosis. BMC Pulm Med 2022;22:15. [PMID: 34983465 DOI: 10.1186/s12890-021-01799-7] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
311 Hoffmann T, Oelzner P, Busch M, Franz M, Teichgräber U, Kroegel C, Schulze P, Wolf G, Pfeil A. Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases. Diagnostics 2022;12:67. [DOI: 10.3390/diagnostics12010067] [Reference Citation Analysis]
312 Stefano A, Gioè M, Russo G, Palmucci S, Torrisi SE, Bignardi S, Basile A, Comelli A, Benfante V, Sambataro G, Falsaperla D, Torcitto AG, Attanasio M, Yezzi A, Vancheri C. Performance of Radiomics Features in the Quantification of Idiopathic Pulmonary Fibrosis from HRCT. Diagnostics (Basel) 2020;10:E306. [PMID: 32429182 DOI: 10.3390/diagnostics10050306] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
313 Kishaba T, Shimaoka Y, Fukuyama H, Nagano H, Nei Y, Yamashiro S, Tamaki H. Clinical characteristics of idiopathic pulmonary fibrosis patients with gender, age, and physiology staging at Okinawa Chubu Hospital. J Thorac Dis 2015;7:843-9. [PMID: 26101639 DOI: 10.3978/j.issn.2072-1439.2015.04.54] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
314 Pleasants R, Tighe RM. Management of Idiopathic Pulmonary Fibrosis. Ann Pharmacother 2019;53:1238-48. [PMID: 31280590 DOI: 10.1177/1060028019862497] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
315 Tsujino K, Takeda Y, Arai T, Shintani Y, Inagaki R, Saiga H, Iwasaki T, Tetsumoto S, Jin Y, Ihara S, Minami T, Suzuki M, Nagatomo I, Inoue K, Kida H, Kijima T, Ito M, Kitaichi M, Inoue Y, Tachibana I, Takeda K, Okumura M, Hemler ME, Kumanogoh A. Tetraspanin CD151 protects against pulmonary fibrosis by maintaining epithelial integrity. Am J Respir Crit Care Med 2012;186:170-80. [PMID: 22592804 DOI: 10.1164/rccm.201201-0117OC] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
316 Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med 2014;190:867-78. [PMID: 25090037 DOI: 10.1164/rccm.201403-0509PP] [Cited by in Crossref: 154] [Cited by in F6Publishing: 81] [Article Influence: 19.3] [Reference Citation Analysis]
317 Maccarinelli F, Bugatti M, Churruca Schuind A, Ganzerla S, Vermi W, Presta M, Ronca R. Endogenous Long Pentraxin 3 Exerts a Protective Role in a Murine Model of Pulmonary Fibrosis. Front Immunol 2021;12:617671. [PMID: 33679758 DOI: 10.3389/fimmu.2021.617671] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
318 Abdalla M, Sabbineni H, Prakash R, Ergul A, Fagan SC, Somanath PR. The Akt inhibitor, triciribine, ameliorates chronic hypoxia-induced vascular pruning and TGFβ-induced pulmonary fibrosis. Br J Pharmacol 2015;172:4173-88. [PMID: 26033700 DOI: 10.1111/bph.13203] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
319 Campo A, González-Ruiz JM, Andreu E, Alcaide AB, Ocón MM, De-Torres J, Pueyo J, Cordovilla R, Villaron E, Sanchez-Guijo F, Barrueco M, Nuñez-Córdoba J, Prósper F, Zulueta JJ. Endobronchial autologous bone marrow-mesenchymal stromal cells in idiopathic pulmonary fibrosis: a phase I trial. ERJ Open Res 2021;7:00773-2020. [PMID: 34195252 DOI: 10.1183/23120541.00773-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Takahashi K, Taniguchi H, Ando M, Sakamoto K, Kondoh Y, Watanabe N, Kimura T, Kataoka K, Suzuki A, Ito S, Hasegawa Y. Mean pulmonary arterial pressure as a prognostic indicator in connective tissue disease associated with interstitial lung disease: a retrospective cohort study. BMC Pulm Med 2016;16:55. [PMID: 27094018 DOI: 10.1186/s12890-016-0207-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
321 Sullivan DI, Jiang M, Hinchie AM, Roth MG, Bahudhanapati H, Nouraie M, Liu J, McDyer JF, Mallampalli RK, Zhang Y, Kass DJ, Finkel T, Alder JK. Transcriptional and Proteomic Characterization of Telomere-Induced Senescence in a Human Alveolar Epithelial Cell Line. Front Med (Lausanne) 2021;8:600626. [PMID: 33634147 DOI: 10.3389/fmed.2021.600626] [Reference Citation Analysis]
322 Sugino K, Kobayashi M, Nakamura Y, Gocho K, Ishida F, Isobe K, Shiraga N, Homma S. Xenon-Enhanced Dual-Energy CT Imaging in Combined Pulmonary Fibrosis and Emphysema. PLoS One 2017;12:e0170289. [PMID: 28107411 DOI: 10.1371/journal.pone.0170289] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
323 Wuyts WA, Kolb M, Stowasser S, Stansen W, Huggins JT, Raghu G. First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value. Lung 2016;194:739-43. [PMID: 27377558 DOI: 10.1007/s00408-016-9912-1] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 10.7] [Reference Citation Analysis]
324 Rathinasabapathy A, Horowitz A, Horton K, Kumar A, Gladson S, Unger T, Martinez D, Bedse G, West J, Raizada MK, Steckelings UM, Sumners C, Katovich MJ, Shenoy V. The Selective Angiotensin II Type 2 Receptor Agonist, Compound 21, Attenuates the Progression of Lung Fibrosis and Pulmonary Hypertension in an Experimental Model of Bleomycin-Induced Lung Injury. Front Physiol 2018;9:180. [PMID: 29636695 DOI: 10.3389/fphys.2018.00180] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 6.5] [Reference Citation Analysis]
325 Koo HJ, Do KH, Lee JB, Alblushi S, Lee SM. Lung Cancer in Combined Pulmonary Fibrosis and Emphysema: A Systematic Review and Meta-Analysis. PLoS One 2016;11:e0161437. [PMID: 27618692 DOI: 10.1371/journal.pone.0161437] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
326 Calvello M, Flore MC, Richeldi L. Novel drug targets in idiopathic pulmonary fibrosis. Expert Opinion on Orphan Drugs 2019;7:125-46. [DOI: 10.1080/21678707.2019.1590196] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
327 Ryerson CJ, Corte TJ, Martinez FJ, Collard HR. Reply: The New Idiopathic Pulmonary Fibrosis Acute Exacerbations Document: One Step Ahead but Still Suspended in the Air. Am J Respir Crit Care Med 2017;195:269. [PMID: 28084823 DOI: 10.1164/rccm.201608-1607LE] [Reference Citation Analysis]
328 Oliveira MR, Pereira DA, Dias OM, Kairalla RA, Carvalho CR, Baldi BG. Idiopathic pulmonary fibrosis can be a transient diagnosis. J Bras Pneumol 2016;42:74-5. [PMID: 26982047 DOI: 10.1590/S1806-37562016000000003] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
329 Magnani D, Lenoci G, Balduzzi S, Artioli G, Ferri P. Effectiveness of support groups to improve the quality of life of people with idiopathic pulmonary fibrosis a pre-post test pilot study. Acta Biomed 2017;88:5-12. [PMID: 29189700 DOI: 10.23750/abm.v88i5-S.6870] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
330 Samarelli AV, Tonelli R, Marchioni A, Bruzzi G, Gozzi F, Andrisani D, Castaniere I, Manicardi L, Moretti A, Tabbì L, Cerri S, Beghè B, Dominici M, Clini E. Fibrotic Idiopathic Interstitial Lung Disease: The Molecular and Cellular Key Players. Int J Mol Sci 2021;22:8952. [PMID: 34445658 DOI: 10.3390/ijms22168952] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
331 Wilfong EM, Lentz RJ, Guttentag A, Tolle JJ, Johnson JE, Kropski JA, Kendall PL, Blackwell TS, Crofford LJ. Interstitial Pneumonia With Autoimmune Features: An Emerging Challenge at the Intersection of Rheumatology and Pulmonology. Arthritis Rheumatol 2018;70:1901-13. [PMID: 30058242 DOI: 10.1002/art.40679] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
332 Tsitoura E, Vasarmidi E, Bibaki E, Trachalaki A, Koutoulaki C, Papastratigakis G, Papadogiorgaki S, Chalepakis G, Tzanakis N, Antoniou KM. Accumulation of damaged mitochondria in alveolar macrophages with reduced OXPHOS related gene expression in IPF. Respir Res 2019;20:264. [PMID: 31775876 DOI: 10.1186/s12931-019-1196-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
333 Tjin G, White ES, Faiz A, Sicard D, Tschumperlin DJ, Mahar A, Kable EPW, Burgess JK. Lysyl oxidases regulate fibrillar collagen remodelling in idiopathic pulmonary fibrosis. Dis Model Mech 2017;10:1301-12. [PMID: 29125826 DOI: 10.1242/dmm.030114] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 11.8] [Reference Citation Analysis]
334 Bendstrup E, Hyldgaard C, Altraja A, Sjåheim T, Myllärniemi M, Gudmundsson G, Sköld M, Hilberg O. Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries. Eur Clin Respir J 2015;2. [PMID: 26557259 DOI: 10.3402/ecrj.v2.28348] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
335 Hoyer N, Thomsen LH, Wille MMW, Wilcke T, Dirksen A, Pedersen JH, Saghir Z, Ashraf H, Shaker SB. Increased respiratory morbidity in individuals with interstitial lung abnormalities. BMC Pulm Med 2020;20:67. [PMID: 32188453 DOI: 10.1186/s12890-020-1107-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
336 Tielemans B, Dekoster K, Verleden SE, Sawall S, Leszczyński B, Laperre K, Vanstapel A, Verschakelen J, Kachelriess M, Verbeken E, Swoger J, Vande Velde G. From Mouse to Man and Back: Closing the Correlation Gap between Imaging and Histopathology for Lung Diseases. Diagnostics (Basel) 2020;10:E636. [PMID: 32859103 DOI: 10.3390/diagnostics10090636] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
337 Case AH, Hellkamp AS, Neely ML, Bender S, Dilling DF, Gulati M, Hotchkin DL, Huie TJ, Lancaster L, Snyder LD, Conoscenti CS, Palmer SM. Associations between Patient-reported Outcomes and Death or Lung Transplant in Idiopathic Pulmonary Fibrosis. Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry. Ann Am Thorac Soc 2020;17:699-705. [PMID: 32040340 DOI: 10.1513/AnnalsATS.201906-437OC] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
338 Johannson KA, Vittinghoff E, Morisset J, Wolters PJ, Noth EM, Balmes JR, Collard HR. Air Pollution Exposure Is Associated With Lower Lung Function, but Not Changes in Lung Function, in Patients With Idiopathic Pulmonary Fibrosis. Chest 2018;154:119-25. [PMID: 29355549 DOI: 10.1016/j.chest.2018.01.015] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
339 Liu J, Deng Y, Wang Z, Mo B, Wei J, Cheng Z, Peng Q, Wei G, Li J, Shu Y, Yang H, Fang S, Luo G, Yang S, Wang Y, Zhu J, Yang J, Wu M, Xu X, Ge R, Zhang X, Xiong W, Wang X, Li Z. A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese. J Clin Lab Anal 2021;35:e23782. [PMID: 33942374 DOI: 10.1002/jcla.23782] [Reference Citation Analysis]
340 Xiao X, Senavirathna LK, Gou X, Huang C, Liang Y, Liu L. EZH2 enhances the differentiation of fibroblasts into myofibroblasts in idiopathic pulmonary fibrosis. Physiol Rep 2016;4:e12915. [PMID: 27582065 DOI: 10.14814/phy2.12915] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 5.8] [Reference Citation Analysis]
341 Cottin V, Bonniaud P, Cadranel J, Crestani B, Jouneau S, Marchand-Adam S, Nunes H, Wémeau-Stervinou L, Bergot E, Blanchard E, Borie R, Bourdin A, Chenivesse C, Clément A, Gomez E, Gondouin A, Hirschi S, Lebargy F, Marquette CH, Montani D, Prévot G, Quetant S, Reynaud-Gaubert M, Salaun M, Sanchez O, Trumbic B, Berkani K, Brillet PY, Campana M, Chalabreysse L, Chatté G, Debieuvre D, Ferretti G, Fourrier JM, Just N, Kambouchner M, Legrand B, Le Guillou F, Lhuillier JP, Mehdaoui A, Naccache JM, Paganon C, Rémy-Jardin M, Si-Mohamed S, Terrioux P; OrphaLung. [French practical guidelines for the diagnosis and management of IPF - 2021 update, short version]. Rev Mal Respir 2022:S0761-8425(22)00026-2. [PMID: 35304014 DOI: 10.1016/j.rmr.2022.01.005] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
342 Scholand MB, Coon H, Wolff R, Cannon-Albright L. Use of a genealogical database demonstrates heritability of pulmonary fibrosis. Lung 2013;191:475-81. [PMID: 23867963 DOI: 10.1007/s00408-013-9484-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
343 Nakano A, Ohkubo H, Fukumitsu K, Fukuda S, Kanemitsu Y, Takemura M, Maeno K, Ito Y, Oguri T, Niimi A. Remarkable Improvement in a Patient with Idiopathic Pulmonary Fibrosis after Treatment with Nintedanib. Intern Med 2019;58:1141-4. [PMID: 30568147 DOI: 10.2169/internalmedicine.1890-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
344 Saito A, Horie M, Micke P, Nagase T. The Role of TGF-β Signaling in Lung Cancer Associated with Idiopathic Pulmonary Fibrosis. Int J Mol Sci 2018;19:E3611. [PMID: 30445777 DOI: 10.3390/ijms19113611] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 5.8] [Reference Citation Analysis]
345 Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res 2021;22:257. [PMID: 34592998 DOI: 10.1186/s12931-021-01851-4] [Reference Citation Analysis]
346 Tatler AL, Habgood A, Porte J, John AE, Stavrou A, Hodge E, Kerama-Likoko C, Violette SM, Weinreb PH, Knox AJ, Laurent G, Parfrey H, Wolters PJ, Wallace W, Alberti S, Nordheim A, Jenkins G. Reduced Ets Domain-containing Protein Elk1 Promotes Pulmonary Fibrosis via Increased Integrin αvβ6 Expression. J Biol Chem 2016;291:9540-53. [PMID: 26861876 DOI: 10.1074/jbc.M115.692368] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
347 Cherubini E, Mariotta S, Scozzi D, Mancini R, Osman G, D'Ascanio M, Bruno P, Cardillo G, Ricci A. BDNF/TrkB axis activation promotes epithelial-mesenchymal transition in idiopathic pulmonary fibrosis. J Transl Med. 2017;15:196. [PMID: 28938915 DOI: 10.1186/s12967-017-1298-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
348 Doyle TJ, Dellaripa PF, Batra K, Frits ML, Iannaccone CK, Hatabu H, Nishino M, Weinblatt ME, Ascherman DP, Washko GR, Hunninghake GM, Choi AMK, Shadick NA, Rosas IO. Functional impact of a spectrum of interstitial lung abnormalities in rheumatoid arthritis. Chest 2014;146:41-50. [PMID: 24305643 DOI: 10.1378/chest.13-1394] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 5.6] [Reference Citation Analysis]
349 Kim JH, Lee JH, Ryu YJ, Chang JH. Clinical predictors of survival in idiopathic pulmonary fibrosis. Tuberc Respir Dis (Seoul) 2012;73:162-8. [PMID: 23166549 DOI: 10.4046/trd.2012.73.3.162] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
350 Kim HC, Lee S, Song JW. Impact of idiopathic pulmonary fibrosis on clinical outcomes of lung cancer patients. Sci Rep 2021;11:8312. [PMID: 33859288 DOI: 10.1038/s41598-021-87747-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
351 Storebø ML, Eagan TM, Eide GE, Gulsvik A, Thorsen E, Bakke PS. Change in pulmonary diffusion capacity in a general population sample over 9 years. Eur Clin Respir J 2016;3:31265. [PMID: 27600696 DOI: 10.3402/ecrj.v3.31265] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
352 Rochwerg B, Neupane B, Zhang Y, Garcia CC, Raghu G, Richeldi L, Brozek J, Beyene J, Schünemann H. Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. BMC Med 2016;14:18. [PMID: 26843176 DOI: 10.1186/s12916-016-0558-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 8.2] [Reference Citation Analysis]
353 Kawamura K, Ichikado K, Ichiyasu H, Anan K, Yasuda Y, Suga M, Sakagami T. Acute exacerbation of chronic fibrosing interstitial pneumonia in patients receiving antifibrotic agents: incidence and risk factors from real-world experience. BMC Pulm Med 2019;19:113. [PMID: 31238929 DOI: 10.1186/s12890-019-0880-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
354 Fan Y, He R, Zou L, Meng J. [Clinical value of biomarkers in diagnosis and treatment of idiopathic pulmonary fibrosis]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:1062-5. [PMID: 32895164 DOI: 10.12122/j.issn.1673-4254.2020.07.23] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
355 Ho ATN, Shmelev A, Charbek E. Trends and seasonal variation of hospitalization and mortality of interstitial lung disease in the United States from 2006 to 2016. Respir Res 2020;21:152. [PMID: 32546158 DOI: 10.1186/s12931-020-01421-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
356 Yanagiya M, Kitano K, Yotsumoto T, Takai D, Asahina H, Nagayama K, Nakajima J. Effect of normal saline flush injection into a bronchus on lung decellularization. J Thorac Dis 2019;11:5321-7. [PMID: 32030249 DOI: 10.21037/jtd.2019.11.59] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
357 Serra López-Matencio JM, Gómez M, Vicente-Rabaneda EF, González-Gay MA, Ancochea J, Castañeda S. Pharmacological Interactions of Nintedanib and Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis in Times of COVID-19 Pandemic. Pharmaceuticals (Basel) 2021;14:819. [PMID: 34451916 DOI: 10.3390/ph14080819] [Reference Citation Analysis]
358 Saijo A, Hanibuchi M, Ogino H, Otsuka K, Goto H, Nokihara H, Nishioka Y. Paclitaxel for relapsed small-cell lung cancer patients with idiopathic interstitial pneumonias. Mol Clin Oncol 2019;10:541-6. [PMID: 30967948 DOI: 10.3892/mco.2019.1828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
359 Tian Y, Li H, Gao Y, Liu C, Qiu T, Wu H, Cao M, Zhang Y, Ding H, Chen J, Cai H. Quantitative proteomic characterization of lung tissue in idiopathic pulmonary fibrosis. Clin Proteomics 2019;16:6. [PMID: 30774578 DOI: 10.1186/s12014-019-9226-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
360 Pesonen I, Carlson L, Murgia N, Kaarteenaho R, Sköld CM, Myllärniemi M, Ferrara G. Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries. Multidiscip Respir Med 2018;13:14. [PMID: 29785264 DOI: 10.1186/s40248-018-0126-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
361 Organ LA, Duggan AR, Oballa E, Taggart SC, Simpson JK, Kang'ombe AR, Braybrooke R, Molyneaux PL, North B, Karkera Y, Leeming DJ, Karsdal MA, Nanthakumar CB, Fahy WA, Marshall RP, Jenkins RG, Maher TM. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort. Respir Res 2019;20:148. [PMID: 31299951 DOI: 10.1186/s12931-019-1118-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 9.7] [Reference Citation Analysis]
362 Yao MY, Zhang WH, Ma WT, Liu QH, Xing LH, Zhao GF. microRNA-328 in exosomes derived from M2 macrophages exerts a promotive effect on the progression of pulmonary fibrosis via FAM13A in a rat model. Exp Mol Med 2019;51:1-16. [PMID: 31164635 DOI: 10.1038/s12276-019-0255-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
363 Deconinck B, Verschakelen J, Coolen J, Verbeken E, Verleden G, Wuyts W. Diagnostic workup for diffuse parenchymal lung disease: schematic flowchart, literature review, and pitfalls. Lung 2013;191:19-25. [PMID: 23149802 DOI: 10.1007/s00408-012-9433-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
364 Minnis P, Henry K, Keane M. Reflux in idiopathic pulmonary fibrosis: Table 1,. QJM 2015;109:7-10. [DOI: 10.1093/qjmed/hcv148] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
365 Canora A, Nicoletta C, Ghinassi G, Bruzzese D, Rea G, Capaccio A, Castaldo S, Coppola A, Polistina GE, Sanduzzi A, Bocchino M. First Description of the Hyperpnea-Hypopnea Periodic Breathing in Patients with Interstitial Lung Disease-Obstructive Sleep Apnea: Treatment Implications in a Real-Life Setting. Int J Environ Res Public Health 2019;16:E4712. [PMID: 31779226 DOI: 10.3390/ijerph16234712] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
366 Degrado JR, Gilmore JF. Update on New Treatments for Idiopathic Pulmonary Fibrosis. Curr Emerg Hosp Med Rep 2015;3:134-8. [DOI: 10.1007/s40138-015-0076-8] [Reference Citation Analysis]
367 Kumagai S, Marumo S, Arita M, Yamanashi K, Sumitomo R, Otake Y, Shoji T, Fukui M, Katayama T, Okumura N, Huang CL. Development and validation of a preoperative prognostic index independent of TNM stage in resected non-small cell lung cancer. BMC Pulm Med 2017;17:166. [PMID: 29202834 DOI: 10.1186/s12890-017-0529-9] [Reference Citation Analysis]
368 Geng J, Huang X, Li Y, Xu X, Li S, Jiang D, Liang J, Jiang D, Wang C, Dai H. Down-regulation of USP13 mediates phenotype transformation of fibroblasts in idiopathic pulmonary fibrosis. Respir Res 2015;16:124. [PMID: 26453058 DOI: 10.1186/s12931-015-0286-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.9] [Reference Citation Analysis]
369 Suzuki Y, Mori K, Aono Y, Kono M, Hasegawa H, Yokomura K, Naoi H, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Nakamura H, Suda T. Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study. BMC Pulm Med 2021;21:221. [PMID: 34247593 DOI: 10.1186/s12890-021-01587-3] [Reference Citation Analysis]
370 Oda K, Yatera K, Izumi H, Ishimoto H, Yamada S, Nakao H, Hanaka T, Ogoshi T, Noguchi S, Mukae H. Profibrotic role of WNT10A via TGF-β signaling in idiopathic pulmonary fibrosis. Respir Res 2016;17:39. [PMID: 27071460 DOI: 10.1186/s12931-016-0357-0] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
371 Cottin V, Teague R, Nicholson L, Langham S, Baldwin M. The Burden of Progressive-Fibrosing Interstitial Lung Diseases. Front Med (Lausanne) 2022;9:799912. [PMID: 35178411 DOI: 10.3389/fmed.2022.799912] [Reference Citation Analysis]
372 Yamashita M, Utsumi Y, Nagashima H, Nitanai H, Yamauchi K. S100A9/CD163 expression profiles in classical monocytes as biomarkers to discriminate idiopathic pulmonary fibrosis from idiopathic nonspecific interstitial pneumonia. Sci Rep 2021;11:12135. [PMID: 34108546 DOI: 10.1038/s41598-021-91407-9] [Reference Citation Analysis]
373 Salonen J, Purokivi M, Bloigu R, Kaarteenaho R. Prognosis and causes of death of patients with acute exacerbation of fibrosing interstitial lung diseases. BMJ Open Respir Res 2020;7:e000563. [PMID: 32265195 DOI: 10.1136/bmjresp-2020-000563] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
374 Cotton CV, Spencer LG, New RP, Cooper RG. The utility of comprehensive autoantibody testing to differentiate connective tissue disease associated and idiopathic interstitial lung disease subgroup cases. Rheumatology (Oxford) 2017;56:1264-71. [PMID: 28339528 DOI: 10.1093/rheumatology/kew320] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
375 Singh S, Collins BF, Sharma BB, Joshi JM, Talwar D, Katiyar S, Singh N, Ho L, Samaria JK, Bhattacharya P, Chaudhari S, Singh T, Pilania K, Pipavath S, Ahuja J, Chetambath R, Ghoshal AG, Jain NK, Gayathri Devi HJ, Kant S, Koul P, Dhar R, Swarnakar R, Katiyar SK, Jindal A, Mangal DK, Singh V, Raghu G. Hypersensitivity pneumonitis: Clinical manifestations - Prospective data from the interstitial lung disease-India registry. Lung India 2019;36:476-82. [PMID: 31670294 DOI: 10.4103/lungindia.lungindia_263_19] [Reference Citation Analysis]
376 Wang Z, Bier EA, Swaminathan A, Parikh K, Nouls J, He M, Mammarappallil JG, Luo S, Driehuys B, Rajagopal S. Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. Eur Respir J 2019;54:1900831. [PMID: 31619473 DOI: 10.1183/13993003.00831-2019] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
377 Takahashi Y, Saito A, Chiba H, Kuronuma K, Ikeda K, Kobayashi T, Ariki S, Takahashi M, Sasaki Y, Takahashi H. Impaired diversity of the lung microbiome predicts progression of idiopathic pulmonary fibrosis. Respir Res 2018;19:34. [PMID: 29486761 DOI: 10.1186/s12931-018-0736-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
378 Giacomi F, Andreano A, Faverio P, Biffi A, Ruvolo L, Sverzellati N, Grazia Valsecchi M, Pesci A. Utility of precipitating antibody testing in the diagnostic evaluation of chronic hypersensitivity pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2017;34:149-55. [PMID: 32476836 DOI: 10.36141/svdld.v34i2.5467] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
379 Ruan H, Luan J, Gao S, Li S, Jiang Q, Liu R, Liang Q, Zhang R, Zhang F, Li X, Zhou H, Yang C. Fedratinib Attenuates Bleomycin-Induced Pulmonary Fibrosis via the JAK2/STAT3 and TGF-β1 Signaling Pathway. Molecules 2021;26:4491. [PMID: 34361644 DOI: 10.3390/molecules26154491] [Reference Citation Analysis]
380 de Vega Sánchez B, Roig Figueroa V. Endoscopic Cyanoacrylate for Persistent Air Leak from A Bronchopleural Fistula in A Patient with Idiopathic Pulmonary Fibrosis. Arch Bronconeumol 2017;53:164-5. [PMID: 27492751 DOI: 10.1016/j.arbres.2016.06.014] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
381 Arai T, Kida H, Ogata Y, Marumo S, Matsuoka H, Gohma I, Yamamoto S, Mori M, Sugimoto C, Tachibana K, Akira M, Inoue Y. Efficacy of recombinant thrombomodulin for poor prognostic cases of acute exacerbation in idiopathic interstitial pneumonia: secondary analysis of the SETUP trial. BMJ Open Respir Res 2020;7:e000558. [PMID: 32423894 DOI: 10.1136/bmjresp-2020-000558] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
382 Suzuki Y, Mori K, Aono Y, Kono M, Hasegawa H, Yokomura K, Naoi H, Hozumi H, Karayama M, Furuhashi K, Enomoto N, Fujisawa T, Nakamura Y, Inui N, Nakamura H, Suda T. Combined assessment of the GAP index and body mass index at antifibrotic therapy initiation for prognosis of idiopathic pulmonary fibrosis. Sci Rep 2021;11:18579. [PMID: 34535738 DOI: 10.1038/s41598-021-98161-y] [Reference Citation Analysis]
383 Bocchino M, Zanotta S, Capitelli L, Galati D. Dendritic Cells Are the Intriguing Players in the Puzzle of Idiopathic Pulmonary Fibrosis Pathogenesis. Front Immunol 2021;12:664109. [PMID: 33995394 DOI: 10.3389/fimmu.2021.664109] [Reference Citation Analysis]
384 Zhang Y, Zhao M, Guo P, Wang Y, Liu L, Zhao J, Gao L, Yuan Z, Xue F, Zhao J. Mendelian randomisation highlights hypothyroidism as a causal determinant of idiopathic pulmonary fibrosis. EBioMedicine 2021;73:103669. [PMID: 34749302 DOI: 10.1016/j.ebiom.2021.103669] [Reference Citation Analysis]
385 Ribeiro Neto ML, Arrossi AV, Yadav R, Culver DA, Mukhopadhyay S, Parambil JG, Southern BD, Tolle L, Pande A, Almeida FA, Sahoo D, Glennie J, Ahmad U, Mehta AC, Gildea TR. Prospective cohort of cryobiopsy in interstitial lung diseases: a single center experience. BMC Pulm Med 2022;22. [DOI: 10.1186/s12890-022-01990-4] [Reference Citation Analysis]
386 Kinoshita T, Goto T. Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review. Int J Mol Sci 2019;20:E1461. [PMID: 30909462 DOI: 10.3390/ijms20061461] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 9.0] [Reference Citation Analysis]
387 Tsubochi H, Shibano T, Endo S. Recommendations for perioperative management of lung cancer patients with comorbidities. Gen Thorac Cardiovasc Surg 2018;66:71-80. [PMID: 29147917 DOI: 10.1007/s11748-017-0864-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
388 Collard HR, Brown KK, Martinez FJ, Raghu G, Roberts RS, Anstrom KJ. Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. Chest 2014;146:1256-62. [PMID: 25144827 DOI: 10.1378/chest.14-0492] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
389 Kato E, Takayanagi N, Takaku Y, Kagiyama N, Kanauchi T, Ishiguro T, Sugita Y. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res 2018;4:00111-2016. [PMID: 29410958 DOI: 10.1183/23120541.00111-2016] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
390 Guo H, Mann J, Goh N, Smallwood N. Investigation burden for patients with fibrotic interstitial lung disease at the end of life. Intern Med J 2020;50:748-52. [PMID: 32537928 DOI: 10.1111/imj.14856] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
391 Jones MG, Fabre A, Schneider P, Cinetto F, Sgalla G, Mavrogordato M, Jogai S, Alzetani A, Marshall BG, O'Reilly KM, Warner JA, Lackie PM, Davies DE, Hansell DM, Nicholson AG, Sinclair I, Brown KK, Richeldi L. Three-dimensional characterization of fibroblast foci in idiopathic pulmonary fibrosis. JCI Insight 2016;1:e86375. [PMID: 27275013 DOI: 10.1172/jci.insight.86375] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
392 Witt S, Krauss E, Barbero MAN, Müller V, Bonniaud P, Vancheri C, Wells AU, Vasakova M, Pesci A, Klepetko W, Seeger W, Crestani B, Leidl R, Holle R, Schwarzkopf L, Guenther A. Psychometric properties and minimal important differences of SF-36 in Idiopathic Pulmonary Fibrosis. Respir Res 2019;20:47. [PMID: 30823880 DOI: 10.1186/s12931-019-1010-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
393 Vaz Fragoso CA, McAvay G, Van Ness PH, Metter EJ, Ferrucci L, Yaggi HK, Concato J, Gill TM. Aging-Related Considerations When Evaluating the Forced Expiratory Volume in 1 Second (FEV1) Over Time. J Gerontol A Biol Sci Med Sci 2016;71:929-34. [PMID: 26525091 DOI: 10.1093/gerona/glv201] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
394 Parra ER, Ruppert AD, Capelozzi VL. Angiotensin II type 1 and 2 receptors and lymphatic vessels modulate lung remodeling and fibrosis in systemic sclerosis and idiopathic pulmonary fibrosis. Clinics (Sao Paulo) 2014;69:47-54. [PMID: 24473559 DOI: 10.6061/clinics/2014(01)07] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
395 Lancaster L, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, King TE Jr, Lederer DJ, Lin Z, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, Noble PW. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials. BMJ Open Respir Res 2016;3:e000105. [PMID: 26835133 DOI: 10.1136/bmjresp-2015-000105] [Cited by in Crossref: 67] [Cited by in F6Publishing: 62] [Article Influence: 11.2] [Reference Citation Analysis]
396 Wuyts WA, Papiris S, Manali E, Kilpeläinen M, Davidsen JR, Miedema J, Robalo-Cordeiro C, Morais A, Artés M, Asijee G, Cendoya D, Soulard S. The Burden of Progressive Fibrosing Interstitial Lung Disease: A DELPHI Approach. Adv Ther 2020;37:3246-64. [PMID: 32445186 DOI: 10.1007/s12325-020-01384-0] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
397 Machahua C, Montes-Worboys A, Planas-Cerezales L, Buendia-Flores R, Molina-Molina M, Vicens-Zygmunt V. Serum AGE/RAGEs as potential biomarker in idiopathic pulmonary fibrosis. Respir Res 2018;19:215. [PMID: 30409203 DOI: 10.1186/s12931-018-0924-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
398 Lee JH, Park JH, Kim HJ, Kim HK, Jang JH, Kim YK, Park BS, Park SH, Kim IH, Kim SH, Heo W, Jang HJ. The effects of direct hemoperfusion with polymyxin B-immobilized fiber in patients with acute exacerbation of interstitial lung disease. Acute Crit Care 2021;36:126-32. [PMID: 33853291 DOI: 10.4266/acc.2021.00073] [Reference Citation Analysis]
399 Nathan SD, Yang M, Morgenthien EA, Stauffer JL. FVC variability in patients with idiopathic pulmonary fibrosis and role of 6-min walk test to predict further change. Eur Respir J 2020;55:1902151. [PMID: 32029447 DOI: 10.1183/13993003.02151-2019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
400 Snetselaar R, van Batenburg AA, van Oosterhout MFM, Kazemier KM, Roothaan SM, Peeters T, van der Vis JJ, Goldschmeding R, Grutters JC, van Moorsel CHM. Short telomere length in IPF lung associates with fibrotic lesions and predicts survival. PLoS One 2017;12:e0189467. [PMID: 29281671 DOI: 10.1371/journal.pone.0189467] [Cited by in Crossref: 52] [Cited by in F6Publishing: 48] [Article Influence: 10.4] [Reference Citation Analysis]
401 Troy LK, Grainge C, Corte T, Williamson JP, Vallely MP, Cooper W, Mahar AM, Lai S, Mulyadi E, Torzillo PJ, Salamonsen M, Don G, Myers J, Raghu G, Lau EMT; COLDICE Investigator Team. Cryobiopsy versus open lung biopsy in the diagnosis of interstitial lung disease (COLDICE): protocol of a multicentre study. BMJ Open Respir Res 2019;6:e000443. [PMID: 31321059 DOI: 10.1136/bmjresp-2019-000443] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
402 Saraswat M, Joenväärä S, Tohmola T, Sutinen E, Vartiainen V, Koli K, Myllärniemi M, Renkonen R. Label-free plasma proteomics identifies haptoglobin-related protein as candidate marker of idiopathic pulmonary fibrosis and dysregulation of complement and oxidative pathways. Sci Rep 2020;10:7787. [PMID: 32385381 DOI: 10.1038/s41598-020-64759-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
403 Radu AF, Bungau SG. Management of Rheumatoid Arthritis: An Overview. Cells 2021;10:2857. [PMID: 34831081 DOI: 10.3390/cells10112857] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Cunningham PS, Meijer P, Nazgiewicz A, Anderson SG, Borthwick LA, Bagnall J, Kitchen GB, Lodyga M, Begley N, Venkateswaran RV, Shah R, Mercer PF, Durrington HJ, Henderson NC, Piper-Hanley K, Fisher AJ, Chambers RC, Bechtold DA, Gibbs JE, Loudon AS, Rutter MK, Hinz B, Ray DW, Blaikley JF. The circadian clock protein REVERBα inhibits pulmonary fibrosis development. Proc Natl Acad Sci U S A 2020;117:1139-47. [PMID: 31879343 DOI: 10.1073/pnas.1912109117] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
405 Leuschner G, Neurohr C. [What rheumatologists can learn from pneumologists]. Z Rheumatol 2018;77:477-83. [PMID: 30006857 DOI: 10.1007/s00393-018-0507-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
406 Nakshbandi G, Moor CC, Johannson KA, Maher TM, Kreuter M, Wijsenbeek MS. Worldwide experiences and opinions of healthcare providers on eHealth for patients with interstitial lung diseases in the COVID-19 era. ERJ Open Res 2021;7:00405-2021. [PMID: 34471631 DOI: 10.1183/23120541.00405-2021] [Reference Citation Analysis]
407 Putman RK, Gudmundsson G, Axelsson GT, Hida T, Honda O, Araki T, Yanagawa M, Nishino M, Miller ER, Eiriksdottir G, Gudmundsson EF, Tomiyama N, Honda H, Rosas IO, Washko GR, Cho MH, Schwartz DA, Gudnason V, Hatabu H, Hunninghake GM. Imaging Patterns Are Associated with Interstitial Lung Abnormality Progression and Mortality. Am J Respir Crit Care Med 2019;200:175-83. [PMID: 30673508 DOI: 10.1164/rccm.201809-1652OC] [Cited by in Crossref: 44] [Cited by in F6Publishing: 23] [Article Influence: 22.0] [Reference Citation Analysis]
408 Kim HY, Kim MS, Kim SH, Joen D, Lee K. Protective Effects of Nintedanib against Polyhexamethylene Guanidine Phosphate-Induced Lung Fibrosis in Mice. Molecules 2018;23:E1974. [PMID: 30087305 DOI: 10.3390/molecules23081974] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
409 Vainshelboim B. Exercise training in idiopathic pulmonary fibrosis: is it of benefit? Breathe (Sheff) 2016;12:130-8. [PMID: 27408631 DOI: 10.1183/20734735.006916] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
410 Somade OT, Adeyi OE, Ajayi BO, Asunde OO, Iloh PD, Adesanya AA, Babalola OI, Folorunsho OT, Olakunle DA, Lawal OF. Syringic and ascorbic acids prevent NDMA-induced pulmonary fibrogenesis, inflammation, apoptosis, and oxidative stress through the regulation of PI3K-Akt/PKB-mTOR-PTEN signaling pathway. Metabolism Open 2022;14:100179. [DOI: 10.1016/j.metop.2022.100179] [Reference Citation Analysis]
411 Khan F, Stewart I, Howard L, McKeever TM, Jones S, Hearson G, Braybrooke R, Edwards C, Jenkins G, Saini G. The Its Not JUST Idiopathic pulmonary fibrosis Study (INJUSTIS): description of the protocol for a multicentre prospective observational cohort study identifying biomarkers of progressive fibrotic lung disease. BMJ Open Respir Res 2019;6:e000439. [PMID: 31258922 DOI: 10.1136/bmjresp-2019-000439] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
412 Nakamura Y, Suda T. Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. Clin Med Insights Circ Respir Pulm Med 2015;9:163-71. [PMID: 27625576 DOI: 10.4137/CCRPM.S39897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
413 Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2016;194:711-8. [PMID: 26938706 DOI: 10.1164/rccm.201508-1546OC] [Cited by in Crossref: 51] [Cited by in F6Publishing: 23] [Article Influence: 10.2] [Reference Citation Analysis]
414 Bosi M, Milioli G, Fanfulla F, Tomassetti S, Ryu JH, Parrino L, Riccardi S, Melpignano A, Vaudano AE, Ravaglia C, Tantalocco P, Rossi A, Poletti V. OSA and Prolonged Oxygen Desaturation During Sleep are Strong Predictors of Poor Outcome in IPF. Lung 2017;195:643-51. [PMID: 28674777 DOI: 10.1007/s00408-017-0031-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 5.8] [Reference Citation Analysis]
415 Kolb TM, Hassoun PM. Right ventricular dysfunction in chronic lung disease. Cardiol Clin 2012;30:243-56. [PMID: 22548815 DOI: 10.1016/j.ccl.2012.03.005] [Cited by in Crossref: 31] [Cited by in F6Publishing: 20] [Article Influence: 3.1] [Reference Citation Analysis]
416 Orzechowska B, Awsiuk K, Wnuk D, Pabijan J, Stachura T, Soja J, Sładek K, Raczkowska J. Discrimination between NSIP- and IPF-Derived Fibroblasts Based on Multi-Parameter Characterization of Their Growth, Morphology and Physic-Chemical Properties. Int J Mol Sci 2022;23:2162. [PMID: 35216278 DOI: 10.3390/ijms23042162] [Reference Citation Analysis]
417 Adams CJ, Shapera S, Ryerson CJ, Assayag D, Johannson KA, Fell CD, Morisset J, Manganas H, Kolb M, Hambly N, Cox G, Khalil N, Marcoux V, Wilcox PG, To T, Sadatsafavi M, Halayko AJ, Gershon A, Garlick K, Fisher JH. Effect of continued antifibrotic therapy after forced vital capacity decline in patients with idiopathic pulmonary fibrosis; a real world multicenter cohort study. Respir Med 2021;191:106722. [PMID: 34959146 DOI: 10.1016/j.rmed.2021.106722] [Reference Citation Analysis]
418 Inomata M, Ikushima S, Awano N, Kondoh K, Satake K, Masuo M, Kusunoki Y, Moriya A, Kamiya H, Ando T, Yanagawa N, Kumasaka T, Ogura T, Sakai F, Azuma A, Gemma A, Takemura T. An autopsy study of combined pulmonary fibrosis and emphysema: correlations among clinical, radiological, and pathological features. BMC Pulm Med 2014;14:104. [PMID: 24972672 DOI: 10.1186/1471-2466-14-104] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 5.1] [Reference Citation Analysis]
419 Sala V, Della Sala A, Ghigo A, Hirsch E. Roles of phosphatidyl inositol 3 kinase gamma (PI3Kγ) in respiratory diseases. Cell Stress 2021;5:40-51. [PMID: 33821232 DOI: 10.15698/cst2021.04.246] [Reference Citation Analysis]
420 Ogawa K, Uruga H, Fujii T, Fujimori S, Kohno T, Kurosaki A, Kishi K, Abe S. Characteristics of non-small-cell lung cancer with interstitial pneumonia: variation in cancer location, histopathology, and frequency of postoperative acute exacerbations in interstitial pneumonia. BMC Pulm Med 2020;20:307. [PMID: 33218332 DOI: 10.1186/s12890-020-01347-9] [Reference Citation Analysis]
421 Guiot J, Moermans C, Henket M, Corhay JL, Louis R. Blood Biomarkers in Idiopathic Pulmonary Fibrosis. Lung 2017;195:273-80. [PMID: 28353114 DOI: 10.1007/s00408-017-9993-5] [Cited by in Crossref: 60] [Cited by in F6Publishing: 53] [Article Influence: 12.0] [Reference Citation Analysis]
422 Sueblinvong V, Neujahr DC, Mills ST, Roser-Page S, Ritzenthaler JD, Guidot D, Rojas M, Roman J. Predisposition for disrepair in the aged lung. Am J Med Sci 2012;344:41-51. [PMID: 22173045 DOI: 10.1097/MAJ.0b013e318234c132] [Cited by in Crossref: 96] [Cited by in F6Publishing: 61] [Article Influence: 9.6] [Reference Citation Analysis]
423 Gu Y, Huang B, Yang Y, Qi M, Lu G, Xia D, Li H. Ibrutinib Exacerbates Bleomycin-Induced Pulmonary Fibrosis via Promoting Inflammation. Inflammation 2018;41:904-13. [PMID: 29532266 DOI: 10.1007/s10753-018-0745-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
424 Costabel U, Bonella F. [Treatment of pulmonary fibrosis. New substances and new interventions]. Internist (Berl) 2011;52:1422-8. [PMID: 22095049 DOI: 10.1007/s00108-011-2926-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
425 Guiot J, Struman I, Chavez V, Henket M, Herzog M, Scoubeau K, Hardat N, Bondue B, Corhay JL, Moermans C, Louis R. Altered epigenetic features in circulating nucleosomes in idiopathic pulmonary fibrosis. Clin Epigenetics 2017;9:84. [PMID: 28824731 DOI: 10.1186/s13148-017-0383-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
426 Maazi H, Akbari O. Type two innate lymphoid cells: the Janus cells in health and disease. Immunol Rev 2017;278:192-206. [PMID: 28658553 DOI: 10.1111/imr.12554] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
427 Walsh SLF, Maher TM, Kolb M, Poletti V, Nusser R, Richeldi L, Vancheri C, Wilsher ML, Antoniou KM, Behr J, Bendstrup E, Brown K, Calandriello L, Corte TJ, Cottin V, Crestani B, Flaherty K, Glaspole I, Grutters J, Inoue Y, Kokosi M, Kondoh Y, Kouranos V, Kreuter M, Johannson K, Judge E, Ley B, Margaritopoulos G, Martinez FJ, Molina-Molina M, Morais A, Nunes H, Raghu G, Ryerson CJ, Selman M, Spagnolo P, Taniguchi H, Tomassetti S, Valeyre D, Wijsenbeek M, Wuyts W, Hansell D, Wells A; IPF Project Consortium. Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. Eur Respir J 2017;50:1700936. [PMID: 28860269 DOI: 10.1183/13993003.00936-2017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 40] [Article Influence: 11.2] [Reference Citation Analysis]
428 Angulo M, Lecuona E, Sznajder JI. Role of MicroRNAs in lung disease. Arch Bronconeumol 2012;48:325-30. [PMID: 22607962 DOI: 10.1016/j.arbres.2012.04.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 54] [Article Influence: 5.1] [Reference Citation Analysis]
429 Ryu JH, Moua T, Azadeh N, Baqir M, Yi ES. Current concepts and dilemmas in idiopathic interstitial pneumonias. F1000Res 2016;5:2661. [PMID: 27853529 DOI: 10.12688/f1000research.9601.1] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
430 Takao S, Nakashima T, Masuda T, Namba M, Sakamoto S, Yamaguchi K, Horimasu Y, Miyamoto S, Iwamoto H, Fujitaka K, Hamada H, Takahashi S, Nakashima A, Hattori N. Human bone marrow-derived mesenchymal stromal cells cultured in serum-free media demonstrate enhanced antifibrotic abilities via prolonged survival and robust regulatory T cell induction in murine bleomycin-induced pulmonary fibrosis. Stem Cell Res Ther 2021;12:506. [PMID: 34530920 DOI: 10.1186/s13287-021-02574-5] [Reference Citation Analysis]
431 Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE Jr. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J 2016;47:243-53. [PMID: 26647432 DOI: 10.1183/13993003.00026-2015] [Cited by in Crossref: 210] [Cited by in F6Publishing: 187] [Article Influence: 30.0] [Reference Citation Analysis]
432 Oldham JM, Collard HR. Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. Front Med (Lausanne) 2017;4:123. [PMID: 28824912 DOI: 10.3389/fmed.2017.00123] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 8.2] [Reference Citation Analysis]
433 Yip R, Jirapatnakul A, Hu M, Chen X, Han D, Ma T, Zhu Y, Salvatore MM, Margolies LR, Yankelevitz DF, Henschke CI. Added benefits of early detection of other diseases on low-dose CT screening. Transl Lung Cancer Res 2021;10:1141-53. [PMID: 33718052 DOI: 10.21037/tlcr-20-746] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
434 Gui YS, Wang L, Tian X, Li X, Ma A, Zhou W, Zeng N, Zhang J, Cai B, Zhang H, Chen JY, Xu KF. mTOR Overactivation and Compromised Autophagy in the Pathogenesis of Pulmonary Fibrosis. PLoS One 2015;10:e0138625. [PMID: 26382847 DOI: 10.1371/journal.pone.0138625] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 7.9] [Reference Citation Analysis]
435 Beghé B, Cerri S, Fabbri LM, Marchioni A. COPD, Pulmonary Fibrosis and ILAs in Aging Smokers: The Paradox of Striking Different Responses to the Major Risk Factors. Int J Mol Sci 2021;22:9292. [PMID: 34502194 DOI: 10.3390/ijms22179292] [Reference Citation Analysis]
436 Rinaldi S, Balsillie C, Truchon C, Al‐mubarak A, Mura M, Madill J. Nutrition implications of intrinsic restrictive lung disease. Nut in Clin Prac. [DOI: 10.1002/ncp.10849] [Reference Citation Analysis]
437 Liu H, Wu X, Gan C, Wang L, Wang G, Yue L, Liu Z, Wei W, Su X, Zhang Q, Tan Z, Yao Y, Ouyang L, Yu L, Ye T. A novel multikinase inhibitor SKLB-YTH-60 ameliorates inflammation and fibrosis in bleomycin-induced lung fibrosis mouse models. Cell Prolif 2021;54:e13081. [PMID: 34121240 DOI: 10.1111/cpr.13081] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
438 Cottin V, Schmidt A, Catella L, Porte F, Fernandez-Montoya C, Le Lay K, Bénard S. Burden of Idiopathic Pulmonary Fibrosis Progression: A 5-Year Longitudinal Follow-Up Study. PLoS One 2017;12:e0166462. [PMID: 28099456 DOI: 10.1371/journal.pone.0166462] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
439 Chuang HM, Ho LI, Huang MH, Huang KL, Chiou TW, Lin SZ, Su HL, Harn HJ. Non-Canonical Regulation of Type I Collagen through Promoter Binding of SOX2 and Its Contribution to Ameliorating Pulmonary Fibrosis by Butylidenephthalide. Int J Mol Sci 2018;19:E3024. [PMID: 30287739 DOI: 10.3390/ijms19103024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
440 Schruf E, Schroeder V, Kuttruff CA, Weigle S, Krell M, Benz M, Bretschneider T, Holweg A, Schuler M, Frick M, Nicklin P, Garnett JP, Sobotta MC. Human lung fibroblast-to-myofibroblast transformation is not driven by an LDH5-dependent metabolic shift towards aerobic glycolysis. Respir Res 2019;20:87. [PMID: 31072408 DOI: 10.1186/s12931-019-1058-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
441 Fukunaga K, Yokoe S, Kawashima S, Uchida Y, Nakagawa H, Nakano Y. Nintedanib prevented fibrosis progression and lung cancer growth in idiopathic pulmonary fibrosis. Respirol Case Rep 2018;6:e00363. [PMID: 30237884 DOI: 10.1002/rcr2.363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
442 Kamiya H, Panlaqui OM. Prognostic factors for acute exacerbation of idiopathic pulmonary fibrosis: protocol for a systematic review and meta-analysis. BMJ Open 2019;9:e028226. [PMID: 31129597 DOI: 10.1136/bmjopen-2018-028226] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
443 Kopf S, Kumar V, Kender Z, Han Z, Fleming T, Herzig S, Nawroth PP. Diabetic Pneumopathy-A New Diabetes-Associated Complication: Mechanisms, Consequences and Treatment Considerations. Front Endocrinol (Lausanne) 2021;12:765201. [PMID: 34899603 DOI: 10.3389/fendo.2021.765201] [Reference Citation Analysis]
444 Fireman E, Mahamed AE, Rosengarten D, Ophir NN, Kramer MR. Quantitation of Silica Contents in Lung Explants of Transplanted Patients: Artificial Stone-Induced Silicosis vs. Idiopathic Pulmonary Fibrosis. Int J Environ Res Public Health 2021;18:7237. [PMID: 34299685 DOI: 10.3390/ijerph18147237] [Reference Citation Analysis]
445 Shin YJ, Yun G, Yoon SH, Song H, Kim J, Kim J, Park JS, Lee KW, Lee KH. Accuracy and complications of percutaneous transthoracic needle lung biopsy for the diagnosis of malignancy in patients with idiopathic pulmonary fibrosis. Eur Radiol 2021. [PMID: 34003347 DOI: 10.1007/s00330-021-08038-x] [Reference Citation Analysis]
446 Aschner Y, Downey GP. Transforming Growth Factor-β: Master Regulator of the Respiratory System in Health and Disease. Am J Respir Cell Mol Biol 2016;54:647-55. [PMID: 26796672 DOI: 10.1165/rcmb.2015-0391TR] [Cited by in Crossref: 104] [Cited by in F6Publishing: 66] [Article Influence: 20.8] [Reference Citation Analysis]
447 Salisbury ML, Gu T, Murray S, Gross BH, Chughtai A, Sayyouh M, Kazerooni EA, Myers JL, Lagstein A, Konopka KE, Belloli EA, Sheth JS, White ES, Holtze C, Martinez FJ, Flaherty KR. Hypersensitivity Pneumonitis: Radiologic Phenotypes Are Associated With Distinct Survival Time and Pulmonary Function Trajectory. Chest 2019;155:699-711. [PMID: 30243979 DOI: 10.1016/j.chest.2018.08.1076] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 16.3] [Reference Citation Analysis]
448 Makiguchi T, Yamada M, Yoshioka Y, Sugiura H, Koarai A, Chiba S, Fujino N, Tojo Y, Ota C, Kubo H, Kobayashi S, Yanai M, Shimura S, Ochiya T, Ichinose M. Serum extracellular vesicular miR-21-5p is a predictor of the prognosis in idiopathic pulmonary fibrosis. Respir Res 2016;17:110. [PMID: 27596748 DOI: 10.1186/s12931-016-0427-3] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 8.8] [Reference Citation Analysis]
449 Xie B, Ren Y, Geng J, He X, Ban C, Wang S, Jiang D, Luo S, Chen Q, Liu M, Feng R, Zhao L, Dai H, Wang C. Idiopathic Pulmonary Fibrosis Registry China study (PORTRAY): protocol for a prospective, multicentre registry study. BMJ Open 2020;10:e036809. [PMID: 33177132 DOI: 10.1136/bmjopen-2020-036809] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
450 Rajala K, Lehto JT, Sutinen E, Kautiainen H, Myllärniemi M, Saarto T. Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life. BMC Pulm Med 2018;18:172. [PMID: 30458739 DOI: 10.1186/s12890-018-0738-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
451 Humphries SM, Yagihashi K, Huckleberry J, Rho BH, Schroeder JD, Strand M, Schwarz MI, Flaherty KR, Kazerooni EA, van Beek EJR, Lynch DA. Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up. Radiology 2017;285:270-8. [PMID: 28493789 DOI: 10.1148/radiol.2017161177] [Cited by in Crossref: 61] [Cited by in F6Publishing: 51] [Article Influence: 12.2] [Reference Citation Analysis]
452 Fabbrizzi A, Amedei A, Lavorini F, Renda T, Fontana G. The lung microbiome: clinical and therapeutic implications. Intern Emerg Med 2019;14:1241-50. [PMID: 31667699 DOI: 10.1007/s11739-019-02208-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
453 Keenan CR, Langenbach SY, Jativa F, Harris T, Li M, Chen Q, Xia Y, Gao B, Schuliga MJ, Jaffar J, Prodanovic D, Tu Y, Berhan A, Lee PVS, Westall GP, Stewart AG. Casein Kinase 1δ/ε Inhibitor, PF670462 Attenuates the Fibrogenic Effects of Transforming Growth Factor-β in Pulmonary Fibrosis. Front Pharmacol 2018;9:738. [PMID: 30042678 DOI: 10.3389/fphar.2018.00738] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
454 van der Velden JL, Ye Y, Nolin JD, Hoffman SM, Chapman DG, Lahue KG, Abdalla S, Chen P, Liu Y, Bennett B, Khalil N, Sutherland D, Smith W, Horan G, Assaf M, Horowitz Z, Chopra R, Stevens RM, Palmisano M, Janssen-Heininger YM, Schafer PH. JNK inhibition reduces lung remodeling and pulmonary fibrotic systemic markers. Clin Transl Med 2016;5:36. [PMID: 27590145 DOI: 10.1186/s40169-016-0117-2] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 6.0] [Reference Citation Analysis]
455 Hetzel J, Eberhardt R, Petermann C, Gesierich W, Darwiche K, Hagmeyer L, Muche R, Kreuter M, Lewis R, Ehab A, Boeckeler M, Haentschel M. Bleeding risk of transbronchial cryobiopsy compared to transbronchial forceps biopsy in interstitial lung disease - a prospective, randomized, multicentre cross-over trial. Respir Res 2019;20:140. [PMID: 31277659 DOI: 10.1186/s12931-019-1091-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 7.7] [Reference Citation Analysis]
456 Angelino E, Reano S, Ferrara M, Agosti E, Graziani A, Filigheddu N. Antifibrotic activity of acylated and unacylated ghrelin. Int J Endocrinol 2015;2015:385682. [PMID: 25960743 DOI: 10.1155/2015/385682] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
457 Reilkoff RA, Peng H, Murray LA, Peng X, Russell T, Montgomery R, Feghali-Bostwick C, Shaw A, Homer RJ, Gulati M, Mathur A, Elias JA, Herzog EL. Semaphorin 7a+ regulatory T cells are associated with progressive idiopathic pulmonary fibrosis and are implicated in transforming growth factor-β1-induced pulmonary fibrosis. Am J Respir Crit Care Med 2013;187:180-8. [PMID: 23220917 DOI: 10.1164/rccm.201206-1109OC] [Cited by in Crossref: 79] [Cited by in F6Publishing: 46] [Article Influence: 7.9] [Reference Citation Analysis]
458 Cho SJ, Moon JS, Lee CM, Choi AM, Stout-Delgado HW. Glucose Transporter 1-Dependent Glycolysis Is Increased during Aging-Related Lung Fibrosis, and Phloretin Inhibits Lung Fibrosis. Am J Respir Cell Mol Biol 2017;56:521-31. [PMID: 27997810 DOI: 10.1165/rcmb.2016-0225OC] [Cited by in Crossref: 49] [Cited by in F6Publishing: 30] [Article Influence: 9.8] [Reference Citation Analysis]
459 Cameli P, Refini RM, Bergantini L, d'Alessandro M, Alonzi V, Magnoni C, Rottoli P, Sestini P, Bargagli E. Long-Term Follow-Up of Patients With Idiopathic Pulmonary Fibrosis Treated With Pirfenidone or Nintedanib: A Real-Life Comparison Study. Front Mol Biosci 2020;7:581828. [PMID: 33102528 DOI: 10.3389/fmolb.2020.581828] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
460 Leitl D, Jarosch I, Glöckl R, Schneeberger T, Rembert Koczulla A. [Rehabilitation in pneumology]. Pneumologe (Berl) 2021;:1-10. [PMID: 33976600 DOI: 10.1007/s10405-021-00395-0] [Reference Citation Analysis]
461 Scott MKD, Quinn K, Li Q, Carroll R, Warsinske H, Vallania F, Chen S, Carns MA, Aren K, Sun J, Koloms K, Lee J, Baral J, Kropski J, Zhao H, Herzog E, Martinez FJ, Moore BB, Hinchcliff M, Denny J, Kaminski N, Herazo-Maya JD, Shah NH, Khatri P. Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. Lancet Respir Med 2019;7:497-508. [PMID: 30935881 DOI: 10.1016/S2213-2600(18)30508-3] [Cited by in Crossref: 58] [Cited by in F6Publishing: 36] [Article Influence: 19.3] [Reference Citation Analysis]
462 Kelly BT, Thao V, Dempsey TM, Sangaralingham LR, Payne SR, Teague TT, Moua T, Shah ND, Limper AH. Outcomes for hospitalized patients with idiopathic pulmonary fibrosis treated with antifibrotic medications. BMC Pulm Med 2021;21:239. [PMID: 34273943 DOI: 10.1186/s12890-021-01607-2] [Reference Citation Analysis]
463 Kern RM, Singer JP, Koth L, Mooney J, Golden J, Hays S, Greenland J, Wolters P, Ghio E, Jones KD, Leard L, Kukreja J, Blanc PD. Lung transplantation for hypersensitivity pneumonitis. Chest 2015;147:1558-65. [PMID: 25412059 DOI: 10.1378/chest.14-1543] [Cited by in Crossref: 44] [Cited by in F6Publishing: 29] [Article Influence: 6.3] [Reference Citation Analysis]
464 Lou Y, Zheng Y, Fan B, Zhang L, Zhu F, Wang X, Chen Z, Tan X. Serum S100A12 levels are correlated with clinical severity in patients with dermatomyositis-associated interstitial lung disease. J Int Med Res 2020;48:300060519887841. [PMID: 31865833 DOI: 10.1177/0300060519887841] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
465 Poletti V, Vancheri C, Albera C, Harari S, Pesci A, Metella RR, Campolo B, Crespi G, Rizzoli S; FIBRONET study group. Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study. Respir Res 2021;22:66. [PMID: 33627105 DOI: 10.1186/s12931-021-01643-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
466 Kishaba T, Nagano H, Nei Y, Yamashiro S. Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients. J Thorac Dis 2016;8:3596-604. [PMID: 28149554 DOI: 10.21037/jtd.2016.12.49] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
467 Ikezoe K, Handa T, Tanizawa K, Chen-Yoshikawa TF, Kubo T, Aoyama A, Motoyama H, Hijiya K, Tokuda S, Nakatsuka Y, Yamamoto Y, Oshima A, Harashima SI, Nagai S, Hirai T, Date H, Chin K. Prognostic factors and outcomes in Japanese lung transplant candidates with interstitial lung disease. PLoS One 2017;12:e0183171. [PMID: 28800589 DOI: 10.1371/journal.pone.0183171] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
468 Sala MA, Balderas-Martínez YI, Buendía-Roldan I, Abdala-Valencia H, Nam K, Jain M, Bhorade S, Bharat A, Reyfman PA, Ridge KM, Pardo A, Sznajder JI, Budinger GRS, Misharin AV, Selman M. Inflammatory pathways are upregulated in the nasal epithelium in patients with idiopathic pulmonary fibrosis. Respir Res 2018;19:233. [PMID: 30477498 DOI: 10.1186/s12931-018-0932-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
469 Noor S, Nawaz S, Chaudhuri N. Real-World Study Analysing Progression and Survival of Patients with Idiopathic Pulmonary Fibrosis with Preserved Lung Function on Antifibrotic Treatment. Adv Ther 2021;38:268-77. [PMID: 33098554 DOI: 10.1007/s12325-020-01523-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
470 Awano N, Jo T, Izumo T, Inomata M, Morita K, Matsui H, Fushimi K, Urushiyama H, Nagase T, Yasunaga H. Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study. J Intensive Care 2022;10:14. [PMID: 35264250 DOI: 10.1186/s40560-022-00608-5] [Reference Citation Analysis]
471 Iommi M, Bonifazi M, Faragalli A, Latini LL, Mei F, Spazzafumo L, Skrami E, Ferrante L, Carle F, Gesuita R. Occurrence of Idiopathic Pulmonary Fibrosis in Italy: Latest Evidence from Real-World Data. Int J Environ Res Public Health 2022;19:2510. [PMID: 35270205 DOI: 10.3390/ijerph19052510] [Reference Citation Analysis]
472 Depietro N, Rinaldi J, Nieschwitz C, Robinson H, Walter A. Effect of pulmonary rehabilitation on dyspnea and exercise tolerance in patients with interstitial lung disease: a systematic review. Physical Therapy Reviews. [DOI: 10.1080/10833196.2022.2027658] [Reference Citation Analysis]
473 Ackermann M, Kim YO, Wagner WL, Schuppan D, Valenzuela CD, Mentzer SJ, Kreuz S, Stiller D, Wollin L, Konerding MA. Effects of nintedanib on the microvascular architecture in a lung fibrosis model. Angiogenesis 2017;20:359-72. [PMID: 28283856 DOI: 10.1007/s10456-017-9543-z] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 14.4] [Reference Citation Analysis]
474 Jee AS, Adelstein S, Bleasel J, Keir GJ, Nguyen M, Sahhar J, Youssef P, Corte TJ. Role of Autoantibodies in the Diagnosis of Connective-Tissue Disease ILD (CTD-ILD) and Interstitial Pneumonia with Autoimmune Features (IPAF). J Clin Med 2017;6:E51. [PMID: 28471413 DOI: 10.3390/jcm6050051] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
475 Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med 2014;108:819-29. [PMID: 24746629 DOI: 10.1016/j.rmed.2014.03.008] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
476 Nolan CM, Birring SS. PROMising developments in IPF patient-reported outcome measures. Eur Respir J 2022;59:2102312. [PMID: 35027375 DOI: 10.1183/13993003.02312-2021] [Reference Citation Analysis]
477 Strongman H, Kausar I, Maher TM. Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK. Adv Ther 2018;35:724-36. [PMID: 29644539 DOI: 10.1007/s12325-018-0693-1] [Cited by in Crossref: 82] [Cited by in F6Publishing: 64] [Article Influence: 20.5] [Reference Citation Analysis]
478 Barratt SL, Davis R, Sharp C, Pauling JD. The prognostic value of cardiopulmonary exercise testing in interstitial lung disease: a systematic review. ERJ Open Res 2020;6:00027-2020. [PMID: 32832530 DOI: 10.1183/23120541.00027-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
479 Yamaguchi T, Shimizu J, Hasegawa T, Horio Y, Inaba Y, Hanai N, Muro K, Hida T. Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis. BMC Cancer 2021;21:924. [PMID: 34399710 DOI: 10.1186/s12885-021-08661-3] [Reference Citation Analysis]
480 Kalafatis D, Löfdahl A, Näsman P, Dellgren G, Wheelock ÅM, Elowsson Rendin L, Sköld M, Westergren-Thorsson G. Distal Lung Microenvironment Triggers Release of Mediators Recognized as Potential Systemic Biomarkers for Idiopathic Pulmonary Fibrosis. Int J Mol Sci 2021;22:13421. [PMID: 34948231 DOI: 10.3390/ijms222413421] [Reference Citation Analysis]
481 Yoneshima Y, Iwama E, Matsumoto S, Matsubara T, Tagawa T, Ota K, Tanaka K, Takenoyama M, Okamoto T, Goto K, Mori M, Okamoto I. Paired analysis of tumor mutation burden for lung adenocarcinoma and associated idiopathic pulmonary fibrosis. Sci Rep 2021;11:12732. [PMID: 34140559 DOI: 10.1038/s41598-021-92098-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
482 Mai C, Verleden SE, McDonough JE, Willems S, De Wever W, Coolen J, Dubbeldam A, Van Raemdonck DE, Verbeken EK, Verleden GM, Hogg JC, Vanaudenaerde BM, Wuyts WA, Verschakelen JA. Thin-Section CT Features of Idiopathic Pulmonary Fibrosis Correlated with Micro-CT and Histologic Analysis. Radiology 2017;283:252-63. [PMID: 27715655 DOI: 10.1148/radiol.2016152362] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 6.7] [Reference Citation Analysis]
483 Fiddler C, Parfrey H. Diffuse parenchymal lung disease. Medicine 2016;44:359-66. [DOI: 10.1016/j.mpmed.2016.03.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
484 Hung YP, Hunninghake GM, Miller ER, Putman R, Nishino M, Araki T, Hatabu H, Sholl LM, Vivero M. Incidental nonneoplastic parenchymal findings in patients undergoing lung resection for mass lesions. Hum Pathol 2019;86:93-101. [PMID: 30658062 DOI: 10.1016/j.humpath.2019.01.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
485 Maher TM, Simpson JK, Porter JC, Wilson FJ, Chan R, Eames R, Cui Y, Siederer S, Parry S, Kenny J, Slack RJ, Sahota J, Paul L, Saunders P, Molyneaux PL, Lukey PT, Rizzo G, Searle GE, Marshall RP, Saleem A, Kang'ombe AR, Fairman D, Fahy WA, Vahdati-Bolouri M. A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor. Respir Res 2020;21:75. [PMID: 32216814 DOI: 10.1186/s12931-020-01339-7] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 8.0] [Reference Citation Analysis]
486 Wallaert B, Duthoit L, Drumez E, Behal H, Wemeau L, Chenivesse C, Grosbois JM. Long-term evaluation of home-based pulmonary rehabilitation in patients with fibrotic idiopathic interstitial pneumonias. ERJ Open Res 2019;5:00045-2019. [PMID: 30972352 DOI: 10.1183/23120541.00045-2019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
487 Sokai A, Tanizawa K, Handa T, Kanatani K, Kubo T, Ikezoe K, Nakatsuka Y, Tokuda S, Oga T, Hirai T, Nagai S, Chin K, Mishima M. Importance of serial changes in biomarkers in idiopathic pulmonary fibrosis. ERJ Open Res 2017;3:00019-2016. [PMID: 28875146 DOI: 10.1183/23120541.00019-2016] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 3.2] [Reference Citation Analysis]
488 Hatabu H, Hunninghake GM, Richeldi L, Brown KK, Wells AU, Remy-Jardin M, Verschakelen J, Nicholson AG, Beasley MB, Christiani DC, San José Estépar R, Seo JB, Johkoh T, Sverzellati N, Ryerson CJ, Graham Barr R, Goo JM, Austin JHM, Powell CA, Lee KS, Inoue Y, Lynch DA. Interstitial lung abnormalities detected incidentally on CT: a Position Paper from the Fleischner Society. Lancet Respir Med 2020;8:726-37. [PMID: 32649920 DOI: 10.1016/S2213-2600(20)30168-5] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 23.5] [Reference Citation Analysis]
489 Prasse A, Binder H, Schupp JC, Kayser G, Bargagli E, Jaeger B, Hess M, Rittinghausen S, Vuga L, Lynn H, Violette S, Jung B, Quast K, Vanaudenaerde B, Xu Y, Hohlfeld JM, Krug N, Herazo-Maya JD, Rottoli P, Wuyts WA, Kaminski N. BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2019;199:622-30. [PMID: 30141961 DOI: 10.1164/rccm.201712-2551OC] [Cited by in Crossref: 43] [Cited by in F6Publishing: 22] [Article Influence: 21.5] [Reference Citation Analysis]
490 De Logu F, Patacchini R, Fontana G, Geppetti P. TRP functions in the broncho-pulmonary system. Semin Immunopathol 2016;38:321-9. [PMID: 27083925 DOI: 10.1007/s00281-016-0557-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 4.2] [Reference Citation Analysis]
491 Calabrese F, Pezzuto F, Giraudo C, Vedovelli L, Fortarezza F, Del Vecchio C, Lunardi F, Fraia AS, Cocconcelli E, Vuljan SE, Gregori D, Crisanti A, Balestro E, Spagnolo P. The Diagnostic Yield of the Multidisciplinary Discussion in Patients With COVID-19 Pneumonia. Front Med (Lausanne) 2021;8:637872. [PMID: 33869252 DOI: 10.3389/fmed.2021.637872] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
492 Selvarajah B, Azuelos I, Platé M, Guillotin D, Forty EJ, Contento G, Woodcock HV, Redding M, Taylor A, Brunori G, Durrenberger PF, Ronzoni R, Blanchard AD, Mercer PF, Anastasiou D, Chambers RC. mTORC1 amplifies the ATF4-dependent de novo serine-glycine pathway to supply glycine during TGF-β1-induced collagen biosynthesis. Sci Signal 2019;12:eaav3048. [PMID: 31113850 DOI: 10.1126/scisignal.aav3048] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 15.7] [Reference Citation Analysis]
493 O'Dwyer DN, Ashley SL, Moore BB. Influences of innate immunity, autophagy, and fibroblast activation in the pathogenesis of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2016;311:L590-601. [PMID: 27474089 DOI: 10.1152/ajplung.00221.2016] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
494 Dhooria S, Agarwal R, Sehgal IS, Prasad KT, Garg M, Bal A, Aggarwal AN, Behera D. Spectrum of interstitial lung diseases at a tertiary center in a developing country: A study of 803 subjects. PLoS One 2018;13:e0191938. [PMID: 29420550 DOI: 10.1371/journal.pone.0191938] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
495 Sambataro G, Sambataro D, Pignataro F, Torrisi SE, Vancheri A, Pavone M, Palmucci S, Del Papa N, Vancheri C. Interstitial Lung Disease in patients with Polymyalgia Rheumatica: A case series. Respir Med Case Rep 2019;26:126-30. [PMID: 30603602 DOI: 10.1016/j.rmcr.2018.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
496 Choi WI, Lee DY, Choi HG, Lee CW. Lung Cancer development and mortality in interstitial lung disease with and without connective tissue diseases: a five-year Nationwide population-based study. Respir Res 2019;20:117. [PMID: 31182103 DOI: 10.1186/s12931-019-1094-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
497 Laria A, Lurati AM, Zizzo G, Zaccara E, Mazzocchi D, Re KA, Marrazza M, Faggioli P, Mazzone A. Interstitial Lung Disease in Rheumatoid Arthritis: A Practical Review. Front Med 2022;9:837133. [DOI: 10.3389/fmed.2022.837133] [Reference Citation Analysis]
498 Khan P, Fytianos K, Blumer S, Roux J, Gazdhar A, Savic S, Knudsen L, Jonigk D, Kuehnel MP, Mykoniati S, Tamm M, Geiser T, Hostettler KE. Basal-Like Cell-Conditioned Medium Exerts Anti-Fibrotic Effects In Vitro and In Vivo. Front Bioeng Biotechnol 2022;10:844119. [DOI: 10.3389/fbioe.2022.844119] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
499 Blandinières A, Gille T, Sadoine J, Bièche I, Slimani L, Dizier B, Gaussem P, Chaussain C, Planes C, Dorfmüller P, Israël-Biet D, Smadja DM. Endothelial Colony-Forming Cells Do Not Participate to Fibrogenesis in a Bleomycin-Induced Pulmonary Fibrosis Model in Nude Mice. Stem Cell Rev Rep 2018;14:812-22. [PMID: 30267203 DOI: 10.1007/s12015-018-9846-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
500 Roach KM, Wulff H, Feghali-Bostwick C, Amrani Y, Bradding P. Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent. Respir Res 2014;15:155. [PMID: 25476248 DOI: 10.1186/s12931-014-0155-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 4.5] [Reference Citation Analysis]
501 Gürün Kaya A, Özyürek BA, Şahin Özdemirel T, Öz M, Erdoğan Y. Prognostic Significance of Red Cell Distribution Width in Idiopathic Pulmonary Fibrosis and Combined Pulmonary Fibrosis Emphysema. Med Princ Pract 2021;30:154-9. [PMID: 32841950 DOI: 10.1159/000511106] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
502 Lin Y, Xu Z, Zhou B, Ma K, Jiang M. Pentoxifylline Inhibits Pulmonary Fibrosis by Regulating Cellular Senescence in Mice. Front Pharmacol 2022;13:848263. [PMID: 35662697 DOI: 10.3389/fphar.2022.848263] [Reference Citation Analysis]
503 Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and Treatment of Fibrotic Hypersensitivity Pneumonia. Where We Stand and Where We Need to Go. Am J Respir Crit Care Med 2017;196:690-9. [PMID: 28002680 DOI: 10.1164/rccm.201608-1675PP] [Cited by in Crossref: 105] [Cited by in F6Publishing: 43] [Article Influence: 21.0] [Reference Citation Analysis]
504 Arai T, Hirose M, Hamano Y, Kagawa T, Murakami A, Kida H, Kumanogoh A, Inoue Y, Roth M. Anti-Myxovirus Resistance Protein-1 Immunoglobulin A Autoantibody in Idiopathic Pulmonary Fibrosis. Canadian Respiratory Journal 2022;2022:1-10. [DOI: 10.1155/2022/1107673] [Reference Citation Analysis]
505 Vainshelboim B, Kramer MR, Izhakian S, Lima RM, Oliveira J. Physical Activity and Exertional Desaturation Are Associated with Mortality in Idiopathic Pulmonary Fibrosis. J Clin Med 2016;5:E73. [PMID: 27548238 DOI: 10.3390/jcm5080073] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 3.8] [Reference Citation Analysis]
506 Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, Park CS, Jeong SH, Park YB, Lee HL, Shin JW, Lee EJ, Lee JH, Jegal Y, Lee HK, Kim YH, Song JW, Park SW, Park MS. Predicting survival of patients with idiopathic pulmonary fibrosis using GAP score: a nationwide cohort study. Respir Res 2016;17:131. [PMID: 27756398 DOI: 10.1186/s12931-016-0454-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
507 Fois AG, Posadino AM, Giordo R, Cossu A, Agouni A, Rizk NM, Pirina P, Carru C, Zinellu A, Pintus G. Antioxidant Activity Mediates Pirfenidone Antifibrotic Effects in Human Pulmonary Vascular Smooth Muscle Cells Exposed to Sera of Idiopathic Pulmonary Fibrosis Patients. Oxid Med Cell Longev 2018;2018:2639081. [PMID: 30420906 DOI: 10.1155/2018/2639081] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
508 Winters CJ, Koval O, Murthy S, Allamargot C, Sebag SC, Paschke JD, Jaffer OA, Carter AB, Grumbach IM. CaMKII inhibition in type II pneumocytes protects from bleomycin-induced pulmonary fibrosis by preventing Ca2+-dependent apoptosis. Am J Physiol Lung Cell Mol Physiol 2016;310:L86-94. [PMID: 26545899 DOI: 10.1152/ajplung.00132.2015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
509 Tanizawa K, Handa T, Nagai S, Ikezoe K, Kubo T, Yokomatsu T, Ueda S, Fushimi Y, Ogino S, Watanabe K, Nakatsuka Y, Hirai T, Izumi T. Lung function decline in sarcoidosis. Respir Investig 2022:S2212-5345(22)00026-0. [PMID: 35400618 DOI: 10.1016/j.resinv.2022.02.009] [Reference Citation Analysis]
510 Hering KG, Hofmann-Preiß K. [Recognize and classify pneumoconiosis]. Radiologe 2014;54:1189-98. [PMID: 25476403 DOI: 10.1007/s00117-014-2735-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
511 Epstein Shochet G, Brook E, Israeli-Shani L, Edelstein E, Shitrit D. Fibroblast paracrine TNF-α signaling elevates integrin A5 expression in idiopathic pulmonary fibrosis (IPF). Respir Res 2017;18:122. [PMID: 28629363 DOI: 10.1186/s12931-017-0606-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 4.0] [Reference Citation Analysis]
512 Mehrad B, Strieter RM. Fibrocytes and the pathogenesis of diffuse parenchymal lung disease. Fibrogenesis Tissue Repair 2012;5:S22. [PMID: 23259468 DOI: 10.1186/1755-1536-5-S1-S22] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 1.5] [Reference Citation Analysis]
513 Bauer Y, Tedrow J, de Bernard S, Birker-Robaczewska M, Gibson KF, Guardela BJ, Hess P, Klenk A, Lindell KO, Poirey S, Renault B, Rey M, Weber E, Nayler O, Kaminski N. A novel genomic signature with translational significance for human idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 2015;52:217-31. [PMID: 25029475 DOI: 10.1165/rcmb.2013-0310OC] [Cited by in Crossref: 98] [Cited by in F6Publishing: 59] [Article Influence: 14.0] [Reference Citation Analysis]
514 Gui X, Qiu X, Xie M, Tian Y, Min C, Huang M, Hongyan W, Chen T, Zhang X, Chen J, Cao M, Cai H. Prognostic Value of Serum Osteopontin in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Biomed Res Int 2020;2020:3424208. [PMID: 32104688 DOI: 10.1155/2020/3424208] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
515 Borza CM, Pozzi A, Plosa EJ. Discoidin Domain Receptor 2, a Potential Therapeutic Target in Lung Fibrosis. Am J Respir Cell Mol Biol 2018;59:277-8. [PMID: 29924938 DOI: 10.1165/rcmb.2018-0161ED] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
516 Fang C, Huang H, Feng Y, Zhang Q, Wang N, Jing X, Guo J, Ferianc M, Xu Z. Whole-exome sequencing identifies susceptibility genes and pathways for idiopathic pulmonary fibrosis in the Chinese population. Sci Rep 2021;11:1443. [PMID: 33446833 DOI: 10.1038/s41598-020-80944-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
517 Juge PA, Lee JS, Lau J, Kawano-Dourado L, Rojas Serrano J, Sebastiani M, Koduri G, Matteson E, Bonfiglioli K, Sawamura M, Kairalla R, Cavagna L, Bozzalla Cassione E, Manfredi A, Mejia M, Rodríguez-Henriquez P, González-Pérez MI, Falfán-Valencia R, Buendia-Roldán I, Pérez-Rubio G, Ebstein E, Gazal S, Borie R, Ottaviani S, Kannengiesser C, Wallaert B, Uzunhan Y, Nunes H, Valeyre D, Saidenberg-Kermanac'h N, Boissier MC, Wemeau-Stervinou L, Flipo RM, Marchand-Adam S, Richette P, Allanore Y, Dromer C, Truchetet ME, Richez C, Schaeverbeke T, Lioté H, Thabut G, Deane KD, Solomon JJ, Doyle T, Ryu JH, Rosas I, Holers VM, Boileau C, Debray MP, Porcher R, Schwartz DA, Vassallo R, Crestani B, Dieudé P. Methotrexate and rheumatoid arthritis associated interstitial lung disease. Eur Respir J 2021;57:2000337. [PMID: 32646919 DOI: 10.1183/13993003.00337-2020] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
518 Kim GHJ, Shi Y, Yu W, Wong WK. A study design for statistical learning technique to predict radiological progression with an application of idiopathic pulmonary fibrosis using chest CT images. Contemp Clin Trials 2021;104:106333. [PMID: 33753286 DOI: 10.1016/j.cct.2021.106333] [Reference Citation Analysis]
519 Khalil N, Manganas H, Ryerson CJ, Shapera S, Cantin AM, Hernandez P, Turcotte EE, Parker JM, Moran JE, Albert GR, Sawtell R, Hagerimana A, Laurin P, Gagnon L, Cesari F, Kolb M. Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis. Eur Respir J 2019;53:1800663. [PMID: 30578394 DOI: 10.1183/13993003.00663-2018] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
520 Cinetto F, Ceccato J, Caputo I, Cangiano D, Montini B, Lunardi F, Piazza M, Agostini C, Calabrese F, Semenzato G, Rattazzi M, Gurrieri C, Scarpa R, Felice C, Vianello F. GSK-3 Inhibition Modulates Metalloproteases in a Model of Lung Inflammation and Fibrosis. Front Mol Biosci 2021;8:633054. [PMID: 34235177 DOI: 10.3389/fmolb.2021.633054] [Reference Citation Analysis]
521 Zhang Q, Ye H, Xiang F, Song LJ, Zhou LL, Cai PC, Zhang JC, Yu F, Shi HZ, Su Y, Xin JB, Ma WL. miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II. Mol Ther 2017;25:728-38. [PMID: 28131417 DOI: 10.1016/j.ymthe.2016.12.017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 8.4] [Reference Citation Analysis]
522 Takei R, Arita M, Kumagai S, Ito Y, Noyama M, Tokioka F, Ishida T. Impact of lymphocyte differential count > 15% in BALF on the mortality of patients with acute exacerbation of chronic fibrosing idiopathic interstitial pneumonia. BMC Pulm Med 2017;17:67. [PMID: 28427425 DOI: 10.1186/s12890-017-0412-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
523 Feng F, Zhang J, Wang Z, Wu Q, Zhou X. Efficacy and safety of N-acetylcysteine therapy for idiopathic pulmonary fibrosis: An updated systematic review and meta-analysis. Exp Ther Med 2019;18:802-16. [PMID: 31258714 DOI: 10.3892/etm.2019.7579] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
524 Kim GHJ, Goldin JG, Hayes W, Oh A, Soule B, Du S. The value of imaging and clinical outcomes in a phase II clinical trial of a lysophosphatidic acid receptor antagonist in idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2021;15:17534666211004238. [PMID: 33781141 DOI: 10.1177/17534666211004238] [Reference Citation Analysis]
525 Yamazaki R, Nishiyama O, Yoshikawa K, Saeki S, Sano H, Iwanaga T, Tohda Y. Clinical course and prognosis in survivors of acute exacerbations of idiopathic pulmonary fibrosis. Respir Investig 2021;59:408-13. [PMID: 33549542 DOI: 10.1016/j.resinv.2020.12.006] [Reference Citation Analysis]
526 Ravaglia C, Bosi M, Wells AU, Gurioli C, Gurioli C, Dubini A, Piciucchi S, Puglisi S, Mascetti S, Arcadu A, Tomassetti S, Poletti V. Idiopathic pulmonary fibrosis: prognostic impact of histologic honeycombing in transbronchial lung cryobiopsy. Multidiscip Respir Med 2019;14:3. [PMID: 30774952 DOI: 10.1186/s40248-019-0170-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
527 Trusculescu AA, Manolescu D, Tudorache E, Oancea C. Deep learning in interstitial lung disease-how long until daily practice. Eur Radiol 2020;30:6285-92. [PMID: 32537728 DOI: 10.1007/s00330-020-06986-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
528 Phan THG, Paliogiannis P, Nasrallah GK, Giordo R, Eid AH, Fois AG, Zinellu A, Mangoni AA, Pintus G. Emerging cellular and molecular determinants of idiopathic pulmonary fibrosis. Cell Mol Life Sci 2021;78:2031-57. [PMID: 33201251 DOI: 10.1007/s00018-020-03693-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
529 Tzilas V, Tzouvelekis A, Bouros E, Karampitsakos T, Ntassiou M, Avdoula E, Trachalaki A, Antoniou K, Raghu G, Bouros D. Clinical experience with antifibrotics in fibrotic hypersensitivity pneumonitis: a 3-year real-life observational study. ERJ Open Res 2020;6:00152-2020. [PMID: 33263028 DOI: 10.1183/23120541.00152-2020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
530 Ojanguren I, Morell F, Ramón MA, Villar A, Romero C, Cruz MJ, Muñoz X. Long-term outcomes in chronic hypersensitivity pneumonitis. Allergy 2019;74:944-52. [PMID: 30515826 DOI: 10.1111/all.13692] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 11.7] [Reference Citation Analysis]
531 Du W, Zhang T, Yang F, Gul A, Tang Z, Zhang H, Jiang S, Wang S, Dong J. Endocannabinoid signalling/cannabinoid receptor 2 is involved in icariin-mediated protective effects against bleomycin-induced pulmonary fibrosis. Phytomedicine 2022. [DOI: 10.1016/j.phymed.2022.154187] [Reference Citation Analysis]
532 Enomoto N, Naoi H, Aono Y, Katsumata M, Horiike Y, Yasui H, Karayama M, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Inui N, Nakamura Y, Suda T. Acute exacerbation of unclassifiable idiopathic interstitial pneumonia: comparison with idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2020;14:1753466620935774. [PMID: 32600180 DOI: 10.1177/1753466620935774] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
533 Hwang EJ, Park CM. Clinical Implementation of Deep Learning in Thoracic Radiology: Potential Applications and Challenges. Korean J Radiol 2020;21:511-25. [PMID: 32323497 DOI: 10.3348/kjr.2019.0821] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
534 Salonen J, Kreus M, Lehtonen S, Vähänikkilä H, Purokivi M, Kaarteenaho R. Decline in Mast Cell Density During Diffuse Alveolar Damage in Idiopathic Pulmonary Fibrosis. Inflammation 2021. [PMID: 34686945 DOI: 10.1007/s10753-021-01582-0] [Reference Citation Analysis]
535 Kato M, Sasaki S, Nakamura T, Kurokawa K, Yamada T, Ochi Y, Ihara H, Takahashi F, Takahashi K. Gastrointestinal adverse effects of nintedanib and the associated risk factors in patients with idiopathic pulmonary fibrosis. Sci Rep 2019;9:12062. [PMID: 31427707 DOI: 10.1038/s41598-019-48593-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
536 Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc 2020;17:1413-23. [PMID: 32574517 DOI: 10.1513/AnnalsATS.201912-880OC] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
537 Akira M, Morinaga K. The comparison of high-resolution computed tomography findings in asbestosis and idiopathic pulmonary fibrosis. Am J Ind Med 2016;59:301-6. [PMID: 26901505 DOI: 10.1002/ajim.22573] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 2.2] [Reference Citation Analysis]
538 Montesi SB, Mathai SK, Brenner LN, Gorshkova IA, Berdyshev EV, Tager AM, Shea BS. Docosatetraenoyl LPA is elevated in exhaled breath condensate in idiopathic pulmonary fibrosis. BMC Pulm Med 2014;14:5. [PMID: 24468008 DOI: 10.1186/1471-2466-14-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
539 Liu H, Guan Q, Zhao P, Li J. TGF-β-induced CCR8 promoted macrophage transdifferentiation into myofibroblast-like cells. Exp Lung Res 2022;:1-14. [PMID: 35377281 DOI: 10.1080/01902148.2022.2055227] [Reference Citation Analysis]
540 Sverzellati N, Odone A, Silva M, Polverosi R, Florio C, Cardinale L, Cortese G, Addonisio G, Zompatori M, Dalpiaz G, Piciucchi S, Larici AR; Italian Structured Report on Fibrosing Lung Disease Consort. Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist. Radiol Med 2018;123:245-53. [PMID: 29230680 DOI: 10.1007/s11547-017-0835-6] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
541 Filev PD, Little BP, Duong PT. Second-Opinion Reads in Interstitial Lung Disease Imaging: Added Value of Subspecialty Interpretation. J Am Coll Radiol 2020;17:786-90. [PMID: 31930981 DOI: 10.1016/j.jacr.2019.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
542 Jablonski RP, Kim SJ, Cheresh P, Williams DB, Morales-Nebreda L, Cheng Y, Yeldandi A, Bhorade S, Pardo A, Selman M, Ridge K, Gius D, Budinger GRS, Kamp DW. SIRT3 deficiency promotes lung fibrosis by augmenting alveolar epithelial cell mitochondrial DNA damage and apoptosis. FASEB J 2017;31:2520-32. [PMID: 28258190 DOI: 10.1096/fj.201601077R] [Cited by in Crossref: 55] [Cited by in F6Publishing: 37] [Article Influence: 11.0] [Reference Citation Analysis]
543 Moua T, Zamora Martinez AC, Baqir M, Vassallo R, Limper AH, Ryu JH. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 2014;15:154. [PMID: 25472884 DOI: 10.1186/s12931-014-0154-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 6.4] [Reference Citation Analysis]
544 Koo SM, Kim SY, Choi SM, Lee HK; Korean Interstitial Lung Diseases Study Group. Korean Guidelines for Diagnosis and Management of Interstitial Lung Diseases: Part 5. Connective Tissue Disease Associated Interstitial Lung Disease. Tuberc Respir Dis (Seoul) 2019;82:285-97. [PMID: 31172701 DOI: 10.4046/trd.2019.0009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
545 Yoo H, Jeong BH, Chung MJ, Lee KS, Kwon OJ, Chung MP. Risk factors and clinical characteristics of lung cancer in idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med 2019;19:149. [PMID: 31412851 DOI: 10.1186/s12890-019-0905-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 2.7] [Reference Citation Analysis]
546 Kershaw CD, Batra K, Torrealba JR, Terada LS. Characteristics and evaluation of acute exacerbations in chronic interstitial lung diseases. Respir Med 2021;183:106400. [PMID: 33957435 DOI: 10.1016/j.rmed.2021.106400] [Reference Citation Analysis]
547 Ley S, Ley-Zaporozhan J. Novelties in imaging in pulmonary fibrosis and nodules. A narrative review. Pulmonology 2020;26:39-44. [PMID: 31706882 DOI: 10.1016/j.pulmoe.2019.09.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
548 Ipatova AY, Koerner PH, Miller RT, Staskon F, Radi M. Retrospective Analysis of Medication Utilization and Clinical Outcomes in Patients With Idiopathic Pulmonary Fibrosis Treated With Nintedanib or Pirfenidone. Clin Med Insights Circ Respir Pulm Med 2019;13:1179548419834922. [PMID: 30890862 DOI: 10.1177/1179548419834922] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
549 Hecker L. Mechanisms and consequences of oxidative stress in lung disease: therapeutic implications for an aging populace. Am J Physiol Lung Cell Mol Physiol 2018;314:L642-53. [PMID: 29351446 DOI: 10.1152/ajplung.00275.2017] [Cited by in Crossref: 56] [Cited by in F6Publishing: 56] [Article Influence: 11.2] [Reference Citation Analysis]
550 Yoshikawa T, Otsuka M, Chiba H, Ikeda K, Mori Y, Umeda Y, Nishikiori H, Kuronuma K, Takahashi H. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis. BMC Pulm Med 2020;20:27. [PMID: 32005219 DOI: 10.1186/s12890-020-1060-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
551 Shmelev EI. [Idiopathic pulmonary fibrosis: The current state of the problem]. Ter Arkh 2016;88:103-8. [PMID: 28635884 DOI: 10.17116/terarkh20168812103-108] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
552 Karmouty-Quintana H, Philip K, Acero LF, Chen NY, Weng T, Molina JG, Luo F, Davies J, Le NB, Bunge I, Volcik KA, Le TT, Johnston RA, Xia Y, Eltzschig HK, Blackburn MR. Deletion of ADORA2B from myeloid cells dampens lung fibrosis and pulmonary hypertension. FASEB J 2015;29:50-60. [PMID: 25318478 DOI: 10.1096/fj.14-260182] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 5.6] [Reference Citation Analysis]
553 Turan D, Uğur Chousein EG, Koç AS, Çörtük M, Yıldırım Z, Demirkol B, Özgül MA, Çınarka H, Akalın N, Yardımcı AH, Çetinkaya E. Transbronchial cryobiopsy for diagnosing parenchymal lung diseases: real-life experience from a tertiary referral center. Sarcoidosis Vasc Diffuse Lung Dis 2021;38:e2021004. [PMID: 33867791 DOI: 10.36141/svdld.v38i1.11029] [Reference Citation Analysis]
554 Kim YH, Kwon SS. Interstitial lung diseases: respiratory review of 2013. Tuberc Respir Dis (Seoul) 2013;75:47-51. [PMID: 24023556 DOI: 10.4046/trd.2013.75.2.47] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
555 Kärkkäinen M, Kettunen HP, Nurmi H, Selander T, Purokivi M, Kaarteenaho R. Effect of smoking and comorbidities on survival in idiopathic pulmonary fibrosis. Respir Res 2017;18:160. [PMID: 28830514 DOI: 10.1186/s12931-017-0642-6] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
556 Mermigkis C, Bouloukaki I, Antoniou KM, Mermigkis D, Psathakis K, Giannarakis I, Varouchakis G, Siafakas N, Schiza SE. CPAP therapy in patients with idiopathic pulmonary fibrosis and obstructive sleep apnea: does it offer a better quality of life and sleep? Sleep Breath 2013;17:1137-43. [PMID: 23386371 DOI: 10.1007/s11325-013-0813-8] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 4.6] [Reference Citation Analysis]
557 Meltzer EB, Barry WT, Yang IV, Brown KK, Schwarz MI, Patel H, Ashley A, Noble PW, Schwartz DA, Steele MP. Familial and sporadic idiopathic pulmonary fibrosis: making the diagnosis from peripheral blood. BMC Genomics 2014;15:902. [PMID: 25318837 DOI: 10.1186/1471-2164-15-902] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
558 Bargagli E, Madioni C, Bianchi N, Refini RM, Cappelli R, Rottoli P. Serum analysis of coagulation factors in IPF and NSIP. Inflammation 2014;37:10-6. [PMID: 23912648 DOI: 10.1007/s10753-013-9706-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.0] [Reference Citation Analysis]
559 Schnabel PA, Petersen I, Junker K. [Current issues in pulmonary pathology. Report of the working group on pulmonary pathology of the German Society of Pathology]. Pathologe 2012;33 Suppl 2:351-4. [PMID: 23080028 DOI: 10.1007/s00292-012-1644-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
560 Rosado de Christenson M. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Yearbook of Diagnostic Radiology 2012;2012:29-30. [DOI: 10.1016/j.yrad.2012.03.015] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
561 Yamaguchi T, Yamamoto A, Oki Y, Sakai H, Misu S, Iwata Y, Kaneko M, Sawada K, Oki Y, Mitani Y, Ono K, Ishikawa A. Reliability and Validity of the Japanese Version of the Barthel Index Dyspnea Among Patients with Respiratory Diseases. Int J Chron Obstruct Pulmon Dis 2021;16:1863-71. [PMID: 34188463 DOI: 10.2147/COPD.S313583] [Reference Citation Analysis]
562 Kawamura K, Ichikado K, Yasuda Y, Anan K, Suga M. Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study. BMC Pulm Med 2017;17:94. [PMID: 28629448 DOI: 10.1186/s12890-017-0437-z] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 6.4] [Reference Citation Analysis]
563 Yamagata A, Arita M, Tachibana H, Tokioka F, Sugimoto C, Sumikawa H, Tanaka T, Yasui H, Fujisawa T, Nakamura Y, Suda T, Ishida T. Impact of bronchoalveolar lavage lymphocytosis on the effects of anti-inflammatory therapy in idiopathic non-specific interstitial pneumonia, idiopathic pleuroparenchymal fibroelastosis, and unclassifiable idiopathic interstitial pneumonia. Respir Res 2021;22:115. [PMID: 33879137 DOI: 10.1186/s12931-021-01726-8] [Reference Citation Analysis]
564 Gonzalez-Gonzalez FJ, Chandel NS, Jain M, Budinger GRS. Reactive oxygen species as signaling molecules in the development of lung fibrosis. Transl Res. 2017;190:61-68. [PMID: 29080401 DOI: 10.1016/j.trsl.2017.09.005] [Cited by in Crossref: 41] [Cited by in F6Publishing: 39] [Article Influence: 8.2] [Reference Citation Analysis]
565 Salisbury ML, Han MK, Dickson RP, Molyneaux PL. Microbiome in interstitial lung disease: from pathogenesis to treatment target. Curr Opin Pulm Med 2017;23:404-10. [PMID: 28650861 DOI: 10.1097/MCP.0000000000000399] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 5.5] [Reference Citation Analysis]
566 Guiot J, Duysinx B, Seidel L, Henket M, Gester F, Bonhomme O, Corhay JL, Louis R. Clinical experience in idiopathic pulmonary fibrosis: a retrospective study. Acta Clin Belg 2018;73:139-43. [PMID: 29125071 DOI: 10.1080/17843286.2017.1399228] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
567 Skandamis A, Kani C, Markantonis SL, Souliotis K. Systematic review and network meta-analysis of approved medicines for the treatment of idiopathic pulmonary fibrosis. J Drug Assess 2019;8:55-61. [PMID: 31044096 DOI: 10.1080/21556660.2019.1597726] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
568 Kurihara C, Tolly B, DeWolf A, Nader A, Kim S, Odell DD, Argento AC, Budinger GRS, Bharat A. Thoracoscopic lung biopsy under regional anesthesia for interstitial lung disease. Reg Anesth Pain Med 2020;45:255-9. [PMID: 32066592 DOI: 10.1136/rapm-2019-100686] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
569 Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, Torres F, Kaza V, Girod CE, Jones KD, Elicker BM, Ma SF, Vij R, Collard HR, Wolters PJ, Garcia CK. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med 2014;2:557-65. [PMID: 24948432 DOI: 10.1016/S2213-2600(14)70124-9] [Cited by in Crossref: 157] [Cited by in F6Publishing: 81] [Article Influence: 19.6] [Reference Citation Analysis]
570 Cao M, Sheng J, Qiu X, Wang D, Wang D, Wang Y, Xiao Y, Cai H. Acute exacerbations of fibrosing interstitial lung disease associated with connective tissue diseases: a population-based study. BMC Pulm Med 2019;19:215. [PMID: 31727051 DOI: 10.1186/s12890-019-0960-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
571 Shieh JM, Tseng HY, Jung F, Yang SH, Lin JC. Elevation of IL-6 and IL-33 Levels in Serum Associated with Lung Fibrosis and Skeletal Muscle Wasting in a Bleomycin-Induced Lung Injury Mouse Model. Mediators Inflamm 2019;2019:7947596. [PMID: 31049028 DOI: 10.1155/2019/7947596] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
572 Luppi F, Kalluri M, Faverio P, Kreuter M, Ferrara G. Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir Res 2021;22:109. [PMID: 33865386 DOI: 10.1186/s12931-021-01711-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
573 Matsuo S, Okamoto M, Ikeuchi T, Zaizen Y, Inomoto A, Haraguchi R, Mori S, Sasaki R, Nouno T, Tanaka T, Hoshino T, Tsuda T. Early Intervention of Pulmonary Rehabilitation for Fibrotic Interstitial Lung Disease Is a Favorable Factor for Short-Term Improvement in Health-Related Quality of Life. J Clin Med 2021;10:3153. [PMID: 34300319 DOI: 10.3390/jcm10143153] [Reference Citation Analysis]
574 Zhang Y, Gu L, Xia Q, Tian L, Qi J, Cao M. Radix Astragali and Radix Angelicae Sinensis in the Treatment of Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-analysis. Front Pharmacol 2020;11:415. [PMID: 32425767 DOI: 10.3389/fphar.2020.00415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
575 Khor YH, Renzoni EA, Visca D, McDonald CF, Goh NSL. Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. ERJ Open Res 2019;5:00118-2019. [PMID: 31544111 DOI: 10.1183/23120541.00118-2019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
576 Fernández Pérez ER, Zelarney P, Thomas S, Shoop DA, Munson JL, Johnson KD, Stern ME, Meadows S. An educational initiative to improve the team-based care of patients with idiopathic pulmonary fibrosis. ERJ Open Res 2018;4:00093-2017. [PMID: 29479538 DOI: 10.1183/23120541.00093-2017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
577 Kahloon RA, Xue J, Bhargava A, Csizmadia E, Otterbein L, Kass DJ, Bon J, Soejima M, Levesque MC, Lindell KO, Gibson KF, Kaminski N, Banga G, Oddis CV, Pilewski JM, Sciurba FC, Donahoe M, Zhang Y, Duncan SR. Patients with idiopathic pulmonary fibrosis with antibodies to heat shock protein 70 have poor prognoses. Am J Respir Crit Care Med 2013;187:768-75. [PMID: 23262513 DOI: 10.1164/rccm.201203-0506OC] [Cited by in Crossref: 123] [Cited by in F6Publishing: 55] [Article Influence: 13.7] [Reference Citation Analysis]
578 Marjański T, Halman J, Taniewska S, Burzyńska N, Piekarska A, Sawicka W. Open lung biopsy performed in idiopathic pulmonary fibrosis is a safe procedure. Kardiochir Torakochirurgia Pol 2017;14:236-40. [PMID: 29354175 DOI: 10.5114/kitp.2017.72227] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
579 Podolanczuk AJ, Putman RK. Clinical Relevance and Management of "Pre-Interstitial Lung Disease". Clin Chest Med 2021;42:241-9. [PMID: 34024400 DOI: 10.1016/j.ccm.2021.03.009] [Reference Citation Analysis]
580 Purokivi M, Hodgson U, Myllärniemi M, Salomaa ER, Kaarteenaho R. Are physicians in primary health care able to recognize pulmonary fibrosis? Eur Clin Respir J 2017;4:1290339. [PMID: 28326180 DOI: 10.1080/20018525.2017.1290339] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
581 Cuttica MJ. Pulmonary hypertension associated with lung diseases and hypoxemia. Heart Fail Rev 2016;21:299-308. [PMID: 27086030 DOI: 10.1007/s10741-016-9551-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
582 Portillo K, Morera J. Combined Pulmonary Fibrosis and Emphysema Syndrome: A New Phenotype within the Spectrum of Smoking-Related Interstitial Lung Disease. Pulm Med 2012;2012:867870. [PMID: 22448331 DOI: 10.1155/2012/867870] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
583 Kubo N, Araki K, Yamanaka T, Hoshino K, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Hirai K, Saitoh F, Kuwano H, Shirabe K. Perioperative management of hepatectomy in patients with interstitial pneumonia: a report of three cases and a literature review. Surg Today 2017;47:1173-9. [PMID: 28251374 DOI: 10.1007/s00595-017-1489-7] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
584 Prasad R, Gupta N, Singh A, Gupta P. Diagnosis of idiopathic pulmonary fibrosis: Current issues. Intractable Rare Dis Res 2015;4:65-9. [PMID: 25984423 DOI: 10.5582/irdr.2015.01009] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
585 Salisbury ML, Tolle LB, Xia M, Murray S, Tayob N, Nambiar AM, Schmidt SL, Lagstein A, Myers JL, Gross BH, Kazerooni EA, Sundaram B, Chughtai AR, Martinez FJ, Flaherty KR. Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med 2017;131:229-35. [PMID: 28947036 DOI: 10.1016/j.rmed.2017.08.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
586 Chen H, Chen H, Liang J, Gu X, Zhou J, Xie C, Lv X, Wang R, Li Q, Mao Z, Sun H, Zuo G, Miao D, Jin J. TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency. Exp Mol Med 2020;52:130-51. [PMID: 31959867 DOI: 10.1038/s12276-019-0371-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
587 Tilbury K, Hocker J, Wen BL, Sandbo N, Singh V, Campagnola PJ. Second harmonic generation microscopy analysis of extracellular matrix changes in human idiopathic pulmonary fibrosis. J Biomed Opt 2014;19:086014. [PMID: 25134793 DOI: 10.1117/1.JBO.19.8.086014] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 4.7] [Reference Citation Analysis]
588 Mathai SK, Schwartz DA, Warg LA. Genetic susceptibility and pulmonary fibrosis. Curr Opin Pulm Med 2014;20:429-35. [PMID: 25022318 DOI: 10.1097/MCP.0000000000000074] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.9] [Reference Citation Analysis]
589 Olson AL, Graney B, Baird S, Churney T, Fier K, Korn M, McCormick M, Sprunger D, Vierzba T, Wamboldt FS, Swigris JJ. Tracking dyspnea up to supplemental oxygen prescription among patients with pulmonary fibrosis. BMC Pulm Med 2017;17:152. [PMID: 29166901 DOI: 10.1186/s12890-017-0497-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.4] [Reference Citation Analysis]
590 Omair MA. The role of serological testing in idiopathic interstitial pneumonia: a rheumatologist perspective. Curr Pulmonol Rep 2015;4:130-4. [DOI: 10.1007/s13665-015-0118-4] [Reference Citation Analysis]
591 Jovanovic D, Roksandic Milenkovic M, Kotur Stevuljevic J, Markovic J, Ceriman V, Kontic M, Skodric Trifunovic V. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study. J Thorac Dis 2018;10:6660-9. [PMID: 30746211 DOI: 10.21037/jtd.2018.11.16] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
592 Hellbach K, Yaroshenko A, Willer K, Conlon TM, Braunagel MB, Auweter S, Yildirim AÖ, Eickelberg O, Pfeiffer F, Reiser MF, Meinel FG. X-ray dark-field radiography facilitates the diagnosis of pulmonary fibrosis in a mouse model. Sci Rep 2017;7:340. [PMID: 28336945 DOI: 10.1038/s41598-017-00475-3] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.8] [Reference Citation Analysis]
593 Huang SK, Scruggs AM, Donaghy J, Horowitz JC, Zaslona Z, Przybranowski S, White ES, Peters-Golden M. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis 2013;4:e621. [PMID: 23640463 DOI: 10.1038/cddis.2013.146] [Cited by in Crossref: 90] [Cited by in F6Publishing: 79] [Article Influence: 10.0] [Reference Citation Analysis]
594 Easton‐jones CA, Cissell DD, Mohr FC, Chigerwe M, Pusterla N. Prognostic indicators and long‐term survival in 14 horses with equine multinodular pulmonary fibrosis. Equine Vet Educ 2020;32:41-6. [DOI: 10.1111/eve.13204] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
595 Manjunath KS, Udnur H. HRCT diagnosis of combined pulmonary fibrosis and emphysema in a patient of chronic obstructive pulmonary disease with pulmonary hypertension and clinical or radiograph suspicion of pulmonary fibrosis. BJR Case Rep 2016;2:20150070. [PMID: 30460002 DOI: 10.1259/bjrcr.20150070] [Reference Citation Analysis]
596 Vicary GW, Vergne Y, Santiago-Cornier A, Young LR, Roman J. Pulmonary Fibrosis in Hermansky-Pudlak Syndrome. Ann Am Thorac Soc 2016;13:1839-46. [PMID: 27529121 DOI: 10.1513/AnnalsATS.201603-186FR] [Cited by in Crossref: 11] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
597 Kyung SY, Kim DY, Yoon JY, Son ES, Kim YJ, Park JW, Jeong SH. Sulforaphane attenuates pulmonary fibrosis by inhibiting the epithelial-mesenchymal transition. BMC Pharmacol Toxicol 2018;19:13. [PMID: 29609658 DOI: 10.1186/s40360-018-0204-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 6.8] [Reference Citation Analysis]
598 Xue T, Ma Z, Liu F, Du W, He L, Wang J, An C. Pneumocystis jirovecii colonization and its association with pulmonary diseases: a multicenter study based on a modified loop-mediated isothermal amplification assay. BMC Pulm Med 2020;20:70. [PMID: 32197601 DOI: 10.1186/s12890-020-1111-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
599 Hanada M, Kasawara KT, Mathur S, Rozenberg D, Kozu R, Hassan SA, Reid WD. Aerobic and breathing exercises improve dyspnea, exercise capacity and quality of life in idiopathic pulmonary fibrosis patients: systematic review and meta-analysis. J Thorac Dis 2020;12:1041-55. [PMID: 32274173 DOI: 10.21037/jtd.2019.12.27] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
600 Jarman ER, Khambata VS, Yun Ye L, Cheung K, Thomas M, Duggan N, Jarai G. A translational preclinical model of interstitial pulmonary fibrosis and pulmonary hypertension: mechanistic pathways driving disease pathophysiology. Physiol Rep 2014;2:e12133. [PMID: 25214520 DOI: 10.14814/phy2.12133] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
601 Matsuda T, Kondoh Y, Furukawa T, Suzuki A, Takei R, Sasano H, Yamano Y, Yokoyama T, Kataoka K, Kimura T. The prognostic value of the COPD Assessment Test in fibrotic interstitial lung disease. Respir Investig 2021:S2212-5345(21)00144-1. [PMID: 34548272 DOI: 10.1016/j.resinv.2021.07.007] [Reference Citation Analysis]
602 López-Muñiz Ballesteros B, López-Herranz M, Lopez-de-Andrés A, Hernandez-Barrera V, Jiménez-García R, Carabantes-Alarcon D, Jiménez-Trujillo I, de Miguel-Diez J. Sex Differences in the Incidence and Outcomes of Patients Hospitalized by Idiopathic Pulmonary Fibrosis (IPF) in Spain from 2016 to 2019. J Clin Med 2021;10:3474. [PMID: 34441772 DOI: 10.3390/jcm10163474] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
603 Jacquerie P, Henket M, André B, Moermans C, de Seny D, Gester F, Louis R, Malaise M, Guiot J. Inflammatory profile of induced sputum composition in systemic sclerosis and comparison with healthy volunteers. Sci Rep 2021;11:10679. [PMID: 34021175 DOI: 10.1038/s41598-021-87701-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
604 Marsaa K, Gundestrup S, Jensen JU, Lange P, Løkke A, Roberts NB, Shaker SB, Sørensen AR, Titlestad IL, Thomsen LH, Weinreich UM, Bendstrup E, Wilcke T. Danish respiratory society position paper: palliative care in patients with chronic progressive non-malignant lung diseases. Eur Clin Respir J 2018;5:1530029. [PMID: 30357015 DOI: 10.1080/20018525.2018.1530029] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
605 Moor CC, van den Berg CAL, Visser LS, Aerts JGJV, Cottin V, Wijsenbeek MS. Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. ERJ Open Res 2020;6:00054-2020. [PMID: 32280666 DOI: 10.1183/23120541.00054-2020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
606 Chahal A, Sharif R, Watts J, de Andrade J, Luckhardt T, Kim YI, Ramchandran R, Sonavane S. Predicting Outcome in Idiopathic Pulmonary Fibrosis: Addition of Fibrotic Score at Thin-Section CT of the Chest to Gender, Age, and Physiology Score Improves the Prediction Model. Radiol Cardiothorac Imaging 2019;1:e180029. [PMID: 33778502 DOI: 10.1148/ryct.2019180029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
607 Chin M, Johns C, Currie BJ, Weatherley N, Hill C, Elliot C, Rajaram S, Wild JM, Condliffe R, Bianchi S, Kiely DG, Swift AJ. Pulmonary Artery Size in Interstitial Lung Disease and Pulmonary Hypertension: Association with Interstitial Lung Disease Severity and Diagnostic Utility. Front Cardiovasc Med 2018;5:53. [PMID: 29938208 DOI: 10.3389/fcvm.2018.00053] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
608 Ramazzini C. Comments on the 2014 helsinki consensus report on asbestos. J Occup Health 2016;58:224-7. [PMID: 27040481 DOI: 10.1539/joh.16-2004-LT] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
609 Maher TM, Stowasser S, Nishioka Y, White ES, Cottin V, Noth I, Selman M, Blahova Z, Wachtlin D, Diefenbach C, Jenkins RG. Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial. BMJ Open Respir Res 2018;5:e000325. [PMID: 30167310 DOI: 10.1136/bmjresp-2018-000325] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
610 Jani M, Hirani N, Matteson EL, Dixon WG. The safety of biologic therapies in RA-associated interstitial lung disease. Nat Rev Rheumatol 2014;10:284-94. [PMID: 24366321 DOI: 10.1038/nrrheum.2013.197] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
611 James DS, Jambor AN, Chang HY, Alden Z, Tilbury KB, Sandbo NK, Campagnola PJ. Probing ECM remodeling in idiopathic pulmonary fibrosis via second harmonic generation microscopy analysis of macro/supramolecular collagen structure. J Biomed Opt 2019;25:1-13. [PMID: 31785093 DOI: 10.1117/1.JBO.25.1.014505] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
612 Schroll S, Lange TJ, Arzt M, Sebah D, Nowrotek A, Lehmann H, Wensel R, Pfeifer M, Blumberg FC. Effects of simvastatin on pulmonary fibrosis, pulmonary hypertension and exercise capacity in bleomycin-treated rats. Acta Physiol (Oxf) 2013;208:191-201. [PMID: 23527830 DOI: 10.1111/apha.12085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
613 Pilling D, Gomer RH. Persistent lung inflammation and fibrosis in serum amyloid P component (APCs-/-) knockout mice. PLoS One 2014;9:e93730. [PMID: 24695531 DOI: 10.1371/journal.pone.0093730] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
614 Tomioka H, Mamesaya N, Yamashita S, Kida Y, Kaneko M, Sakai H. Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease. BMJ Open Respir Res 2016;3:e000099. [PMID: 26933506 DOI: 10.1136/bmjresp-2015-000099] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
615 Honda H, Fujimoto M, Serada S, Urushima H, Mishima T, Lee H, Ohkawara T, Kohno N, Hattori N, Yokoyama A, Naka T. Leucine-rich α-2 glycoprotein promotes lung fibrosis by modulating TGF-β signaling in fibroblasts. Physiol Rep 2017;5:e13556. [PMID: 29279415 DOI: 10.14814/phy2.13556] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
616 Stratton MS, Haldar SM, McKinsey TA. BRD4 inhibition for the treatment of pathological organ fibrosis. F1000Res 2017;6:F1000 Faculty Rev-1015. [PMID: 28721198 DOI: 10.12688/f1000research.11339.1] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
617 Moll SA, Wiertz IA, Vorselaars ADM, Ruven HJT, van Moorsel CHM, Grutters JC. Change in Serum Biomarker CA 15-3 as an Early Predictor of Response to Treatment and Survival in Hypersensitivity Pneumonitis. Lung 2020;198:385-93. [PMID: 31993739 DOI: 10.1007/s00408-020-00330-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
618 Sato R, Handa T, Matsumoto H, Kubo T, Hirai T. Clinical significance of self-reported cough intensity and frequency in patients with interstitial lung disease: a cross-sectional study. BMC Pulm Med 2019;19:247. [PMID: 31842848 DOI: 10.1186/s12890-019-1012-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
619 Paolocci G, Folletti I, Torén K, Ekström M, Dell'Omo M, Muzi G, Murgia N. Occupational risk factors for idiopathic pulmonary fibrosis in Southern Europe: a case-control study. BMC Pulm Med 2018;18:75. [PMID: 29784045 DOI: 10.1186/s12890-018-0644-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
620 Morisset J, Dubé BP, Garvey C, Bourbeau J, Collard HR, Swigris JJ, Lee JS. The Unmet Educational Needs of Patients with Interstitial Lung Disease. Setting the Stage for Tailored Pulmonary Rehabilitation. Ann Am Thorac Soc 2016;13:1026-33. [PMID: 27064659 DOI: 10.1513/AnnalsATS.201512-836OC] [Cited by in Crossref: 31] [Cited by in F6Publishing: 6] [Article Influence: 7.8] [Reference Citation Analysis]
621 Morell F, Esser D, Lim J, Stowasser S, Villacampa A, Nieves D, Brosa M. Treatment patterns, resource use and costs of idiopathic pulmonary fibrosis in Spain--results of a Delphi Panel. BMC Pulm Med 2016;16:7. [PMID: 26758510 DOI: 10.1186/s12890-016-0168-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
622 Vu TN, Chen X, Foda HD, Smaldone GC, Hasaneen NA. Interferon-γ enhances the antifibrotic effects of pirfenidone by attenuating IPF lung fibroblast activation and differentiation. Respir Res 2019;20:206. [PMID: 31511015 DOI: 10.1186/s12931-019-1171-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
623 Chen SS, Yin ZF, Chen T, Qiu H, Wei YR, Du SS, Jin YP, Zhao MM, Wu Q, Weng D, Li HP. Development of a non-infectious rat model of acute exacerbation of idiopathic pulmonary fibrosis. J Thorac Dis 2017;9:96-105. [PMID: 28203411 DOI: 10.21037/jtd.2017.01.22] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
624 Abe M, Tsushima K, Sakayori M, Suzuki K, Ikari J, Terada J, Tatsumi K. Utility of nintedanib for severe idiopathic pulmonary fibrosis: a single-center retrospective study. Drug Des Devel Ther 2018;12:3369-75. [PMID: 30349191 DOI: 10.2147/DDDT.S179427] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
625 Raghunath S, Rajagopalan S, Karwoski RA, Maldonado F, Peikert T, Moua T, Ryu JH, Bartholmai BJ, Robb RA. Quantitative stratification of diffuse parenchymal lung diseases. PLoS One 2014;9:e93229. [PMID: 24676019 DOI: 10.1371/journal.pone.0093229] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.0] [Reference Citation Analysis]
626 Li M, Wang K, Zhang Y, Fan M, Li A, Zhou J, Yang T, Shi P, Li D, Zhang G, Chen M, Ren H. Ferroptosis-Related Genes in Bronchoalveolar Lavage Fluid Serves as Prognostic Biomarkers for Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 2021;8:693959. [PMID: 34671612 DOI: 10.3389/fmed.2021.693959] [Reference Citation Analysis]
627 Rubin JM, Horowitz JC, Sisson TH, Kim K, Ortiz LA, Hamilton JD. Ultrasound Strain Measurements for Evaluating Local Pulmonary Ventilation. Ultrasound Med Biol 2016;42:2525-31. [PMID: 27520395 DOI: 10.1016/j.ultrasmedbio.2016.05.020] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
628 Tashiro J, Rubio GA, Limper AH, Williams K, Elliot SJ, Ninou I, Aidinis V, Tzouvelekis A, Glassberg MK. Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis. Front Med (Lausanne) 2017;4:118. [PMID: 28804709 DOI: 10.3389/fmed.2017.00118] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 17.0] [Reference Citation Analysis]
629 Chae KJ, Jin GY, Jung HN, Kwon KS, Choi H, Lee YC, Chung MJ, Park HS. Differentiating Smoking-Related Interstitial Fibrosis (SRIF) from Usual Interstitial Pneumonia (UIP) with Emphysema Using CT Features Based on Pathologically Proven Cases. PLoS One 2016;11:e0162231. [PMID: 27611866 DOI: 10.1371/journal.pone.0162231] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
630 Liu X, Ali MK, Dua K, Xu R. The Role of Zinc in the Pathogenesis of Lung Disease. Nutrients 2022;14:2115. [DOI: 10.3390/nu14102115] [Reference Citation Analysis]
631 Samitas K, Kolilekas L, Vamvakaris I, Gkogkou C, Filippousis P, Gaga M, Zervas E. Introducing transbronchial cryobiopsies in diagnosing diffuse parenchymal lung diseases in Greece: Implementing training into clinical practice. PLoS One 2019;14:e0217554. [PMID: 31158264 DOI: 10.1371/journal.pone.0217554] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
632 Lopez-de la Mora DA, Sanchez-Roque C, Montoya-Buelna M, Sanchez-Enriquez S, Lucano-Landeros S, Macias-Barragan J, Armendariz-Borunda J. Role and New Insights of Pirfenidone in Fibrotic Diseases. Int J Med Sci 2015;12:840-7. [PMID: 26640402 DOI: 10.7150/ijms.11579] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 7.9] [Reference Citation Analysis]
633 Ten Klooster L, van Moorsel CH, Kwakkel-van Erp JM, van Velzen-Blad H, Grutters JC. Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis. Clin Exp Immunol 2015;181:357-61. [PMID: 25845491 DOI: 10.1111/cei.12636] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
634 Allen RJ, Stockwell A, Oldham JM, Guillen-Guio B, Schwartz DA, Maher TM, Flores C, Noth I, Yaspan BL, Jenkins RG, Wain LV; International IPF Genetics Consortium. Genome-wide association study across five cohorts identifies five novel loci associated with idiopathic pulmonary fibrosis. Thorax 2022:thoraxjnl-2021-218577. [PMID: 35688625 DOI: 10.1136/thoraxjnl-2021-218577] [Reference Citation Analysis]
635 Prior TS, Hoyer N, Hilberg O, Shaker SB, Davidsen JR, Bendstrup E. Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis. Respir Res 2020;21:91. [PMID: 32316976 DOI: 10.1186/s12931-020-01359-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
636 Vozoris NT, Wilton AS, Austin PC, Kendzerska T, Ryan CM, Gershon AS. Morbidity and mortality reduction associated with polysomnography testing in idiopathic pulmonary fibrosis: a population-based cohort study. BMC Pulm Med 2021;21:185. [PMID: 34078346 DOI: 10.1186/s12890-021-01555-x] [Reference Citation Analysis]
637 d'Alessandro M, Bergantini L, Cameli P, Pieroni M, Refini RM, Sestini P, Bargagli E. Serum Concentrations of KL-6 in Patients with IPF and Lung Cancer and Serial Measurements of KL-6 in IPF Patients Treated with Antifibrotic Therapy. Cancers (Basel) 2021;13:689. [PMID: 33572070 DOI: 10.3390/cancers13040689] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
638 Çirak AK, Katgi N, Erer OF, Çimen P, Tuksavul FF, Hakoğlu B. Diagnostic approach in parenchymal lung diseases: transbronchial lung biopsy or cryobiopsy? Turk J Med Sci 2020;50:1535-9. [PMID: 32490646 DOI: 10.3906/sag-1910-47] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
639 Ho JE, Gao W, Levy D, Santhanakrishnan R, Araki T, Rosas IO, Hatabu H, Latourelle JC, Nishino M, Dupuis J, Washko GR, O'Connor GT, Hunninghake GM. Galectin-3 Is Associated with Restrictive Lung Disease and Interstitial Lung Abnormalities. Am J Respir Crit Care Med 2016;194:77-83. [PMID: 26771117 DOI: 10.1164/rccm.201509-1753OC] [Cited by in Crossref: 36] [Cited by in F6Publishing: 18] [Article Influence: 7.2] [Reference Citation Analysis]
640 Cabrera Cesar E, Lopez-Lopez L, Lara E, Hidalgo-San Juan MV, Parrado Romero C, Palencia JLRS, Martín-Montañez E, Garcia-Fernandez M. Serum Biomarkers in Differential Diagnosis of Idiopathic Pulmonary Fibrosis and Connective Tissue Disease-Associated Interstitial Lung Disease. J Clin Med 2021;10:3167. [PMID: 34300333 DOI: 10.3390/jcm10143167] [Reference Citation Analysis]
641 Hilberg O, Hoffmann-vold A, Smith V, Bouros D, Kilpeläinen M, Guiot J, Morais A, Clemente S, Daniil Z, Papakosta D, Fretheim H, Neves S, Alfaro TM, Antoniou KM, Valveny N, Asijee G, Soulard S, Wuyts W. Epidemiology of interstitial lung diseases and their progressive-fibrosing behaviour in six European countries. ERJ Open Res 2022;8:00597-2021. [DOI: 10.1183/23120541.00597-2021] [Reference Citation Analysis]
642 Wang B, Bai W, Ma H, Li F. Regulatory Effect of PD1/PD-Ligand 1 (PD-L1) on Treg Cells in Patients with Idiopathic Pulmonary Fibrosis. Med Sci Monit 2021;27:e927577. [PMID: 33386384 DOI: 10.12659/MSM.927577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
643 Kopp K, Lichtenauer M, Motloch LJ, Hoppe UC, Egle A, Salzer HJF, Lamprecht B, Tomasits J, Müller HM, Dieplinger A. Interdisciplinary Model for Scheduling Post-discharge Cardiopulmonary Care of Patients Following Severe and Critical SARS-CoV-2 (Coronavirus) Infection. Front Cardiovasc Med 2020;7:157. [PMID: 32923461 DOI: 10.3389/fcvm.2020.00157] [Reference Citation Analysis]
644 Kishaba T. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. Medicina (Kaunas) 2019;55:E70. [PMID: 30884853 DOI: 10.3390/medicina55030070] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
645 Jo HE, Randhawa S, Corte TJ, Moodley Y. Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. Drugs Aging 2016;33:321-34. [PMID: 27083934 DOI: 10.1007/s40266-016-0366-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 3.5] [Reference Citation Analysis]
646 Chen X, Talati M, Fessel JP, Hemnes AR, Gladson S, French J, Shay S, Trammell A, Phillips JA, Hamid R, Cogan JD, Dawson EP, Womble KE, Hedges LK, Martinez EG, Wheeler LA, Loyd JE, Majka SJ, West J, Austin ED. Estrogen Metabolite 16α-Hydroxyestrone Exacerbates Bone Morphogenetic Protein Receptor Type II-Associated Pulmonary Arterial Hypertension Through MicroRNA-29-Mediated Modulation of Cellular Metabolism. Circulation 2016;133:82-97. [PMID: 26487756 DOI: 10.1161/CIRCULATIONAHA.115.016133] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
647 Borges LF, Jagadeesan V, Goldberg H, Gavini S, Lo WK, Burakoff R, Feldman N, Chan WW. Abnormal Bolus Reflux Is Associated With Poor Pulmonary Outcome in Patients With Idiopathic Pulmonary Fibrosis. J Neurogastroenterol Motil 2018;24:395-402. [PMID: 29969857 DOI: 10.5056/jnm18023] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
648 Jarosch I, Schneeberger T, Glöckl R, Leitl D, Koczulla AR. [Referral to pulmonary rehabilitation and its options for chronic lung disease patients]. MMW Fortschr Med 2021;163:40-7. [PMID: 33961258 DOI: 10.1007/s15006-021-9811-0] [Reference Citation Analysis]
649 Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, Fujita Y, Hayashi S, Inoue Y. Hemosiderin-Laden Macrophages in Bronchoalveolar Lavage: Predictive Role for Acute Exacerbation of Idiopathic Interstitial Pneumonias. Can Respir J 2021;2021:4595019. [PMID: 34966470 DOI: 10.1155/2021/4595019] [Reference Citation Analysis]
650 Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 2016;71:429-35. [PMID: 26968970 DOI: 10.1136/thoraxjnl-2015-207011] [Cited by in Crossref: 102] [Cited by in F6Publishing: 84] [Article Influence: 17.0] [Reference Citation Analysis]
651 Perez-Bogerd S, Wuyts W, Barbier V, Demeyer H, Van Muylem A, Janssens W, Troosters T. Short and long-term effects of pulmonary rehabilitation in interstitial lung diseases: a randomised controlled trial. Respir Res 2018;19:182. [PMID: 30236104 DOI: 10.1186/s12931-018-0884-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 11.8] [Reference Citation Analysis]
652 Strock SB, Alder JK, Kass DJ. From bad to worse: when lung cancer complicates idiopathic pulmonary fibrosis. J Pathol 2018;244:383-5. [PMID: 29282737 DOI: 10.1002/path.5027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
653 Meyer KC, Raghu G. Reply: The Clinical Utility of Bronchoalveolar Lavage Cellular Analysis in Interstitial Lung Disease. Am J Respir Crit Care Med 2013;187:777-8. [DOI: 10.1164/ajrccm.187.7.777a] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
654 Cisneros J, Hagood J, Checa M, Ortiz-Quintero B, Negreros M, Herrera I, Ramos C, Pardo A, Selman M. Hypermethylation-mediated silencing of p14(ARF) in fibroblasts from idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2012;303:L295-303. [PMID: 22707614 DOI: 10.1152/ajplung.00332.2011] [Cited by in Crossref: 59] [Cited by in F6Publishing: 57] [Article Influence: 5.9] [Reference Citation Analysis]
655 Tomizawa K, Sato K, Ohara S, Fujino T, Koga T, Nishino M, Kobayashi Y, Chiba M, Shimoji M, Suda K, Takemoto T, Mitsudomi T. Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysis. Surg Today 2019;49:513-20. [PMID: 30706240 DOI: 10.1007/s00595-019-1773-9] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
656 Ermis H, Parlakpinar H, Gulbas G, Vardi N, Polat A, Cetin A, Kilic T, Aytemur ZA. Protective effect of dexpanthenol on bleomycin-induced pulmonary fibrosis in rats. Naunyn Schmiedebergs Arch Pharmacol 2013;386:1103-10. [PMID: 23995256 DOI: 10.1007/s00210-013-0908-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
657 Dong J, Yu X, Porter DW, Battelli LA, Kashon ML, Ma Q. Common and distinct mechanisms of induced pulmonary fibrosis by particulate and soluble chemical fibrogenic agents. Arch Toxicol 2016;90:385-402. [PMID: 26345256 DOI: 10.1007/s00204-015-1589-3] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.7] [Reference Citation Analysis]
658 Andrade J, Schwarz M, Collard HR, Gentry-Bumpass T, Colby T, Lynch D, Kaner RJ; IPFnet Investigators. The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. Chest 2015;148:1034-42. [PMID: 26111071 DOI: 10.1378/chest.14-2889] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 4.5] [Reference Citation Analysis]
659 Hohberger LA, Montero-Arias F, Roden AC, Vassallo R. Normalization of lung function following treatment of secondary usual interstitial pneumonia: a case report. Clin Med Insights Circ Respir Pulm Med 2015;9:23-5. [PMID: 25922588 DOI: 10.4137/CCRPM.S22878] [Reference Citation Analysis]
660 Veigh CM, Reid J, Larkin P, Porter S, Hudson P. The provision of generalist and specialist palliative care for patients with non-malignant respiratory disease in the North and Republic of Ireland: a qualitative study. BMC Palliat Care 2017;17:6. [PMID: 28693466 DOI: 10.1186/s12904-017-0220-1] [Cited by in F6Publishing: 13] [Reference Citation Analysis]
661 Chaudhuri N, Spencer L, Greaves M, Bishop P, Chaturvedi A, Leonard C. A Review of the Multidisciplinary Diagnosis of Interstitial Lung Diseases: A Retrospective Analysis in a Single UK Specialist Centre. J Clin Med 2016;5:E66. [PMID: 27472372 DOI: 10.3390/jcm5080066] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
662 Hozumi H, Nakamura Y, Johkoh T, Sumikawa H, Colby TV, Kono M, Hashimoto D, Enomoto N, Fujisawa T, Inui N, Suda T, Chida K. Acute exacerbation in rheumatoid arthritis-associated interstitial lung disease: a retrospective case control study. BMJ Open 2013;3:e003132. [PMID: 24038004 DOI: 10.1136/bmjopen-2013-003132] [Cited by in Crossref: 78] [Cited by in F6Publishing: 66] [Article Influence: 8.7] [Reference Citation Analysis]
663 Jiwrajka N, Loizidis G, Patterson KC, Kreider ME, Johnson CR, Miller WT Jr, Barbosa EJM Jr, Patel N, Beers MF, Litzky LA, George MD, Porteous MK. Identification and Prognosis of Patients With Interstitial Pneumonia With Autoimmune Features. J Clin Rheumatol 2022. [PMID: 35697042 DOI: 10.1097/RHU.0000000000001847] [Reference Citation Analysis]
664 Porteous MK, Rivera-Lebron BN, Kreider M, Lee J, Kawut SM. Determinants of 6-minute walk distance in patients with idiopathic pulmonary fibrosis undergoing lung transplant evaluation. Pulm Circ 2016;6:30-6. [PMID: 27076905 DOI: 10.1086/685022] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
665 Lancaster L, Morrison L, Auais A, Ding B, Iqbal A, Polman B, Flaherty KR. Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis: Experience from 92 Sites in an Open-Label US Expanded Access Program. Pulm Ther 2017;3:317-25. [PMID: 32026347 DOI: 10.1007/s41030-017-0049-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.6] [Reference Citation Analysis]
666 Camp R, Smith ML, Larsen BT, Roden AC, Farver C, Moreira AL, Attanoos R, Pillappa R, Sansano I, Fabro AT, Homer RJ. Reliability of histopathologic diagnosis of fibrotic interstitial lung disease: an international collaborative standardization project. BMC Pulm Med 2021;21:184. [PMID: 34074264 DOI: 10.1186/s12890-021-01522-6] [Reference Citation Analysis]
667 Bonella F, Costabel U. The perpetual enigma of bronchoalveolar lavage fluid lymphocytosis in chronic hypersensitivity pneumonitis: is it of diagnostic value? Eur Respir J 2020;56:2001534. [PMID: 32763963 DOI: 10.1183/13993003.01534-2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
668 Veit T, Barnikel M, Crispin A, Kneidinger N, Ceelen F, Arnold P, Munker D, Schmitzer M, Barton J, Schiopu S, Schiller HB, Frankenberger M, Milger K, Behr J, Neurohr C, Leuschner G. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study. Respir Res 2020;21:270. [PMID: 33076914 DOI: 10.1186/s12931-020-01524-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
669 Wollin L, Wex E, Pautsch A, Schnapp G, Hostettler KE, Stowasser S, Kolb M. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J 2015;45:1434-45. [PMID: 25745043 DOI: 10.1183/09031936.00174914] [Cited by in Crossref: 349] [Cited by in F6Publishing: 316] [Article Influence: 49.9] [Reference Citation Analysis]
670 Ajayi IO, Sisson TH, Higgins PD, Booth AJ, Sagana RL, Huang SK, White ES, King JE, Moore BB, Horowitz JC. X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis. Am J Respir Cell Mol Biol 2013;49:86-95. [PMID: 23492187 DOI: 10.1165/rcmb.2012-0224OC] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
671 van Batenburg AA, Kazemier KM, van Oosterhout MFM, van der Vis JJ, van Es HW, Grutters JC, Goldschmeding R, van Moorsel CHM. From organ to cell: Multi-level telomere length assessment in patients with idiopathic pulmonary fibrosis. PLoS One 2020;15:e0226785. [PMID: 31910222 DOI: 10.1371/journal.pone.0226785] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
672 Collum SD, Chen NY, Hernandez AM, Hanmandlu A, Sweeney H, Mertens TCJ, Weng T, Luo F, Molina JG, Davies J, Horan IP, Morrell NW, Amione-Guerra J, Al-Jabbari O, Youker K, Sun W, Rajadas J, Bollyky PL, Akkanti BH, Jyothula S, Sinha N, Guha A, Karmouty-Quintana H. Inhibition of hyaluronan synthesis attenuates pulmonary hypertension associated with lung fibrosis. Br J Pharmacol. 2017;174:3284-3301. [PMID: 28688167 DOI: 10.1111/bph.13947] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
673 Newton CA, Batra K, Torrealba J, Kozlitina J, Glazer CS, Aravena C, Meyer K, Raghu G, Collard HR, Garcia CK. Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 2016;48:1710-20. [PMID: 27540018 DOI: 10.1183/13993003.00308-2016] [Cited by in Crossref: 150] [Cited by in F6Publishing: 121] [Article Influence: 25.0] [Reference Citation Analysis]
674 Liu X, Qin X, Qin H, Jia C, Yuan Y, Sun T, Chen B, Chen C, Zhang H. Characterization of the heterogeneity of endothelial cells in bleomycin-induced lung fibrosis using single-cell RNA sequencing. Angiogenesis 2021. [PMID: 34028626 DOI: 10.1007/s10456-021-09795-5] [Reference Citation Analysis]
675 Hanaka T, Kido T, Noguchi S, Yamada S, Noguchi H, Guo X, Nawata A, Wang KY, Oda K, Takaki T, Izumi H, Ishimoto H, Yatera K, Mukae H. The overexpression of peroxiredoxin-4 affects the progression of idiopathic pulmonary fibrosis. BMC Pulm Med 2019;19:265. [PMID: 31888585 DOI: 10.1186/s12890-019-1032-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
676 d'Alessandro M, Bergantini L, Bargagli E, Vidal S. Extracellular Vesicles in Pulmonary Fibrosis Models and Biological Fluids of Interstitial Lung Disease Patients: A Scoping Review. Life (Basel) 2021;11:1401. [PMID: 34947932 DOI: 10.3390/life11121401] [Reference Citation Analysis]
677 Mikamo M, Kitagawa K, Sakai S, Uchida C, Ohhata T, Nishimoto K, Niida H, Suzuki S, Nakayama KI, Inui N, Suda T, Kitagawa M. Inhibiting Skp2 E3 Ligase Suppresses Bleomycin-Induced Pulmonary Fibrosis. Int J Mol Sci 2018;19:E474. [PMID: 29415439 DOI: 10.3390/ijms19020474] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
678 Samuel J, Smaldone GC. Maximizing Deep Lung Deposition in Healthy and Fibrotic Subjects During Jet Nebulization. J Aerosol Med Pulm Drug Deliv 2020;33:108-15. [PMID: 31855492 DOI: 10.1089/jamp.2019.1552] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
679 Huang Y, Ma SF, Vij R, Oldham JM, Herazo-Maya J, Broderick SM, Strek ME, White SR, Hogarth DK, Sandbo NK, Lussier YA, Gibson KF, Kaminski N, Garcia JG, Noth I. A functional genomic model for predicting prognosis in idiopathic pulmonary fibrosis. BMC Pulm Med 2015;15:147. [PMID: 26589497 DOI: 10.1186/s12890-015-0142-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
680 Moghadam-kia S, Aggarwal R, Oddis CV. Myositis in clinical practice—relevance of new antibodies. Best Practice & Research Clinical Rheumatology 2018;32:887-901. [DOI: 10.1016/j.berh.2019.03.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
681 Paudel KR, Dharwal V, Patel VK, Galvao I, Wadhwa R, Malyla V, Shen SS, Budden KF, Hansbro NG, Vaughan A, Yang IA, Kohonen-Corish MRJ, Bebawy M, Dua K, Hansbro PM. Role of Lung Microbiome in Innate Immune Response Associated With Chronic Lung Diseases. Front Med (Lausanne) 2020;7:554. [PMID: 33043031 DOI: 10.3389/fmed.2020.00554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
682 Espindola MS, Habiel DM, Coelho AL, Stripp B, Parks WC, Oldham J, Martinez FJ, Noth I, Lopez D, Mikels-Vigdal A, Smith V, Hogaboam CM. Differential Responses to Targeting Matrix Metalloproteinase 9 in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med 2021;203:458-70. [PMID: 33052708 DOI: 10.1164/rccm.201910-1977OC] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
683 Ochman M, Urlik M, Tatoj Z, Zawadzki F, Wajda-Pokrontka M, Latos M, Przybyłowski P, Zembala M. Retrospective cohort study of patients qualified for lung transplantation due to idiopathic pulmonary fibrosis - single-centre experience. Arch Med Sci 2020;16:621-6. [PMID: 32399111 DOI: 10.5114/aoms.2019.82662] [Reference Citation Analysis]
684 Tang J, Li J, Li G, Zhang H, Wang L, Li D, Ding J. Spermidine-mediated poly(lactic-co-glycolic acid) nanoparticles containing fluorofenidone for the treatment of idiopathic pulmonary fibrosis. Int J Nanomedicine 2017;12:6687-704. [PMID: 28932114 DOI: 10.2147/IJN.S140569] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 2.6] [Reference Citation Analysis]
685 JafariNezhad A, YektaKooshali MH. Lung cancer in idiopathic pulmonary fibrosis: A systematic review and meta-analysis. PLoS One 2018;13:e0202360. [PMID: 30114238 DOI: 10.1371/journal.pone.0202360] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
686 Buschulte K, Hoffmann-Vold AM, Dobrota RD, Höger P, Krause A, Kreuter M. [Treatment of lung fibrosis in systemic rheumatic diseases (new treatment)]. Z Rheumatol 2021;80:743-54. [PMID: 34505934 DOI: 10.1007/s00393-021-01067-3] [Reference Citation Analysis]
687 Norman KC, Moore BB, Arnold KB, O'Dwyer DN. Proteomics: Clinical and research applications in respiratory diseases. Respirology 2018;23:993-1003. [PMID: 30105802 DOI: 10.1111/resp.13383] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
688 Beers MF, Knudsen L, Tomer Y, Maronn J, Zhao M, Ochs M, Mulugeta S. Aberrant lung remodeling in a mouse model of surfactant dysregulation induced by modulation of the Abca3 gene. Ann Anat 2017;210:135-46. [PMID: 28034695 DOI: 10.1016/j.aanat.2016.11.015] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
689 Pereira CA, Gimenez A, Kuranishi L, Storrer K. Chronic hypersensitivity pneumonitis. J Asthma Allergy 2016;9:171-81. [PMID: 27703382 DOI: 10.2147/JAA.S81540] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 6.2] [Reference Citation Analysis]
690 Kulkarni T, Kurundkar AR, Kim YI, de Andrade J, Luckhardt T, Thannickal VJ. The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. Respir Med 2020;161:105821. [PMID: 31765873 DOI: 10.1016/j.rmed.2019.105821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
691 Biondini D, Balestro E, Lacedonia D, Cerri S, Milaneschi R, Luppi F, Cocconcelli E, Bazzan E, Clini E, Foschino Barbaro MP, Gregori D, Cosio MG, Saetta M, Spagnolo P. Pretreatment rate of decay in forced vital capacity predicts long-term response to pirfenidone in patients with idiopathic pulmonary fibrosis. Sci Rep 2018;8:5961. [PMID: 29654244 DOI: 10.1038/s41598-018-24303-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]